<SEC-DOCUMENT>0001558370-20-011974.txt : 20201029
<SEC-HEADER>0001558370-20-011974.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029072633
ACCESSION NUMBER:		0001558370-20-011974
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		201270522

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20200930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/29/2020 11:25:51 AM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: c12cbfbe-c8af-48b8-bc25-45bcca13391a -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:plx="http://www.protalix.com/20200930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" xs:nil="true" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_xdFpZTDUUUmvlnSscrMvyQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" xs:nil="true" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_nF2grAOuTEiTir1RtpXs8A"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityCentralIndexKey" id="Tc_yaHo7uX_EEuZbcZG8U3Cww_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:CurrentFiscalYearEndDate" id="Tc_H0OTMgO5_Ui1dv3MhmA_FQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentFiscalYearFocus" id="Tc_Iy_LBDBvvEqn2ojsncFkOQ_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentFiscalPeriodFocus" id="Tc_A-FYqUg1VEaO0Z64g0nUEA_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:AmendmentFlag" id="Narr__dHczwVpUk-w3sW-OBbolA">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ" decimals="-5" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" id="Hidden_2X7HaISLh0Kcb4gJc90IJw">25000000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_1fRceHFMtEWWoTuOudr_4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E7ojsykV9EKg72W5j6pVFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-19</xbrli:startDate><xbrli:endDate>2019-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IRzIhsYvXUKaSF2OewJ56A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O6L8OVTlsEu_2HaEKKHaow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8HscStIMCky71Xpz36-FCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rNDZG8xgrkK9Eqv3ngpLpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AHiYkPc4FUK56R6zTg4LjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cr_aPjmKT0mYjDg02J2Z7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_fef2AszHPU-bAj2nZEQDdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yB5LZFDEhEyvveEfDJ5-QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fK7QWqX6s0q9WkkFwHaS9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_awAX9aPeuk2iZshhHY-mww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-22</xbrli:startDate><xbrli:endDate>2020-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qrzLO1Itnk-vHNuLIHMrCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_okYXxp9UpUmRkgl9piR4yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z72QeSjod0mfL9i7a-nY-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_4CFqkzlEM0a0ykFUdbprNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JUeLT0AOY0GhjA3MadGoNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Mzmg7jvLfEe4iybt5-W0xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_V4-yU8AA-0avjmtvGhaOeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CsulLJ3GXEOV9Zoac507-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3utDIYnGnk23SwkpDHFalw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_c-o4-zlu6k-zZmFIhIvfgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ECNMuJ7DQkuqCfY-v0kl1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_m0iRbIUWmE-NwcxiFKbfxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uJj9XUZ3jEK_nwNQ1ytYrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_Gx20S_jXlEO4XT5ZwA9LaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-14</xbrli:startDate><xbrli:endDate>2020-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_uMfCJEZpY02sFvVTznIY5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_7TPGAQhZOUmeeaZ_5HG55g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vbfxSpJnx0SCEmInPOXG3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VCj1F6qAZEeCpBg6hY-teg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sfvdWUnu6EO7cndkxiekuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZNbuEF-wWkuGqpCEaHk7nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bjCDIQN02Uam1toNzw9LSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2oLx1XpEpEeKkThOFBF0qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WZZ4r5XXfEOp6GCJNBLRVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_pJdr0YSp5USwhCNaVQZ9eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_Nrylmm7X3kaU8w3XPffnbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hXjv6Jrv6kedC9tuTT8GcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_pRcDTGYiEECDc0dojMQDWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZdfRPnCjeEyvM5HwjCNBXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4MopdnOnJEGxDhBhT6bjmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uoOZj9fvI0O5KtUKJ2QUVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e1_nZMaTIE-COHRAayOIMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oKcfDa3A0kGpkbFODB1jxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__Df5EeyoJU2aHMqKSUD2rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kM2vCYwSV0uRlWIJmg2-4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:VicePresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_KfZU-gIvU0mW3QuavJGUpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_edPTlz70sE-KPAY6iEzxFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:VicePresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_NLt0-efPfky_nzLBvyGDpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6ofRVpdY5EC3THAh6MbRNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Jv4KEHGwEEGDjCnT8dmZzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PdUn1DLSjky-oL6yd58gsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_2bYIXNG5N0WSrA0hwUb6RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2020_To_3_16_2020_WyJvhboxckK2jqSgzcbqVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_qPVNjr3QxkiUTyW7b-790A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2020_ruhy-1MfX0uWd0p6iXkV2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xRzNdpnGEk-71eO8pSDPbw_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qRD60oHS9UGoDx0QmtTcbA_28_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Z0C-RXLin0u-6-F5E72_fw_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_JkhJ73vHckieh1cGPG-l9g_24_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zELekXqrakWfZkOwtmNM4Q_31_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_B85fPue9QEOekGI75LcOcw_18_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_iBvrbfXZck-rpBcJGOChjw_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_EfV7eJncpE2tWe9AeHtcuA_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_95eda0d5_8d82_463a_b9d3_428d6b682abf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentType" id="Narr_CyCKlZL-sEqnK8troakvYQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentQuarterlyReport" id="Narr_e4QZBLRISE-05cnurUERUQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentPeriodEndDate" id="Narr_E-G0GQshv0C4zX4MbDZNMQ"><b style="font-size:8pt;font-weight:bold;">September 30, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:DocumentTransitionReport" id="Narr_lh7O0SQ03UWUU3fTXeiecQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityFileNumber" id="Narr_vLJdIZGJo0C-hBSnSZqxxw"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityRegistrantName" id="Narr_C9ujogqWnUqjODkjW2o9Gw"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_UxWbMINExUGA6-i_ax4z5w_1_1"></a><a id="Tc_Aj2zFRIUD0ylUu2j1VTI5w_2_0"></a><a id="Tc_oxaU4pFtxkOQ-XDvPMzjoQ_2_1"></a><a id="Tc_CMRwyHO1DUC7-XMumjL1Qw_4_0"></a><a id="Tc_nicEIm-XikmWDyNyEFiSTg_5_0"></a><a id="Tc_jRCnO_AqJ0WuXrh89MHs9A_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityIncorporationStateCountryCode" id="Tc__BpqH_3Rt0m-CoyQWx8NIw_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityTaxIdentificationNumber" id="Narr_qSuGNJlz40eV4iD0tqMsBA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressAddressLine1" id="Narr_Z_5A5VVqWEemGLPToLkgBw"><b style="font-size:8pt;font-weight:bold;">2 Snunit Street</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressAddressLine2" id="Narr_5mL_DlE1q0GnPl8Hl_6Dqg"><b style="font-size:8pt;font-weight:bold;">Science Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressAddressLine3" id="Narr_Dy0X4urIVEmX5KvThGueKg"><b style="font-size:8pt;font-weight:bold;">POB 455</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressCityOrTown" id="Narr_ywLXmF0Ji0eFchac5kj0MA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Carmiel</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressCountry" id="Narr_mgLAg9KKtkCP-hx6A9MxyA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Israel</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityAddressPostalZipCode" id="Tc_SVq1qiKkmE2s_XIFIg82lQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">2161401</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">+</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:CityAreaCode" id="Narr_2Pt2HHYa20m25KOHrekSFw"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">972-4</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">-</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:LocalPhoneNumber" id="Narr_NStUCrkwBEaAc5fP5EdcsA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">988-9488</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_i2fLSv_QK0G2g1kHs-KN7g_1_0"></a><a id="Tc_fPQDdTXGCkS60XyK3lF5mw_1_2"></a><a id="Tc_9ryTVa-OMU-Q0Hc870j0oA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:Security12bTitle" id="Tc_vXaDFNbXN0OBcVC8MNSxKA_2_0"><span style="font-size:8pt;">Common stock, par value $0.001 par value, </span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:TradingSymbol" id="Tc_YoWXzpXhk0-KncP9ghZdog_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:SecurityExchangeName" id="Tc_7v5Ez7celkOJrpQ0UnGouw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityCurrentReportingStatus" id="Narr_5qQ9gMDO3Eiv8KStcjonHA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityInteractiveDataCurrent" id="Narr_UCbrFH549E2OkJon3__81w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_l1j9hQmRykGpMlC-TPo2hg_1_0"></a><a id="Tc_XbeM3U4oQk2BmEX8-wWRng_1_1"></a><a id="Tc_uwm70wCAbkGroYwzHv1W6w_1_3"></a><a id="Tc_l_eQ3zBJaEOG6tUl8Fnw7Q_2_0"></a><a id="Tc_TNS7ChbCc0CkX9yzlnlT-w_2_1"></a><a id="Tc_v7AmFStAo0Sgvpuhy0bBNw_2_2"></a><a id="Tc_Sed2CZJjIUuBZRqOjGxuiw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityFilerCategory" id="Tc_84NN43IF1USN_gI6_GMSbw_1_2"><span style="font-size:8pt;">Accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntitySmallBusiness" id="Tc_ff_Py9lU7Uec8OtrcVZakg_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityEmergingGrowthCompany" id="Tc_BO4u_Dx8W0SLR4EiKIPI5g_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="dei:EntityShellCompany" id="Narr_On8gfe3QK0ukBhk8DeI0ZA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On October&#160;15, 2020, approximately <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_10_15_2020_ruhy-1MfX0uWd0p6iXkV2Q" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_n6iUjCoSlEyAt6LdMmc1ag">33,336,709</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca812b1b_617e_4274_8dde_577dcf1a0c06"></a></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets (Unaudited) &#8211;As of September&#160;30, 2020 and December&#160;31, 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations (Unaudited) &#8211;For the Nine and Three Months Ended September&#160;30, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2020 and 2019</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211;For the Nine Months Ended September&#160;30, 2020 and 2019</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_3aae51b8_2efb_4879_a380_f0153560fa49"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_P9_EcQLdQEGWjJMMZwwJPQ_1_2"></a><a id="Tc_zWpAgbY9WUazIuOkRdVtCw_1_5"></a><a id="Tc_OHjhBmABUkKvC5xIaLUVow_3_0"></a><a id="Tc_-Esmd1sHD0aLveetKwhg5g_5_0"></a><a id="Tc_AeJOtrnHfE6XMl2bNhxyow_6_0"></a><a id="Tc_NUMVv5Y9HkOGpPRPDy_Mtg_6_2"></a><a id="Tc_xtila2dGHUiWVLBJDb9JRw_6_5"></a><a id="Tc_voHMfLxNtUid0fMHyx9qdA_7_0"></a><a id="Tc_-zVjKM-nREakVUs-g8Ot0w_7_6"></a><a id="Tc_42m1p2sCBEWcj8FNV_gEBQ_8_0"></a><a id="Tc_14k8bqjG2kWf0rYy9MQmDg_9_0"></a><a id="Tc_8NB-0L4CvEOddyEpXWxVSg_10_0"></a><a id="Tc_cSNR-GFg2UOzNm1GwCPGmg_11_0"></a><a id="Tc_8_PYT0GGYE-9HQbdCs8llg_11_2"></a><a id="Tc_HifEAx9tV0GvqYN0fnuqZw_11_5"></a><a id="Tc_bh_Y_x6ljE2394R3-wRpGQ_13_0"></a><a id="Tc_QaHCwgBLLEqZXhWqplNa4Q_14_0"></a><a id="Tc_DTk7bnrkyEiqIbL0w0kqJg_14_5"></a><a id="Tc__iEktlKdMUOVWROpHl_fDw_15_0"></a><a id="Tc_1oP3lWI4_kC-U7IEaGRJoA_16_0"></a><a id="Tc_pAmrzB0IX0aKoFXPrvg5WQ_17_0"></a><a id="Tc_Z0Hv9LklhE6v7s2WdIXJ2w_17_2"></a><a id="Tc_2pBghRUrwUekzvrqaOAxvQ_17_5"></a><a id="Tc_pK4lUpPrDkamGOQJdv4abw_18_0"></a><a id="Tc_9QnrloJcl0ij9En0O68Z4g_18_2"></a><a id="Tc_jOZgc1bo-UapdN37Sk8bfw_18_5"></a><a id="Tc_UTKiJkXylEOR-VefOQkhMQ_20_0"></a><a id="Tc_rR8ub3EQR0eCW6PGzb9g2w_22_0"></a><a id="Tc_5WskZb3A3027aKSLALjkvA_23_0"></a><a id="Tc_Ag6Hb3eqm0qu09deOfoAfA_24_0"></a><a id="Tc_dTDYGef2-UqkAi3YelaW6A_24_2"></a><a id="Tc_H1lvyVi23EqYAcEUIqlT0Q_24_5"></a><a id="Tc_PzPHqlFdgk2yoAp4REkc3g_25_0"></a><a id="Tc_xBmPmV3oCEiLO6vFKccjjQ_26_0"></a><a id="Tc_3SdKKt3hk0KMnmjGc5KgeA_27_0"></a><a id="Tc_Rq4Amx2Z-0Wa_fAQ2_jNzQ_28_0"></a><a id="Tc_cEo0uAFtJUmSxPKqD3m3KQ_29_0"></a><a id="Tc_QxqxjRj0q06-RdZ3FJqkUg_29_2"></a><a id="Tc_irismov33k2uCxKLmu7qyQ_29_5"></a><a id="Tc_bee4BIYq3kucevCl4vLfTA_31_0"></a><a id="Tc_-L7szrl2jkK6Q63RkiJwIg_32_0"></a><a id="Tc_kPQzSm9eMkmn5rMZniWbUQ_32_2"></a><a id="Tc_LKZEvzT6lkqIPBBMMOVDhw_32_5"></a><a id="Tc_CI2XaacS6ECujI3AxRjKig_33_0"></a><a id="Tc_kt4kmkX0J0mTENdDDc9NWg_34_0"></a><a id="Tc_uF-AROXWjEGEq0mj5MOLHA_35_0"></a><a id="Tc_jNT54W7rrUi-gmVfHGnYhA_36_0"></a><a id="Tc_uG_vxxNMykGDyQqwrGVoKw_37_0"></a><a id="Tc_Ru0DLrewPU-cS0R6If4NFg_37_2"></a><a id="Tc_OKUcqtBYdkSaNV-MXs46kw_37_5"></a><a id="Tc_Ea7mmEBHa0mblJoWVOExLg_38_0"></a><a id="Tc_ZX0C6PL5JUCcsHU3PLaJiw_38_2"></a><a id="Tc_EvUWvoFIJ0GATFOFuqzLGw_38_5"></a><a id="Tc_U3WOX4ipHkKKk0k3oHHNGA_40_0"></a><a id="Tc_5K3BeWG6Y0SzCIc7KrtRRA_42_0"></a><a id="Tc_gZe-PDQDrUqXq8vVE8sHQA_43_0"></a><a id="Tc_9RNd5Nr9jE2CINiQzKXrTQ_43_2"></a><a id="Tc_WlQ0MqYlKkSxPBLr88PH1Q_43_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LoqexGX04k-8dqS7UHEJwA_6_3">13,533</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_L9vCM8v3rkmEGI3eeplQRQ_6_6">17,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_pKE0NzJlnk6xV030DwNvVw_7_3">27,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_8Y0vRkpN1EixkwC8UtSO8g_8_3">3,146</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc__KgX0KrkZkW3bxhFhNrZyQ_8_6">4,700</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_ZMdGPKqyj0y13Eu4uALn8A_9_3">2,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_lEmTuJHUSkyCRGiHuEKh1g_9_6">1,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_0m9mNqnKYU269u3rCkJFbw_10_3">13,281</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_RTlDA6mvk0WEkP5JR43OcQ_10_6">8,155</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_DqBDn3kKZkqkV79f3uctoQ_11_3">60,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_VLAz9hvETEOKgT4Ri_mFvg_11_6">32,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_BkgbjyUdk0ycbXe7EvpFVQ_14_3">1,639</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_kIN4cRqPeUOYX53pVOIXbQ_14_6">1,963</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_GJZxr66KtEWjo7tPE58k4Q_15_3">4,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_FmvOIwiBgE6uSI6i1huyfQ_15_6">5,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_yWSY-Uf01EKGhvmQPMpJVQ_16_3">5,700</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_IBYsboH-F06rW-NwvPKVDg_16_6">5,677</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_9QCdlmk4RkWelM8K0qlLEQ_17_3">11,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_Ac_e_wVHNEO9SBfiYPop4A_17_6">12,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_iqtBukd_wUOlwl60ByDRYQ_18_3">72,310</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_cymuoKOYzU6-kHM2cX4JvA_18_6">45,392</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_ZqeNROjdpUa-bRQFnUoV0g_24_3">8,351</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_C18akNK0fkWUsJjCcAyKmw_24_6">6,495</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_d4kYEdG5l0WovMa-6LNOFg_25_3">13,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_Rmf-XMRlJ0eE4muYQXFc9Q_25_6">11,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_D8wb5mIaPECPa1BVAqwilg_26_3">1,176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_HCnB2Jy07Uqanw8sKZsGow_26_6">1,139</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_xRYdYfsCg0-wbn-RuqjW5A_27_3">16,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_G91iDCAza0ybUsNt8IxElA_27_6">16,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_uov9kIss1kOtGxS8zfS6nw_28_3">4,301</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_ZGzw_D15mEiCj3on5Zkppg_28_6">4,301</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_l2fMhG2pSUyHdChq7yo0ug_29_3">43,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_0aEGD7yu20-WWmf22Ppm2w_29_6">40,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_aCj8F70rd0yLGDAR3gWKhA_32_3">53,505</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_NO94G4pgH0iN-TyN3I4Elg_32_6">50,957</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_rmexSZh4w02G1iUlFY-vUA_33_3">1,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_1ChgIa9QoEquLP5pN2z9vQ_33_6">16,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_g0rOF2WkQE-8EqMcW2nJMA_34_3">2,088</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_YDL92BlNzkaxBvOgbRgEeA_34_6">2,565</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_HbHYlM9dRE28gApriGAZ9Q_35_3">4,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_esQjipZoYU2MhxtWL-VpYg_35_6">4,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_w9iQlHLoeEy7Q7ydA8126g_36_3">46</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_cXiL53R2QE-FuUhaJ8M48Q_36_6">509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_E-RFqBngVU-5-8DTXZLPNw_37_3">61,730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_04YdR1VC1UuaKrY87AK8qw_37_6">75,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc__svow_mJlU2QBrRx_BXSEQ_38_3">105,625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_xzazQEkPJE2e7dPqPjUiQA_38_6">115,714</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pctpvkvXY0quFzYhXcTk4w_42_3">33,315</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__2hVDcVam0OU79NEvGVGpw_42_6">70,322</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_cAW8KcrNxEuyghIten2okw_43_3">72,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_dt_F6MTKCUWr5ujueRwMsg_43_6">45,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_23a73f13_b26e_4f4c_b9e1_4a4408f46bce"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_BxB8t3w0BUSkWWb-QEJC_w_1_2"></a><a id="Tc_6qU-7NDt1k6gT8ctxC0QHw_1_8"></a><a id="Tc_KuCfQytk7EOH9B2fIKmP7Q_2_2"></a><a id="Tc_tqZq5U7hlUWX354NPCU9eQ_2_5"></a><a id="Tc_qaE4Br1OLUqQl80TgnNrMA_2_8"></a><a id="Tc_glQ2TemF2kKXcIvxTygidg_2_11"></a><a id="Tc_aPpYbOTt-UqsrHbDJ3Kqog_3_0"></a><a id="Tc_uhA_w23zzkGT6H0bzEkhHg_3_2"></a><a id="Tc_zphOkH3td0umxFYY3jUI_w_3_5"></a><a id="Tc_SEDXgGbAAkGY5Xr5aEjRKA_3_8"></a><a id="Tc_syrGsl-CEUu8kP5xpdZMtg_3_11"></a><a id="Tc_n5UVmWKsw0GdJ2f6PM7WSA_4_0"></a><a id="Tc_kqzlZJ-eWUeOy4uRX8NyTQ_5_0"></a><a id="Tc_AH3d7a4mKkiNv2_S56-ZxQ_6_0"></a><a id="Tc_2JDyDkxQ8EeUfw0RLbPiLA_7_0"></a><a id="Tc_IMox1NestU6jbYYSk3f0Vg_8_0"></a><a id="Tc_Dn2u3iRTT0WAjfB5Uirw7w_9_0"></a><a id="Tc_fjuPmM83Ak-B9t2-_BFPBQ_10_0"></a><a id="Tc_1w1zqBAzPEmt71lavyMuXA_11_0"></a><a id="Tc_yW9Yi1ub60iC9lEwyKxnbw_12_0"></a><a id="Tc_fXBHcvIGuEK2mroRAQgVgw_13_0"></a><a id="Tc_lTbcN_54SE6VTt5xhQeBIQ_13_2"></a><a id="Tc_nFB3IJBQskeKr-9SB6UFxw_13_5"></a><a id="Tc_mP_LAXxkCEyAMoMAi60DiQ_13_8"></a><a id="Tc_TdwGBBQE9U6h1SBDi1NBCQ_13_11"></a><a id="Tc_P9MPaHhvKEasQm5ZgaDkBA_14_0"></a><a id="Tc_SpSxYEyN1EOTMp0hoPyC0w_14_2"></a><a id="Tc_GAmv7cq8FEalHUz7k7w9PA_14_5"></a><a id="Tc_R6NyPkB8BUatXB631zkLbA_14_8"></a><a id="Tc_DmsGDPiXC0y6B5VGfTyHqw_14_11"></a><a id="Tc_pJwAy9aauESPHryehYpuhA_15_0"></a><a id="Tc_FHT8li4ShUmq00CxS2wl4A_16_0"></a><a id="Tc_URk1QKIgt0ufbVdR7voq4Q_17_0"></a><a id="_5c341acf_0615_47d7_ac7f_87d4a17ce9e7"></a><a id="Tc_DzOiH-20kkmxhal8z0U-FQ_17_2"></a><a id="Tc_Y5TLqTRxYk6dmvsE8Dqvig_17_5"></a><a id="Tc_Ic3eqXJafE2S-4YulCsZGw_17_8"></a><a id="Tc_T9dZbwqGt0iwqaA9UzI-Xw_17_11"></a><a id="Tc_brmH_5zgm0aHFdBe2Y9I6A_18_0"></a><a id="Tc_QLSvfiSG9U2JbxOUpzTs-A_18_2"></a><a id="Tc_i6Xcj41QnUKZvGJPNmsFIg_18_5"></a><a id="Tc_3lgNj-qMCES_uQ4TKbA67A_18_8"></a><a id="Tc_LFKI_z5QV0GnnpHxfKAyXQ_18_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_foIAy4-Om0yEnXbQveIz_w_3_3">11,975</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vUfcRHI4uUWoN_4F9Xe25Q_3_6">12,086</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_okYXxp9UpUmRkgl9piR4yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_I0RyE2sbwkmhyWpNiOC2OA_3_9">3,296</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_V4-yU8AA-0avjmtvGhaOeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_CPiSIbaOM02LB2PU-j5Ilw_3_12">5,126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_oiPABCvOH02cnmvNrJfkQQ_4_3">31,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_I8cmOpKBV0C7KCil6K2QpQ_4_6">24,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z72QeSjod0mfL9i7a-nY-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_CpQB3f_h_kSq9wQXj1fNig_4_9">7,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CsulLJ3GXEOV9Zoac507-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gK6t3BKDP0GvqXyqRx11Uw_4_12">9,122</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_4gIvhxfROk6iKHtyL4mNDA_5_3">43,403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_xdL7hLf0xUWuF6fI4wB5wA_5_6">36,934</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_jcNYUgMwxEuVx8i09CZDGQ_5_9">10,790</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_lokpR_DYzE6FDNQg5cxVAw_5_12">14,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_zN9adkSrnUeKZolp586GHA_6_3">8,121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_5wgF2n7pMU2iT1MetBWggg_6_6">7,945</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_WWkAMpOKX0q4qZaZQQZH9A_6_9">2,868</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_KZ2Rl4I3bkW9_a327Hejiw_6_12">3,205</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES, NET (1)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3">27,214</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6">35,021</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9">7,688</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12">10,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3">8,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_iBvrbfXZck-rpBcJGOChjw_8_6">6,885</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_EfV7eJncpE2tWe9AeHtcuA_8_9">2,816</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12">2,587</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_GvkYeenIvEumaBuhujdlsg_9_3">129</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_E65KzrZz7Umy-vlku2jm8w_9_6">12,917</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SKn1qe7CDUG37u794S_bNA_9_9">2,582</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_b0HTvWBllEuL1uGqWZ7BEw_9_12">1,544</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_L6d1cqtMIEeDygNXL4xBeQ_10_3">7,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_Tl4EyWQbzEOrM0iWzR6VaA_10_6">5,877</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_NyHELdJj90myT0-fqDPetg_10_9">1,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_LbNLgkWjIU-DT8SU796P0g_10_12">2,050</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Ekvpvvia_kGR31_ThHsAyA_11_3">359</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_xctQp-4KTUKP3qLNaPrEew_11_6">227</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_euFCHphoUEaMNBIQqAedsg_11_9">118</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_fkkHD4O8JUyb4CNaA5vhUA_11_12">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES - NET</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_8YgF4ivIxkGTz6Vrqm9BUg_12_3">6,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_g2JxUdYVeUeA__iwBhicTg_12_6">5,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_oFjbOmx_Tkapay6FK7Zrgg_12_9">1,855</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_0wqGKsCtF0i57zfGQKig1w_12_12">2,016</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-Tdy2p8VYUWSjJjMP2foTQ_13_3">6,920</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_S-HQkkkU4k-DvRFQ0WZu_A_13_6">18,567</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_W-9jny0JyEKqWtBN98uByw_13_9">4,437</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ngmWNXoIpEWV9IFZJuOA4w_13_12">3,560</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS PER SHARE OF COMMON STOCK-BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_AxcstOaPWUKuPZV9qgj27A_14_3">0.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_aHQuyy2UyE6jpBFfvoM2Pw_14_6">1.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_dyly7YG_UU-xmkeUFSbM0Q_14_9">0.14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc__o9M78edu0Ci5uZOu1KUMw_14_12">0.24</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_66pRkI1G30qe_jiSJmT4Vw_16_3">27,758,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_tganHjo-fkyQY6Qru97S5A_16_6">14,838,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_fi7iNumVdE2ihL84ZZz6lw_16_9">32,863,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_6y5hMo-TdUyx1uWp4FQkyQ_16_12">14,838,213</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) </b><b style="font-size:8pt;font-weight:bold;">Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZdfRPnCjeEyvM5HwjCNBXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_LF8Y-hPBFUex_AzWIJ1hrg_17_3">635</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oKcfDa3A0kGpkbFODB1jxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vk_2031rKE-_-u1IPaHs9Q_17_6">426</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ze7kHfT6mkKY6nmLl1bpUQ_17_9">562</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uoOZj9fvI0O5KtUKJ2QUVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gq6tGM-wT06tJAW5hYWOuw_17_12">110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_pRcDTGYiEECDc0dojMQDWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nNDmVVcbK0qi4Jutikp1BA_18_3">1,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e1_nZMaTIE-COHRAayOIMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tWsCZ5M3x0SWoBpLSo-9dw_18_6">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hXjv6Jrv6kedC9tuTT8GcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2YMIJqqNrUSXu68t-bL3mQ_18_9">852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4MopdnOnJEGxDhBhT6bjmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Re1b12ul5UOsTIYDrTO5zQ_18_12">86</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e2c2d562_5401_4cf2_ada4_cb0c68fed21e"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CAPITAL DEFICIENCY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_Z0iDWZbUo0CtvFmfKO6vTQ_1_7"></a><a id="Tc_VWz4oubGrUC5-AQkwfN7tw_2_2"></a><a id="Tc_BnDi5lmVfUaB-ytnZpHGXw_2_4"></a><a id="Tc_I82KMGQ_jEOeMEP1_cPUAw_2_7"></a><a id="Tc_baXq1uZ-O0GXuTwpKimRaA_2_10"></a><a id="Tc_WryIG3PK2EWcQwt9n3nCLg_3_2"></a><a id="Tc_yCGdaYWw9kOJqbL_NJS9HA_3_4"></a><a id="Tc_nQ8AHIzB3Uq-Zs7oug27NQ_3_7"></a><a id="Tc_J182fkkSeU6bB_v6XQXMvg_3_10"></a><a id="Tc_2-e7oXeZDkiXMy7lDyQXtg_3_13"></a><a id="Tc_q8cpNjWHCUqGv4oKF7onOw_4_2"></a><a id="Tc_mmXz8u-Fw0y6xm_gPsZeZQ_5_2"></a><a id="Tc_4cDA9p8PckaYtgOLkrALXw_5_4"></a><a id="Tc_lsdLK0EblkeZqfO-IHQtvw_6_0"></a><a id="Tc_Gopklq71vkia5kwQdV3GuQ_6_4"></a><a id="Tc_YkKt0MWIQEGwS0InhCCPmQ_6_7"></a><a id="Tc_j1Wqbt8aM02LDAJQ30S50A_6_10"></a><a id="Tc_WUjKLcrNv0C7rbcYb0GE6g_6_13"></a><a id="Tc_x0CjnMPCDkmrKLgfVXMhWA_7_0"></a><a id="Tc_ZH5DgN8Af06ZIKqk0Dg8NA_8_0"></a><a id="Tc_ygDl0fS0AEGbgX_8dtk-zQ_9_0"></a><a id="Tc_6wD1B2DbkE-6gl_fUr37FQ_10_0"></a><a id="Tc_Cauf-2ZQrUmFN73-iUK9wA_10_4"></a><a id="Tc_NYJ7oPdf60-JCVuWeHdq8w_10_7"></a><a id="Tc_YGGllOMAGESoLnKwuA5QZg_10_10"></a><a id="Tc_J0XL-pgtuEiXumefH9dnmw_10_13"></a><a id="Tc_wU6krTHMJ0qDs5qOqj-l6A_11_0"></a><a id="Tc_NM0k6XVxPE2Qbv7V0rCbCg_11_4"></a><a id="Tc_JpDlkglPSEOUDStrIX5f5Q_11_7"></a><a id="Tc_FMWQOlB6kUuFOPHtnTt9Qg_11_10"></a><a id="Tc_nQRu-qSBUk2VYO3ymiJVig_11_13"></a><a id="Tc_L16QlFa1G0S1JbhBg8EaRQ_12_0"></a><a id="Tc_CUs7j9161kmvB5Xol6TCVw_13_0"></a><a id="Tc_kd4SlR4Ky0ORbSh_hROneg_14_0"></a><a id="Tc_tmA3ZjzOZ0esI3pUtdVZEg_15_0"></a><a id="Tc_1pbCodjZ_0OSkkvAiyTv3Q_16_0"></a><a id="Tc_06QXG2GDYUOB-Qi5KV_6DA_16_6"></a><a id="Tc_Iqx5pFjx-kOixSwBEEv6Tw_17_0"></a><a id="Tc_629AYtKySUmB1gczMDmaWQ_18_0"></a><a id="Tc_ALdUufPtfkypxPFCkfGM4w_18_4"></a><a id="Tc_aGfIDORox0OgHLYCwrEIuQ_18_7"></a><a id="Tc_D6qcZmOGdU24tLmPzT9eTw_18_10"></a><a id="Tc_-VBPchZ0MEihNDTayLX2mQ_18_13"></a><a id="Tc_Cu_N2hUAxkexG4rzEvqmmQ_19_0"></a><a id="Tc_kR-ZOofDPEyr3a42zGsqNg_19_4"></a><a id="Tc_-_NvNRYxNkOmW1rTmoXpiQ_19_7"></a><a id="Tc_AxsqrVyUrEm5mhSD4hZJGQ_19_10"></a><a id="Tc_id59FjAXc0WMj_J8fT-BWA_19_13"></a><a id="Tc_dnCGkwi8LEy6kWCh2yd-XQ_20_0"></a><a id="Tc_-_OwE_iR7EKtOeWAlkI3qQ_21_0"></a><a id="Tc_lS8RXi3lVkyaZNR4V_d6qA_22_0"></a><a id="Tc_KkIQwx5CR0eFVBR5hjWJsQ_23_0"></a><a id="Tc_KPfXHzH4qEeiQsMqzHhyIQ_23_4"></a><a id="Tc_URsZLwQ5nEaaR3ATZ0kAmw_23_7"></a><a id="Tc_d8-qTbVHBkSTekFuG_mh2g_23_10"></a><a id="Tc_GNLooQlmhUasbGTYAiHXPg_23_13"></a><a id="Tc_e8p1bKptuEKwljGb8G0VmQ_24_0"></a><a id="Tc_T9P3rvfCmEmjuh3HrX-jYA_24_4"></a><a id="Tc_isWgMTOgi0eicb7zKTU2Lw_24_7"></a><a id="Tc_Dc8U1ibc_UueHy2qahxrHg_24_10"></a><a id="Tc_HOeFN_UxfU2BaKDzKqKxAQ_24_13"></a><a id="Tc_XtFtUUpN8km6O93pK7HYLA_25_0"></a><a id="Tc_LElaPD36dEq8rdbfJaR_bA_26_0"></a><a id="Tc_fd1EoIAWo0ezdGs0c9zfvA_27_0"></a><a id="Tc_Mb3q1RM770KT3lCePcDNGQ_28_0"></a><a id="Tc_vCWTnNO920S0OuwJCdF4jg_29_0"></a><a id="Tc_q83K4DebuUCrKQEY9o6uWg_29_6"></a><a id="Tc_X7astkM51EiScD3GEG3XIw_30_0"></a><a id="Tc_tCmOEZxazkavfOT6Qwd2gw_31_0"></a><a id="Tc_5UA9GHiKCUuqSsErQ5jlcQ_31_4"></a><a id="Tc_vJZtSlSLtk2N0kC5DwbTFg_31_7"></a><a id="Tc_qFIBdP6Tqk6S9jQcq1TYvg_31_10"></a><a id="Tc_O2AIVGRciUSmG5n3WbpWzQ_31_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Z0C-RXLin0u-6-F5E72_fw_6_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VanHg4cgLUCj7TMbwVJ81Q_6_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fK7QWqX6s0q9WkkFwHaS9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CljsXcc4MEuFFt-iWbd_vw_6_8">269,657</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yB5LZFDEhEyvveEfDJ5-QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BLksiTkHvUuQS3jyVOnPFA_6_11">322,553</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gTH5W_4IvUChPRqx9UczOA_6_14">52,881</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2019:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kM2vCYwSV0uRlWIJmg2-4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_OYkjckgCs0abp4DtakyrFQ_8_8">599</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_SmPUZf0K5UaHbyFp12jJVw_8_14">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZNbuEF-wWkuGqpCEaHk7nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-5EgfHdIyUKEpOFZDdaU1A_9_11">18,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6aPKzBMsz0u1VllLhFQSVA_9_14">18,567</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cpbzx5G29EOxO_uDaWcaMg_10_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TmvBahuVZ0-V-ulZGMBsXw_10_8">270,256</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ik2gFmrr0kWpWKTAC6G9_Q_10_11">341,120</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_iWjLXcVBNk-ZtLCcnzL4JQ_10_14">70,849</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tfspJqT66EKnDINCQoQffw_11_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rNDZG8xgrkK9Eqv3ngpLpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yU2ZGj3RG0anG2tYMhq9zQ_11_8">270,492</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8HscStIMCky71Xpz36-FCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__MfxwZz2nUaeomGlVlckSQ_11_11">340,829</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FGKu7XnBJUybUWoGfuKVCQ_11_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2020:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q" decimals="0" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_xRzNdpnGEk-71eO8pSDPbw_13_2">17,604,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_Yz_Sy5LAkUW4T--LMyBJCQ_13_5">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_YR2WzZ17vUKarr9Yylg1Ig_13_8">41,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_NJRMGAs-pkGFi9UGtqaFyQ_13_14">41,343</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Jun5lBXS4EGh5jaxTY7qDA_14_8">1,607</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_QnpZyYOE6ky40Hb4zInUqw_14_14">1,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2">694,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_x_claHpmdkCTnJvo-D4ogQ_15_8">505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_8lIVt50MukqMWtsq7YIlFw_15_14">505</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2">200,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_fdqN9TISAUiRcT_TuCG2kA_16_8">472</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_Ub1Bw4_a6UarBS8OdnPI9g_16_14">472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VCj1F6qAZEeCpBg6hY-teg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_l9IjhXAAhkaVKv1PhOlUwQ_17_11">6,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s6DMSFeetkmXfGaPmn09Bw_17_14">6,920</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_B85fPue9QEOekGI75LcOcw_18_2">33,336,709</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ecK5SVmXt0W0MNJ7_OydIw_18_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LtmZTOVAPke1_QOvSIgR9g_18_8">314,401</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wUdjZ3D2m0SOo7mo_n_Pcw_18_11">347,749</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_khQlbynj0kGZt-1AW-sxPg_18_14">33,315</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MHyXaM8T3keaaLV7CeaaUw_19_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cr_aPjmKT0mYjDg02J2Z7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Z9s73ZwURkKlS1F9oVPuCw_19_8">270,060</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AHiYkPc4FUK56R6zTg4LjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_eQQSKmKflkWfoWAueSx3bQ_19_11">337,560</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2019_fef2AszHPU-bAj2nZEQDdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tTsPeLcPZUynuXGFyLT71w_19_14">67,485</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2019:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__Df5EeyoJU2aHMqKSUD2rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_KSTzrJMPm0egfMd7MObdBg_21_8">196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_uPgYQfHCF0O9gGHNlfIgPQ_21_14">196</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sfvdWUnu6EO7cndkxiekuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wIgPu60xyEu4VuI-LlvMTw_22_11">3,560</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1R44scdbcEC7Pp34wbzFsA_22_14">3,560</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fG1tiMvqrECpXEN-jM4bqw_23_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LK01RUXc2ECb97tuBwx34A_23_8">270,256</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kpmNXgqKcUC0xJT7IctToQ_23_11">341,120</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HWobNa4P0UmgZWq7a8VF4A_23_14">70,849</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_JkhJ73vHckieh1cGPG-l9g_24_2">32,442,636</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Yc87nQKkTkeC_Y4n72BNJA_24_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O6L8OVTlsEu_2HaEKKHaow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qJlvL3spA0SN4n1CAMfDfg_24_8">308,515</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IRzIhsYvXUKaSF2OewJ56A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YFPyg6m80Uau30g3EK1x_Q_24_11">343,312</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UHg5AhBO8kuPyoS3mXK0kw_24_14">34,764</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note receivable payment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_COBB3OZxdkK7p_IboKFQ1A_26_8">4,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_xii5ZmbQOEy5Pgx9Yl1Uew_26_14">4,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_GUAzeJKrn0GFbfBaqwgM1Q_27_8">909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wVWzgX_YkEycxvNrHIOQbw_27_14">909</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_qRD60oHS9UGoDx0QmtTcbA_28_2">694,073</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_LsqT8XcLHE-_GUMIsa5cTA_28_8">505</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_TWIy7vb1ckCo9JvgY6ezlw_28_14">505</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_uCF6OpzVOESfzoWciB-tWw_29_8">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_cGcMr92IokKadz2O9dP4iw_29_14">472</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vbfxSpJnx0SCEmInPOXG3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ykyMRT9naEmcDEaneaMbxQ_30_11">4,437</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_LZe2ipUW7UidTv66v35_Gw_30_14">4,437</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zELekXqrakWfZkOwtmNM4Q_31_2">33,336,709</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GPUyJ_0VE06wpayrv6c2eQ_31_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_07h0EtapsUm0xFDL4FpqaA_31_8">314,401</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Gnd1Rl95vE64ClQKNvUMzw_31_11">347,749</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1cnDOKq6VU-tyXDPUviUJQ_31_14">33,315</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">*    Represents an amount less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_svRVGqUFx0GqtCx3CCW_Nw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_vXSG5WYpUkaVtKuyw89i9w">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September 30, 2020 and 2019 - <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_5c_5IplAKEOrBMfFEWopkg">120,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_B8IPN6b6T0SHfRaCNRWQ-g">350,000,000</ix:nonFraction>, respectively.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_894606c5_4cc6_4bc9_aa30_c04c7abb3057"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_mEUGLJo9tESwuar8uF24Cg_1_2"></a><a id="Tc_UqC8Gdp4oUe4q6QWqeqRrg_2_2"></a><a id="Tc_yNh5YxRXGUWI7RG26otbmQ_2_5"></a><a id="Tc_pHowiQXHGkuF4Nqzko7SXw_3_0"></a><a id="Tc_16r6sJyMokiZMuwMVON_HQ_4_0"></a><a id="Tc_qeZ54ykAtUOzBeny51Xt4A_4_2"></a><a id="Tc_JQW4CW46aEeS6fzNuscYQQ_4_5"></a><a id="Tc_oI7wuzcr2kW0AijRoaIxlg_5_0"></a><a id="Tc_JpL0zmPOvEyHOygyqxVNrQ_6_0"></a><a id="Tc_lZ46BueCrUCMAU0p0YAv7w_7_0"></a><a id="Tc_cvOLevDd6UKgmCCmEhTVPg_8_0"></a><a id="Tc_Wo65M-jMTEW895XeZWg8nA_9_0"></a><a id="Tc_fvugMSOoP0Cf0oSia55X2w_10_0"></a><a id="Tc_IJr7RsF_k0mqOnbf05W3Sw_10_6"></a><a id="Tc_zWtlNaGQAkCEdQ-q3VivJQ_11_0"></a><a id="Tc_7eVP1lZjKUqxiSEMvFRtbg_12_0"></a><a id="Tc_OS572XnoMkCVVjolYXbEhw_13_0"></a><a id="Tc_IY5yoSkxvEy0dSjMxPZCVQ_14_0"></a><a id="Tc_fkjjgCbHGkG_8HiKn69_GA_15_0"></a><a id="Tc_mUAb2qljWEywhZ9EuveW-Q_16_0"></a><a id="Tc_Vy4s1CYWPEGlsXdEqFwbmA_17_0"></a><a id="Tc_XwJP5BHCnEex08Zs8_cIDg_18_0"></a><a id="Tc_6oRIOc0LOk6QP8PvoT8W9g_19_0"></a><a id="Tc_qcw-9YpEIU67WrRCmo_hFw_19_2"></a><a id="Tc_e9Rsko4qtUyKOJs-dOCfkg_19_5"></a><a id="Tc_rGGN8w4Bv0iCfdUZHaf5fg_21_0"></a><a id="Tc_aPU3OIr15UGzIcIHMA9lfA_22_0"></a><a id="Tc_DELhnUDwNUWPLsciCJE2JA_22_2"></a><a id="Tc_Tx0YgOuMaU-wbFJ_wjaxWA_22_5"></a><a id="Tc_MP9BPKgV9Eaa0aPUiOIRuw_22_6"></a><a id="Tc_EBcHSBXo9UK0-lfSkEqmNQ_23_0"></a><a id="Tc_8rT-Hbgoh0OeVrz84mnCRg_24_0"></a><a id="Tc_5uO6vm4YyE2B1f8WIs5TAQ_25_0"></a><a id="Tc_37eK9I-AJU6Ky3V20bEGsA_26_0"></a><a id="Tc_trV-NUNl8Ue8NM6Ee3zVBg_26_2"></a><a id="Tc_-oJtulREPkmGXOHMcng5hA_26_5"></a><a id="Tc_SttkM4uesEqC8sRrjtcC_Q_28_0"></a><a id="Tc_6j725_VK7kyxGNWoWV6Qqg_29_0"></a><a id="Tc_gFefBMjlvEyBWzQmZt3FBQ_29_2"></a><a id="Tc_sk1VVSGsCUeM9MXsdWz0hg_29_5"></a><a id="Tc_iV0_iWCqq0e_IgqpDBSkkA_29_6"></a><a id="Tc_TaMeX2zjtEm4RZpl5pwlRA_30_0"></a><a id="Tc_Q3z3HjKbMka1eEvN5vtuyg_31_0"></a><a id="Tc_UYp29BQYgkKGvIsbVMEDGA_31_2"></a><a id="Tc_uucS53DHBUCmbdtnzZyvAQ_31_5"></a><a id="Tc_bXZHQMfoJUOkjGJx36rIZg_31_6"></a><a id="Tc_YqzbYc1CmUi_idqd0TEnGQ_32_0"></a><a id="Tc_PP5PahAWfkOinsEgvTGmcw_32_2"></a><a id="Tc__nG30DCu60CnrZqD1_M1HQ_32_5"></a><a id="Tc_pVMSlN7zZ0iGXml4MNASMQ_33_0"></a><a id="Tc_dYsiHgJjFU6Mrz_V_0TuiA_34_0"></a><a id="Tc_-Oy_sv-8w0KeMivoq_aPQQ_35_0"></a><a id="Tc_S7dMVfHQCU-akB4bSbjinQ_35_2"></a><a id="Tc_e0smqa0UKE6MdbuBBzVgJw_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_41zTmw1fskOzX3hkAE0U5g_4_3">6,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_djED8GJyw0SsJ1u6ADcsFg_4_6">18,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4OzFf5kMZkqd_Opjw7BXtw_6_3">2,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_u2-vS8Pu2kC0sJxUbq9NnA_6_6">599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc__Uw3e_uxI0S-jmhCgxjCyQ_7_3">1,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_IASUgUTf9EaAaJ_gKKW1ig_7_6">1,205</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial expenses (income), net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_4oBFMafwwESZMDNMda__9A_8_3">284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_1z7yk2KmHUKdJA7BMjKmHQ_8_6">371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_Iu5npIead0K2QxIHUwqPWg_9_3">488</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_YSAE1CrB50eVy0FtE1xRuw_9_6">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Gain on amounts funded in respect of employee rights upon retirement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_8QsFsZAo90-0wzM8Gs2AGg_10_3">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_1mLdQzQuKUy9fMwhYxuJdg_11_3">2,548</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="Tc_QCwBW7B0Q0CN45voGOVTeQ_11_6">2,197</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability (including non-current portion)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_7wik-QUxBECIlTxYt9fQDg_13_3">15,062</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_iSOrLTwrdE2y0NFlkyNSZw_13_6">2,697</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_ytIKi6VjQUqncyiaK1iJ6g_14_3">783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_D-Z7jzpNakeHxYQYp7pysQ_14_6">4,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_SLIOGO3FKUCTRqkoQIaH8A_15_3">53</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_eUiUPxXFuUqJxge0DQv55Q_15_6">92</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_L2HA8x0wc0-MclSzE8mWUQ_16_3">5,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_o_M2_o13FUmruNQLJNLu5w_16_6">1,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts payable and accruals</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_Udfz0uXozkevz3sooIJrZQ_17_3">3,291</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_XnN1s6fNt0uTT_55WDA9-A_17_6">4,905</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_p_hIku6gnE25L4dwgxCs4w_18_3">463</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_KhOGwwVQNEq9ToLDTXM4wg_18_6">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_6bFk8MoNzU6_USWFLTLWjA_19_3">18,556</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Gmc7hQ6qr06RbQFeRlUpNg_19_6">15,671</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Increase in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_a8RNvTm8Kk24qCrINj2jbw_22_3">27,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_FW-_8ITToUiDY4IBDbSTYg_23_3">380</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc__GGwgxmZ5ke8Wdl2-03Y7Q_23_6">599</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Increase in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" scale="3" id="Tc_H2Y-Xp7toEu4zcOyM9CBMw_24_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" scale="3" id="Tc_i-DwASesbUyN6fb2uFBTlA_24_6">254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_lalD5ehRwE2dhmZsu___Xg_25_3">340</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_OYypA_lQoEeHFD8wYCGkRg_25_6">59</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_e_iw5IwQFk6KO9-TJtK8NA_26_3">27,544</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_gtWTPdRi8UaHNKO7W2Vy-g_26_6">912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_XiIQRNJjPkiHMzsafiITGQ_29_3">41,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_M9_lYTPCgUmfrEX4luFLkw_30_3">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_gJ1Jlq8JNEqKCf9BG7bnUg_31_3">41,815</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_fpyJd6_rqk2LmDfutbVw_w_32_3">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_b0ceMmiKpUChMoIQjWzUGg_32_6">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DECREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_NprPkzrkCE6o6SAPfYEi9Q_33_3">4,259</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_FkbAqqgQ-0iBEwoMwy0VTQ_33_6">16,366</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LDIXTvdPZUuXeShp5Bon3Q_34_3">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_0YusTHrbMEuTFWfHfTUY-w_34_6">37,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_-T7L7-soYkaH8ioW0mN3BQ_35_3">13,533</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_EbFSw2Zgi0iu_NsiOH9b1w_35_6">21,442</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_N1UKdlzAjEC0NjU808-boA_1_2"></a><a id="Tc_gqmasr0mO0OejddcYS1Ztw_2_2"></a><a id="Tc_I5VWduqpjkWLvrrbELYGxw_2_5"></a><a id="Tc_SlUm4iVEbUuZ-bxXuRhP2w_3_0"></a><a id="Tc_Th-LAHaRVUOHilNUOK66GQ_4_0"></a><a id="Tc_h1janFQNOEKOL_feDs15_g_4_2"></a><a id="Tc_NCV7KfaZXEi_Vgq3iarWxw_4_5"></a><a id="Tc_43zta-1dmkSHGL4hBW-BJA_5_0"></a><a id="Tc__sbuTEDQGkefWxogk1uU6Q_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_m5ZNew9e1kWabTN2Kt_Osw_4_3">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_bFYP-_FcL0S8LK5MbwvtwA_4_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_XyeeNZtwpUWUIGvwI9aFNQ_5_3">564</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_FhGK74rtfU-b5wVE3sRfGQ" continuedAt="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A biologics license application (BLA) PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway. On August&#160;11, 2020, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that the FDA had accepted the BLA and granted Priority Review designation for PRX-102 for the proposed treatment of adult patients with Fabry disease. The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application. The FDA set an action date of January&#160;27, 2021, under the Prescription Drug User Fee Act (PDUFA). The FDA advised that it will have to inspect the Company&#8217;s manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#8217;s review of the BLA application. Due to COVID-19 related FDA travel restrictions, the FDA has advised that it may be unable to conduct the inspections prior to the PDUFA date. The Company, together with Chiesi, is in active dialogue with the FDA and have submitted a request to the FDA for a Type A meeting to seek resolution on the issue of the pre-license inspections of the two manufacturing facilities. The Company anticipates an FDA response to this request in the first week of November 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(1)</span></span>alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(2)</span></span>OPRX-106, the Company&#8217;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(3)</span></span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;1, 2020, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_NLt0-efPfky_nzLBvyGDpw" decimals="-6" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_MhskqdYfjkWDFBYrjkFRtw">30</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont1" continuedAt="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On March&#160;18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_fCJA1rzLN02ibBWH5y4U_A">17,604,423</ix:nonFraction> unregistered shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_x7j0FM0p8ke4V_F0plBPtw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), at a purchase price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues" scale="0" id="Narr_W8HWmAJQ90WUBTmOBpNi7Q">2.485</ix:nonFraction> and warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_IXV5_C3Iuk2By9DEcV2NOg">17,604,423</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_L2gbHhXXg0eOnSnL1-vkpw">2.36</ix:nonFraction> per share. The warrants are exercisable commencing <ix:nonNumeric contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ" format="ixt-sec:durwordsen" name="plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" id="Narr_KVxWDwqAbkaWdU_z4bKRjA"><span style="white-space:pre-wrap;">six months</span></ix:nonNumeric><span style="white-space:pre-wrap;"> following their issuance for a period of </span><ix:nonNumeric contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_ewRS_BEm9EaAEU9JHyxsZA"><span style="white-space:pre-wrap;">five years</span></ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms. The net proceeds generated from the private placement were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_3_18_2020_To_3_18_2020_uMfCJEZpY02sFvVTznIY5w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_PFchXNuH0kuyH0b1qQ1G-A">41.3</ix:nonFraction>&#160;million, after deducting advisory fees and other estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In October 2020, the Company collected total proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uJj9XUZ3jEK_nwNQ1ytYrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndCollectionOfReceivables" scale="6" id="Narr_h7y62ru37kqrheWEbVT0VA">2.7</ix:nonFraction>&#160;million from accounts receivable outstanding at September&#160;30, 2020; approximately $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ECNMuJ7DQkuqCfY-v0kl1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndCollectionOfReceivables" scale="6" id="Narr_DP9DahaUs0WCGJQislmnGA">0.9</ix:nonFraction>&#160;million in connection with its collaboration with Chiesi and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_m0iRbIUWmE-NwcxiFKbfxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndCollectionOfReceivables" scale="6" id="Narr_pRBTNsFaq0ul_LBenubIpw">1.8</ix:nonFraction>&#160;million from sales to Pfizer Inc. (&#8220;Pfizer&#8221;) under the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#8220;Pfizer Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_9qmHWis0RU-ArXdLHl_-Qw">25.0</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_2X7HaISLh0Kcb4gJc90IJw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">million</span></span> in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_4d9-GgfNFECbuO0ofwxfvA">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_nHC2E3bAnkmK0s8uHT6zgg">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_MC4C5PiOdke0mn8hLcGIXQ">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_dypEXHW3CUmacHmTaqAgeg">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_wuP_wsi0hkWGJcEjDVQNKg">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_hi5mMgnGHkiQDWsPoq8jaw">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PdUn1DLSjky-oL6yd58gsg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_M3CgzCb_E0GysNY1XeDJrw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_2bYIXNG5N0WSrA0hwUb6RQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_PLCUtGkzIEeyExSaO4Uihg">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6ofRVpdY5EC3THAh6MbRNQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_UWEIN-_j7Eezk1qlHfIlnw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Jv4KEHGwEEGDjCnT8dmZzw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_9tQIt6vdJkyOItUyxKoBiw">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_qPVNjr3QxkiUTyW7b-790A" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_oGxMvZnmP0eLxOqz8bRjPQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont2" continuedAt="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">The Company believes that its cash and cash equivalents and bank deposits as of September&#160;30, 2020 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, as of September&#160;30, 2020, there was outstanding an aggregate principal amount of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_J5OPXd3thE6NmJrMyIdlvQ">7.50</ix:nonFraction>% convertible secured promissory notes due November&#160;15, 2021 equal to $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="6" id="Narr_nb8yxJTp9E-tkGeYicVlgQ">57.9</ix:nonFraction>&#160;million (the &#8220;2021 Notes&#8221;), unless the notes are refinanced, restructured or converted before that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">The Company expects that by the maturity date of the 2021 Notes its cash and cash equivalents and short term deposits, combined with the cash the Company anticipates generating from the satisfaction of milestones under the Chiesi US Agreement and from its revenues, will be sufficient to satisfy the 2021 Notes payment. If, prior to the maturity date of the 2021 Notes, the Company will not have sufficient cash available to satisfy the full principal amount of the outstanding 2021 Notes, and to otherwise finance its future cash needs<span style="font-family:'Georgia';">,</span> management may pursue corporate collaborations, licensing or similar arrangements, public or private equity offerings, and/or debt financings or restructuring, sell shares under the Company&#39;s ATM Sales Agreement, and if necessary, may need to scale back operations, curtail or cease operations. Other than the ATM Sales Agreement, the Company does not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. There is no assurance that the Company will be successful in obtaining the level of financing needed for its operations.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_a6hNdviYGECzHBbEEJWjKA" continuedAt="Tb_a6hNdviYGECzHBbEEJWjKA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_oxYPhuyre0-bUjmPihpk1w">7,826,946</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_EDuw9HEbN064XasrKX00oA">21,405,733</ix:nonFraction> shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the nine months ended September&#160;30, 2019 and 2020, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_WMceEtAICESmHKEH62vPiA">7,854,729</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_n0uoSvH1dUm6m5iWSH1DAQ">26,905,842</ix:nonFraction> shares of Common Stock for the three months ended September&#160;30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of <ix:nonNumeric contextRef="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E7ojsykV9EKg72W5j6pVFQ" name="us-gaap:StockholdersEquityReverseStockSplit" id="Narr_0mkHvalS_EWuXARHeYYjxQ">one-for-ten</ix:nonNumeric>, effective as of December&#160;19, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont3" continuedAt="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont4"><ix:continuation id="Tb_a6hNdviYGECzHBbEEJWjKA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_7nLGZB21O06GEg47q6tpUg" continuedAt="Tb_7nLGZB21O06GEg47q6tpUg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January&#160;1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FhGK74rtfU-b5wVE3sRfGQ_cont4"><ix:continuation id="Tb_7nLGZB21O06GEg47q6tpUg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_KsafjKpmM061wt1A59LueA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January&#160;1, 2020, with no material impact on its consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_2B9EpLaw8UmKXqYUwgldWA_1_2"></a><a id="Tc_v8nzraSoTkW7zqzCJlUdsw_1_5"></a><a id="Tc_TCt2Pj-KSkqf3kY89gJodQ_2_0"></a><a id="Tc_AtgOIWGjrEuqAT_8EpVD-A_2_2"></a><a id="Tc_n_jR0OlWGkalJUYc3g7ZVA_2_5"></a><a id="Tc_bYin1lP7qkGZlbnN6eCQQA_3_0"></a><a id="Tc_eAc_LqmCiEW7ygegRrxvvw_3_2"></a><a id="Tc_XdVp19j7lUSd77JpYol1qg_3_5"></a><a id="Tc_sepjTI1AmUiMxZxFa4DhmQ_4_0"></a><a id="Tc_7jkTJyLzwUi1kVW8RR6h4A_5_0"></a><a id="Tc_IRzLwq4sYkacLQ3DTReWhQ_6_0"></a><a id="Tc_5dtrtUpTZ0KAakJbpWdhxw_6_2"></a><a id="Tc_7jJNmGmWM0WKdHtT7XE38Q_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_4K4Ajx3TAU-8oD6zDkcoZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_FbMsIfX1F0mNFwFXS68SgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at September&#160;30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_W6gjZTdBNUSnWvnQpqdlOg_3_3">3,941</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_eC4bFmdYdEi9li1EEPAnFQ_3_6">3,607</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_N4Dw0xep10Gbwija3y1y3w_4_3">2,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_cBIgL2Af50iu3v5uszVn4A_4_6">552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_LgRVdE3db0etGei_avzwow_5_3">6,558</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_otKkn4rkRUK0VHYIIvdvMA_5_6">3,996</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_o1Rm7DN9rE6Uu6YOFs8jVw_6_3">13,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_apGU3NVW702bqY7X5EIHdw_6_6">8,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_L_NVcHcca0aC2M8oUhh6yw" continuedAt="Tb_L_NVcHcca0aC2M8oUhh6yw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes (including the conversion option) is based on Level 3 measurement.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d002d227_bf39_47c7_97b0_43f3ca0805ef"></a><a id="Tc_x-befdlCq0qU83sXUjzIiw_1_2"></a><a id="Tc_hPMp1oXkAUmo90U5HLpfcQ_2_0"></a><a id="Tc_BE3Wesiiz023v9WtN14Ygw_3_0"></a><a id="Tc_95tsTXQhCk6VwSLPypCMfw_4_0"></a><a id="Tc_EnGuIv8520ymrq9D82sx1Q_4_3"></a><a id="Tc_eHIT_hTZ40uOj-CdJQ72MQ_5_0"></a><a id="Tc_G_DOWszmb0WAMfHxux2muw_5_3"></a><a id="Tc_32URo46i-UWhad1CYxk78w_6_0"></a><a id="Tc_ENh8RLwd60uVlK4AoBG2hA_6_3"></a><ix:continuation id="Tb_L_NVcHcca0aC2M8oUhh6yw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">As of September&#160;30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_rfsNO0eQEE2IQLan1Bs1MQ">59.7</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_Nrylmm7X3kaU8w3XPffnbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_fanee0kgj0GS3I8msBi9xQ">7.50</ix:nonFraction>% 2021 Notes as of September&#160;30, 2020 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_SFW38Sqg5k2Qgi6Qnw_cOg">62.4</ix:nonFraction>&#160;million based on a Level 3 measurement.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_IEcmbdIKtUef_TAk83amaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_xGzzpIjH90SroDkV-_cT3g_2_2">3.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WZZ4r5XXfEOp6GCJNBLRVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_lHg5UVfWQUisvwzvTiAP4A_3_2">1.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bjCDIQN02Uam1toNzw9LSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_AoRF_95GmkW0IVxbUyv2LQ_4_2">0.12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2oLx1XpEpEeKkThOFBF0qA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_syAhdsc9vkeBKRnLDq7Xuw_5_2">100.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_pJdr0YSp5USwhCNaVQZ9eA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_esMGQ2TFwUK9Nz3Nvtf6JA_6_2">12.34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_37bdf232_f28d_4755_b2b5_4a1dbd36dd54"></a><a id="Tc_GJWEq-VbgU-0M4LhfUz5Ww_1_2"></a><a id="Tc_Uk4-r3ZlaUGhr944MHG_-w_2_0"></a><a id="Tc_CED_iU3vUUuMG-Eq38ISxg_2_2"></a><a id="Tc_Tf1uMBZ6mkaQdpQB9f8WWg_2_5"></a><a id="Tc_8msyBAjQvUWNh_Id2rrzHw_3_0"></a><a id="Tc_JjiXQnB4WU63Xwo_S0lbwQ_3_2"></a><a id="Tc_o9f7PXXgQE-8kA9Jqo94Ag_3_5"></a><a id="Tc_nK7SQ0JNr0yzMfIlg-ZqFg_4_0"></a><a id="Tc_Fw4ceO6buUGsarfcfUmFhQ_4_2"></a><a id="Tc_3BCnKVBj2km5aqYYsvSkzA_4_5"></a><a id="Tc_nxUe5ZzHvk6q6rRaYJjv4w_5_0"></a><a id="Tc_3vfI6oJUvU2fqja5Z9jazQ_5_2"></a><a id="Tc_MpqHNAEk7UielvAlU5kNmg_5_5"></a><a id="Tc_2Z9_PtMYB0iTGTaEzp2miA_5_6"></a><a id="Tc_n44NE5rac0atI9-cidIXqQ_6_0"></a><a id="Tc_8QytGWF-_0GusUmL2DUXtw_6_2"></a><a id="Tc_VmLqYkNuMEyJIX6S4KwH9g_6_5"></a><a id="Tc_rckQsQyZMUW9OeFsq6bnCg_7_0"></a><a id="Tc_-919gn4l50a1MOZIEJYBWw_7_2"></a><a id="Tc_xI5ZfgZPEUGLt63RUb7jrg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="plx:RevenueDisclosureTextBlock" id="Tb_SDdO_pnRDUmqOIWPTfV8oQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_RSiy-sP3W0WvUNSLx30ZsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_4CFqkzlEM0a0ykFUdbprNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_JEZWYC7NJ0yVZNWgYBJraw_3_3">5,844</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3utDIYnGnk23SwkpDHFalw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gFK5ueVbzkiPfh1fchAOkg_3_6">4,701</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Mzmg7jvLfEe4iybt5-W0xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_dVu5WoKpVEOsLFWqArCO1g_4_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_c-o4-zlu6k-zZmFIhIvfgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_IENN086tT0S2I0bmpQSdkg_4_6">7,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JUeLT0AOY0GhjA3MadGoNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_K6QZzr2yrESI6rmu9oHCrA_5_3">131</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UzPdB9YSuUaO76y09JEgLg_6_3">11,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_sKrjuauUjEuorloeVLVg1w_6_6">12,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rUvP4GgQU0ipAN9satYylw_7_3">31,428</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_iqYyjbtpSkmZWSOYZt6siw_7_6">24,848</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the nine months ended September&#160;30, 2020, the Company recorded revenue in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_7TPGAQhZOUmeeaZ_5HG55g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="6" id="Narr_dgh49FUg60CGRLRtl-Ib2g">6.7</ix:nonFraction>&#160;million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the Company&#8217;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_3_16_2020_To_3_16_2020_WyJvhboxckK2jqSgzcbqVQ" decimals="-5" format="ixt:numdotdecimal" name="plx:NonRefundablePayment" scale="6" id="Narr_E-P3o-6m40aTz80kpyPayg">1.0</ix:nonFraction>&#160;million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_8AhXMkrUyUa-fgkRfc_WMQ" continuedAt="Tb_8AhXMkrUyUa-fgkRfc_WMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Zidzb2p4IE2Iph6eA5ilKw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_x2jyJDgtXEGgJ_ga7svZVw">196,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">and Chief Development Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;)</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">. The options have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr__e1yRpmgTUGjAYiW0j4wQQ">3.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_rVrjTd9ALE2KH3nQHPDuyw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">and Chief Development Officer</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">as those terms are defined in the Plan,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and Chief Development Officer</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_s0csoNiTFUeAkC8oH9KyiA">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_DLCdO_qxq0aDVd5UJNaM3Q">3.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_wSQBuQBj30GizjlCDgYLkg">0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_emb2C_6Yeku0ypU7CGVU6w">80.43</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_gVkoEfIoR0SuqmS9kWatuw">0.59</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_hk2thWiS8UqalZ3MIjRNIA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_LgPz8XVMiky9z9LRxu5hkQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_GWGYOa0y2U2t04DnyBwUsw">760,311</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_CaabV06t0E6c7qK_ZU4fEA">3.66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_c3VWQtC_4EqVQn3-k4tDXw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_dQhDgwRR70KYsy72ZqIrtA">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_bwvfY2lhgE6A6TQlAfMCVQ">1.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_yOdbg6QgK0uwatW_eksaNg">3.66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_sOBrbTQuvU69NJ4eDeIYuw">0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_bYSfNt1ukUedqwxkUrerrw">80.49</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_DXlRsPDGnkyF7vq8phQosA">0.45</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><ix:nonNumeric contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_76Oo3lU6NkOzkIQQ6TWaxg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On August&#160;11, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_GN89fNYluUi0_RGxGUezoQ">447,927</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of restricted Common Stock to its President, Chief Executive Officer under the Plan. The restricted shares vest </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">over a </span><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_G609BbsjQ0q_OKFM6urVlw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in <ix:nonFraction unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_VXfGcU-JW0iquJkHJT3myQ">16</ix:nonFraction> equal quarterly increments and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_edPTlz70sE-KPAY6iEzxFw" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_0W7L7bJ250KtPlR3XLuOHg">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_-BY7rTi5ZUu_hIKtNvetFg">246,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_awAX9aPeuk2iZshhHY-mww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Narr_ay91YIKw9kSYaawnwxbY7Q">27,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares vested on September&#160;22, 2020. The remaining </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="As_Of_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qrzLO1Itnk-vHNuLIHMrCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_rx1DICzZbE6BPJOEXK34Fw">218,291</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> of the shares vest in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_-sTJ7isaLk-nesKoVh4ENg">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal, quarterly increments over a </span><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_HE5KORFonEqVPuHV_rhOPw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_KfZU-gIvU0mW3QuavJGUpg" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_G8jnR4sgHU2s3TiY07DKzQ">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_FbeVskc_AEiMgu3c6LaYlQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_XchGQRgTx0e8PQXOISBXTA">122,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_CZgJZQPYaEK5gs76LxEwvQ">3.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Gs34OfzVo0WO0mV0tXDcVA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_WwiB0HnRh0mpLmQJyEDHjA">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_A6JynF759kmFEBXxh5PpGw">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw" contextRef="As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_lXtstp2RbkGsjSaAkvAatw">3.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_2e2l6Bot_k2kRCIvuiJ-TA">0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_zlvxpKv8uE2cduZcbXKPfg">80.51</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg" contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_8ZrgJpRiH0-3YK3sqraDAg">0.365</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_9zFBrAqOiE2GGqfdIIawsg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On September&#160;14, 2020, the Company issued </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kb_bM17UOUKc7v8Igr21jA">200,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_0wESBgyjWk6t775My90DLA">472,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> from the exercise of the warrant.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8AhXMkrUyUa-fgkRfc_WMQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;5&#160;- STOCK TRANSACTIONS (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On October&#160;1, 2020, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_1fRceHFMtEWWoTuOudr_4w" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_VQ0P6OARRk-k1sC9nvhkRQ">30</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million. The ATM Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-230604). The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the Company&#8217;s offering expenses, for general corporate</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> purposes.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_JVoRg4PaZker-ipWQBoO6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; PROMISSORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In September 2020, the Company amended the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="Narr_DJ4QAmBzLEWf8j4x-XHNuA">4.3</ix:nonFraction>&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January 31, 2022 and (b) the date that the Company receive any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q" contextRef="Duration_9_1_2020_To_9_30_2020_Gx20S_jXlEO4XT5ZwA9LaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" sign="-" scale="0" id="Narr_oajqZgT170qK1QySAkjUbA">430,000</ix:nonFraction> to Pfizer. The payment is creditable against the principal amount of the note, in whole or in part, if the Company satisfies the note in full on or prior to September 30, 2021, depending on the date the note is satisfied. The promissory note is presented under the short-term liabilities.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_oNoKN3DsfEK38UeCjaWgvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_25f57c16_e30a_46e2_ae65_67d1543cb70b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2019. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors including those set forth under &#8220;Risk Factors&#8221; in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2019, and in our Quarterly Reports on Form</i>&#160;<i style="font-style:italic;">10-Q for the quarters ended March</i>&#160;<i style="font-style:italic;">31, 2020 and September</i>&#160;<i style="font-style:italic;">30, 2020.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the timing, progress and likelihood of final approval by the FDA of the BLA for PRX-102, by the PDUFA date or at all, which was accepted by the FDA and granted Priority Review designation in August 2020 and, if approved, whether the use of PRX-102 will be commercially successful;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to execute a license agreement with SarcoMed USA Inc., or SarcoMed, with terms and conditions acceptable to us, if at all;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>our dependence on performance by third-party providers of services and supplies;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the impact of development of competing therapies and/or technologies by other companies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our supply of drug product to Pfizer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;11, 2020, we, together with Chiesi, announced that the FDA had accepted the BLA for PRX-102, and granted Priority Review designation for PRX-102, for the proposed treatment of adult patients with Fabry disease. The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application. The FDA set an action date of January&#160;27, 2021, under the Prescription Drug User Fee Act (PDUFA). The FDA advised that it requires an inspection of our manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#8217;s review of the BLA application. Due to COVID-19 related FDA travel restrictions, the FDA has advised that it may be unable to conduct the inspections prior to the PDUFA date. We, together with Chiesi, are in active dialogue with the FDA and have submitted a request to the FDA for a Type A meeting to seek resolution on the issue of the pre-license inspections of the two manufacturing facilities. We anticipate an FDA response to this request in the first week of November 2020.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;24, 2020, we, together with Chiesi, announced completion of the treatment period of the Phase&#160;III BRIGHT clinical trial of pegunigalsidase alfa for the proposed treatment of Fabry disease. We anticipate announcing top-line results from the study by the end of the first quarter, 2021.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On September&#160;3, 2020, we received notification from the NYSE American LLC, or the NYSE American, that we had regained compliance with all of the continued listing standards set forth in Part 10 of the NYSE American Company Guide.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;1, 2020, we entered into the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement with BofA Securities, Inc., as the Agent. Pursuant to the terms of the Sales Agreement, we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $30 million. We intend to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and our offering expenses, for general corporate purposes.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;2, 2020, we, together with Chiesi, announced launch of an Expanded Access Program (EAP) in the United States for pegunigalsidase alfa for the proposed treatment of Fabry disease.</div><div style="margin-top:10pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We continue to actively advance all our clinical programs. We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical trials have not been materially adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In response to the local spread of COVID-19 at the end of March 2020, and with local directives issued in response thereof, we restructured the work day within our facilities to consist of two shifts thereby reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing. Employees that were able to work from home were </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:14pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">instructed to do so. Such efforts resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In June 2020, after local directives allowed more flexibility with respect to social interactions, we returned to a regular work day. Since then, as the pandemic&#8217;s effect locally continued to change, and local Israeli directives continued to evolve to address the changing effects, we returned temporarily to the two-shift work day schedule and to again encourage employees that are able to work from home to do so for parts of September 2020.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell cultures in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; the potential for oral delivery of proteins; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages Versus Mammalian Cell Production</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"><img src="plx-20200930x10q005.jpg" alt="Graphic" style="display:inline-block;height:203.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:464.25pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:315pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"><img src="plx-20200930x10q006.jpg" alt="Graphic" style="display:inline-block;height:315pt;width:468pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack the lysosomal enzyme, &#945;-galactosidase-A leading to the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>) in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood and in the blood vessel walls. The accumulation leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease was approximately $1.7&#160;billion in 2019 (Global Data) and continues to grow at a CAGR of approximately 10% (Data Bridge Market Research).</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On August&#160;11, 2020, we, together with Chiesi, announced that the FDA had accepted the BLA for PRX-102, and granted Priority Review designation for PRX-102, for the proposed treatment of adult patients with Fabry disease. The FDA set an action date of January&#160;27, 2021, under the Prescription Drug User Fee Act (PDUFA). The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Priority Review is granted to therapies that the FDA determines have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. This designation shortens the FDA review period following the acceptance of the BLA to six months compared to 10 months under standard review.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The BLA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> Studies. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. Patients that completed the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial were offered the opportunity to continue PRX-102 treatment as part of a long-term extension study. In the phase III clinical program, we are studying two alternative doses and regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients. Enrolment has been completed in each of the <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIGHT</i> Studies. Topline results from the <i style="font-style:italic;">BRIDGE</i> study were released in May 2020. The last patient/last visit in the <i style="font-style:italic;">BRIGHT</i> study was in July 2020 and the treatment period of the study has been completed. We expect to announce topline data from this study by the end of the first quarter, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span>phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102 for the treatment of Fabry disease, or the<i style="background-color:#ffffff;font-style:italic;"> BALANCE</i><span style="background-color:#ffffff;"> Study, is a 24</span>-<span style="background-color:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background-color:#ffffff;">102 in Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is </span>designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. <span style="background-color:#ffffff;">Patients previously treated with </span>Fabrazyme <span style="background-color:#ffffff;">for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of PRX-102 or 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of </span>Fabrazyme<span style="background-color:#ffffff;">. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt;</span>&#160;<span style="background-color:#ffffff;">or</span>&#160;<span style="background-color:#ffffff;">&#8805;</span>&#160;<span style="background-color:#ffffff;">1</span>&#160;<span style="background-color:#ffffff;">g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint for the <i style="font-style:italic;">BALANCE </i>Study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme and PRX<span style="background-color:#ffffff;">-</span>102. eGFR is considered a clinically valuable, reliable and accepted test to measure the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: <span style="background-color:#ffffff;">cardiac assessment, lyso-Gb</span><sub style="background-color:#ffffff;font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients status)<span style="background-color:#ffffff;">, pain, quality of life, immunogenicity, Fabry clinical events, pharmacokinetics and other parameters. The study also evaluates the safety and tolerability of </span>PRX-102<span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We intend to conduct an interim analysis when the last enrolled patient reaches 12 months of treatment to test for non-inferiority to support anticipated regulatory filings with the EMA. Notwithstanding the interim analysis, patients enrolled in the <i style="font-style:italic;">BALANCE</i> Study will continue to be treated for a total of 24 months, at which point the data will be analyzed to test for superiority in a final analysis of the study data. We expect to use the final analysis of the <i style="font-style:italic;">BALANCE</i> Study to support converting the accelerated approval into a traditional approval, if the May 2020 PRX-102 BLA submission results in an approval from the FDA under the Accelerated Approval pathway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The <i style="font-style:italic;">BRIDGE</i> Study is an open label, switch-over study designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 infused every two weeks, in up to 22 Fabry patients. The trial, which has been completed, enrolled patients previously treated with agalsidase alfa (Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) for at least two years and on a stable dose for at least six months. Patients were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient was enrolled and switched from Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>treatment to receive intravenous (IV) infusions of PRX-102 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks for 12 months. Topline results from the study were released in May 2020.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Topline results of the data generated in the <i style="font-style:italic;">BRIDGE</i> Study showed significant improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) and an amelioration of the course of disease in both male and female patients who were switched from Replagal to PRX-102. Consistent with previously announced interim data, PRX-102 was found to be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:14pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">well tolerated, with all adverse events being transient in nature without sequelae. Twenty-two patients were enrolled in the study; two of those patients withdrew early from the study due to hypersensitivity reaction, and 20 of the patients successfully completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on Replagal to -1.19 mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-1 PRX-10202 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Baseline characteristics of the patients, ranging from ages 24 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year in males and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females; mean residual leucocytes enzymatic activity was 4.8% of lab normal mean in males and 27.9% in females; and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> mean levels were 49.7&#160;nM and 13.8&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> Study was included in the PRX-102 BLA submission to the FDA under the Accelerated Approval pathway, and we anticipate that the final analysis will be used to support the filing of a Marketing Authorization Application (MAA) with the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span>phase&#160;III <i style="font-style:italic;">BRIGHT</i> clinical trial of PRX-102 for the treatment of Fabry disease, or the<i style="background-color:#ffffff;font-style:italic;"> BRIGHT</i><span style="background-color:#ffffff;"> Study, </span>is a 12-month, open-label switch-over study designed to assess the safety, efficacy and pharmacokinetics (PK) of <span style="background-color:#ffffff;">PRX-102</span> via intravenous (IV) infusions of 2&#160;mg/kg administered every 4 weeks in up to 30 patients with Fabry disease, previously treated with an ERT (Fabrazyme or Replagal). The rationale for this open-label switch-over study is based on the enhanced pharmacokinetic (PK) profile of <span style="background-color:#ffffff;">PRX-102</span>. Phase 1/2 study measurements and PK projection modelling data suggest that <span style="background-color:#ffffff;">PRX-102</span> 2.0&#160;mg/kg every 4&#160;weeks may be beneficial in patients with mild to moderate Fabry disease. This treatment dose and regimen is aimed to serve as a maintenance program for Fabry patients without severe clinical symptoms and with relatively slow disease progression, with the potential to delay the risk of developing disease complications. To determine eligibility for participation in the study<i style="font-style:italic;">,</i> candidates were screened to identify and select Fabry patients without severe clinical symptoms and with relatively slow disease progression whom, according to the evaluation of the treating physician, were candidates for the new regimen. Patients who matched the criteria were enrolled in the study and switched from their current treatment of intravenous (IV) infusions every 2&#160;weeks to 2&#160;mg/kg of PRX-102 every 4&#160;weeks for 12&#160;months. Enrollment in the <i style="font-style:italic;">BRIGHT</i> study was completed in June 2019 and <span style="background-color:#ffffff;">the treatment period was completed in July 2020</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients participating in the study are evaluated for various disease-related clinical symptoms and biomarkers, including their kidney disease rate of deterioration, while being treated with the 4-week dosing regimen as measured by eGFR. In addition, participating patients are evaluated to assess the safety and tolerability of PRX-102. This study analysis is descriptive in nature. In February 2019, we announced preliminary PK data from the <i style="font-style:italic;">BRIGHT</i> study. The results demonstrate that <span style="background-color:#ffffff;">PRX</span>-<span style="background-color:#ffffff;">102</span> was present and remained active in the plasma over the 4-week infusion intervals. The mean concentration of PRX-102 at day 28 was 138&#160;ng/mL. In comparison, published data on Fabrazyme (1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every 2 weeks) shows a mean concentration of 20&#160;ng/mL at 10 hours post infusion. In addition, the area under the curve (AUC) for <span style="background-color:#ffffff;">PRX</span>-<span style="background-color:#ffffff;">102 </span>was measured to be approximately 2,000,000&#160;ng&#160;hr/mL over 28 days. Based on published data, the AUC of Fabrazyme is approximately 10,000&#160;ng&#160;hr/mL. A preliminary safety analysis of 19 patients enrolled in the <i style="font-style:italic;">BRIGHT</i> study was also conducted, and indicated that <span style="background-color:#ffffff;">PRX</span>-<span style="background-color:#ffffff;">102</span> is well tolerated. To date, substantially all of the patients who completed the study opted, with the advice of the treating physician, to continue treatment under the 4-week dosing regimen in a long-term extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase III clinical trials of PRX-102 as many of the patients were already treated in home care settings. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our clinical development activities for PRX-102 were initiated with a phase I/II clinical trial; a worldwide, multi-center, first-in-human, open-label, dose-ranging study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and efficacy parameters of PRX-102 administered by IV infusion every other week for 12 weeks to adult na&#239;ve symptomatic Fabry disease patients. Baseline </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">values for renal Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions assessed by Barisoni lipid inclusion scoring system (BLISS), plasma Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> and supportive clinical data were collected at the start of treatment. The phase&#160;I/II clinical trial was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg. Each patient received intravenous (IV) infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, up to 60-month extension study under which all patients receive 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> Study and <i style="font-style:italic;">BRIDGE</i> Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805; 50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24 months from 11 patients who completed 12 months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who could not continue to participate in a clinical study due to personal reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results have shown that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24 months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index (MSSI), a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45.0&#160;million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On July&#160;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease is a $1.5&#160;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed as BioManguinhos alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2019, we generated $9.1&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tulinercept (OPRX-106)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Tulinercept is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting TNF alpha. It is in development for oral administration. When administered orally and while passing through the digestive tract, the plant cells function as a natural delivery vehicle, having the unique attribute of a cellulose cell wall, which makes them resistant to degradation compared to proteins produced via mammalian cell expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Through oral administration, tulinercept is designed to work locally in the gut, thereby avoiding the systemic exposure that occurs when TNF alpha inhibitors are administered by injection or intravenous infusion. Oral administration may potentially lead to a safer to use anti-TNF and may potentially reduce the safety concerns associated with currently approved therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">OPRX-106 may also be less immunogenic which can potentially result in longer-term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our oral delivery mechanism can potentially prove to be a safer and more convenient method of protein administration and could be applied to additional proteins in certain indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our proprietary chemically-modified plant cell-expressed recombinant form of human deoxyribonuclease I (DNase I), administered through inhalation. In cystic fibrosis (CF) patients, the accumulation of thick sputum in the lungs exposes them to recurrent infections and compromises lung function. DNase I therapy, or dornase alfa, is generally recommended for CF patients as a mucus thinning agent (mucolytic) to help with clearance from the airways to improve lung function and reduce exacerbations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">However, DNase&#160;I activity is compromised by actin, a globular multi-functional protein, found in high concentration in the sputum of CF patients, that is a potent inhibitor of DNase&#160;I. As such, we believe that actin may decrease the enzyme&#8217;s DNA degradation activity and potentially interfere with the effectiveness of inhaled DNase&#160;I in the lungs of CF patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In order to reduce the actin-DNase&#160;I interaction and the subsequent inhibition of DNase&#160;I activity by actin, we developed alidornase alfa by chemically modifying the enzyme forming an actin inhibition resistant DNase&#160;I. This novel treatment candidate may result in improved lung function and decreased incidence of recurrent infections in patients. Thus, we believe there is the potential that our form of the enzyme will demonstrate significantly enhanced efficacy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2020, we announced that we had entered into a non-binding term sheet with SarcoMed. The arrangement, if consummated, would relate to the development and commercialization of alidornase alfa for the treatment of Pulmonary Sarcoidosis and related diseases. On July&#160;21, 2020, the FDA granted Orphan Drug Designation for alidornase alfa for the treatment of Sarcoidosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout. The Uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine. We use our proprietary plant-based system to express an optimized recombinant enzyme under development for the potential treatment of Gout which is designed to have an improved half-life, reduced immunogenicity and better efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September&#160;30, 2020, we hold a broad portfolio of over 85 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 35 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development. As disclosed above, we have entered into a non-binding term sheet with SarcoMed. The arrangement, if consummated, would relate to the development and commercialization of alidornase alfa for the treatment of Pulmonary Sarcoidosis and related diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2020 compared to the three months ended September</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We recorded revenues from selling goods of $3.3&#160;million during the three months ended September&#160;30, 2020, a decrease of $1.8&#160;million, or 36%, compared to revenues of $5.1&#160;million for the three months ended September&#160;30, 2019. The decrease resulted primarily from a timing difference in sales to Brazil in 2020 compared to 2019, which was partially offset by an increase in sales to Pfizer Inc.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $7.5&#160;million for the three months ended September&#160;30, 2020, a decrease of $1.6&#160;million, or 18%, compared to revenues of $9.1&#160;million for the three months ended September&#160;30, 2019. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease is primarily due to the completion of two out of the three phase&#160;III clinical trials of PRX-102 as well as lower costs related to the BALANCE Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $2.9&#160;million for the three months ended September&#160;30, 2020, a decrease of $0.3&#160;million, or 11%, from cost of goods sold of $3.2&#160;million for the three months ended September&#160;30, 2019. The decrease is primarily due to a change in the cost structure as well as lower royalties paid to the Israeli Innovation Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $7.7&#160;million for the three months ended September&#160;30, 2020, a decrease of $2.3&#160;million, or 23%, compared to $10.0&#160;million of research and development expenses for the three months ended September&#160;30, 2019. The decrease is primarily due to the completion of two out of the three phase&#160;III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> Study as well as a decrease in costs related to manufacturing of our drug in development as some of the manufactured drug product and related costs have been recorded as inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates<span style="font-family:'Times-Roman';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.8&#160;million for the three months ended September&#160;30, 2020, an increase of $0.2&#160;million, or 9%, compared to $2.6&#160;million for the three months ended September&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $1.9&#160;million for the three months ended September&#160;30, 2020, a decrease of $0.1&#160;million, or 8%, compared to and for financial expenses net of $2.0&#160;million for the three months ended September&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September 30, 2020 compared to the nine months ended September 30, 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $12.0&#160;million during the nine months ended September&#160;30, 2020 and $12.1&#160;million during the nine months ended September&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $31.4&#160;million for the nine months ended September&#160;30, 2020, an increase of $6.6&#160;million, or 26%, compared to revenues from license and R&amp;D services of $24.8&#160;million for the nine months ended September&#160;30, 2019. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The increase is primarily due to revenues recognized in connection with an updated costs estimation throughout the trials until completion in the amount of $6.7<span style="letter-spacing:-0.15pt;">&#160;</span>million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $8.1&#160;million for the nine months ended September&#160;30, 2020, an increase of $0.2&#160;million, or 2%, from cost of goods sold of $7.9&#160;million for the nine months ended September&#160;30, 2019.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $27.2&#160;million for the nine months ended September&#160;30, 2020, a decrease of $7.8&#160;million, or 22%, compared to $35.0&#160;million of research and development expenses for the nine months ended September&#160;30, 2019. The decrease is primarily due to the completion of two out of the three phase&#160;III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> Study as well as a decrease in costs related to manufacturing of our drug in development as some of the manufactured drug product and related costs have been recorded as inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates<span style="font-family:'Times-Roman';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $8.2&#160;million for the nine months ended September&#160;30, 2020, an increase of $1.3&#160;million, or 19%, compared to $6.9&#160;million for the nine months ended September&#160;30, 2019. The increase resulted primarily from a $1.3&#160;million increase in share-based compensation costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $6.8&#160;million for the nine months ended September&#160;30, 2020, an increase of $1.1&#160;million, or 20%, compared to financial expenses net of $5.7&#160;million for the nine months ended September&#160;30, 2019. The increase resulted primarily from expenses related to our outstanding convertible notes equal to $1.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At September&#160;30, 2020, we had $13.5&#160;million in cash and cash equivalents and $27.8&#160;million in bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the nine months ended September&#160;30, 2020, we completed a private placement of common stock and warrants for net proceeds of approximately $41.3&#160;million. In connection with the offering, we issued 17,604,423 unregistered shares of our common stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of common stock at an exercise price of $2.36 per share. In September 2020, we received cash proceeds of $472,000 from the exercise of 200,000 warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and bank deposits as of September&#160;30, 2020 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued. In addition, as of September&#160;30, 2020, we had outstanding 2021 Notes amounting to $57.9&#160;million which are due on November 15, 2021, unless the notes are refinanced, restructured or converted before that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect that by the maturity date of the 2021 Notes, our cash and cash equivalents and short term deposits, combined with the cash we anticipate to generate from the satisfaction of milestones under the Chiesi US Agreement and from our revenues, will be sufficient to satisfy the 2021 Notes payment. If, prior to the maturity date of the 2021 Notes, we will not have sufficient cash available to satisfy the full principal amount of the outstanding 2021 Notes, and to otherwise finance our future cash needs<span style="font-family:'Georgia';">, </span>our management may pursue corporate collaborations, licensing or similar arrangements, public or private equity offerings, and/or debt financings or restructuring, sell shares under our ATM Sales Agreement, and if necessary, may need to scale back operations, curtail or cease operations. Other than the ATM Sales Agreement, we do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. There is no assurance that we will be successful in obtaining the level of financing needed for our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operations was 18.6&#160;million for the nine months ended September&#160;30, 2020. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the nine months ended September&#160;30, 2020 of $6.9&#160;million was increased by a $15.1&#160;million decrease in contracts liability and a $5.1&#160;million increase in inventories, partially offset by an increase of $3.3&#160;million in accounts payable and accruals, $2.5&#160;million amortization of debt issuance costs and debt discount and a $2.1&#160;million in share-based compensation. Net cash used in investing activities for the nine months ended September&#160;30, 2020 was $27.5&#160;million and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $41.8&#160;million resulting from our issuance of common stock and warrants on March&#160;18, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $15.7&#160;million for the nine months ended September&#160;30, 2019. The net loss for the nine months ended September&#160;30, 2019 of $18.6&#160;million was further increased by a $4.8&#160;million increase in accounts receivable, but was partially offset by an increase of $4.9&#160;million in accounts payable and accruals and by a decrease in inventories of $1.0&#160;million. Net cash used in investing activities for the nine months ended September&#160;30, 2019 was $0.9&#160;million and consisted primarily of purchases of property and equipment, and an increase in restricted deposit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2021 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future, including significant research and development expenses related primarily to the clinical trials of PRX-102. Our material cash needs for the next 24 months will include, among other expenses, (i) costs of preclinical and clinical trials, (ii) employee salaries, (iii) payments for rent and operation of our manufacturing facilities, (iv) fees to our consultants and legal advisors, patents and fees for service providers in connection with our research and development efforts and (v) payment of principal and interest on our outstanding convertible promissory notes and other debt. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12 months from the date that the financial statements are issued. In addition, t<span style="font-family:'28mugxoulnobhnx';">he outstanding principal amount of the 2021 Notes must be satisfied by November</span>&#160;<span style="font-family:'28mugxoulnobhnx';">15, 2021, unless the notes are refinanced or converted before that date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may be required to raise additional capital in the future in order to develop and commercialize our product candidates and continue research and development activities, and to satisfy or refinance our outstanding 2021 Notes. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our efforts, combined with those of Chiesi, to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of commercialization activities, including product marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and results of our clinical trials, particularly our clinical trials of PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">conversions of our 2021 Notes from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and outcome of regulatory review of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently, we do not expect the COVID-19 pandemic to have an adverse effect on our ability to raise capital if and to the extent we deem necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the nine months ended September&#160;30, 2020 and September&#160;30, 2019.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2020 and September&#160;30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_51501b2d_9a26_4945_8dc3_e280beccd74b"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the dollar. Most of our revenues and approximately 50% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 40% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.479</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.589</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.565</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.441</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.456</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6a12a9c2_ad97_4d21_9c1c_a9d83503cb42"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2020 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_77580b69_b719_43de_b7c7_5be5926ee18f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_73ddf748_4904_4bdf_86e9_429ddd310cf7"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 and in our Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Risks Related to our ATM Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain, and sales of ATM Shares, or the perception that such sales may occur, may have an adverse effect on the market price of our Common Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Throughout the term of the Sales Agreement, from time to time, we may instruct the Sales Agent to sell ATM Shares or sell ATM Shares to the Agent, subject to certain limitations in the Sales Agreement and compliance with applicable law. The number of ATM Shares that are ultimately sold by the Agent upon our instructions will fluctuate based on the market price of our Common Stock during the applicable sales period and the limits set forth in our instructions. Accordingly, it is not possible at this stage to predict the number of shares that will be ultimately issued, if any. Accordingly, there is no certainty that gross proceeds of $30.0&#160;million, or any proceeds, will be raised under the Sales Agreement. The issuance and sale from time to time of new shares of Common Stock under the ATM program, or the perception that such sales may occur, may have an adverse the effect on the market price of our Common Stock. In addition, we may issue additional shares of our Common Stock in subsequent public offerings or private placements. Any issuance of new shares of our Common Stock may be dilutive to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c4ee5777_5ee1_44ef_903b_6030b4581d6f"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September&#160;14, 2020, we issued 200,000 shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020. Except for the foregoing, there were no unregistered sales of equity securities during the three months ended September&#160;30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d17c84f5_5727_47c7_8452_b29515118868"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2d456c5a_a7fd_46df_a750_cc3e80c32bc1"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2b3c9b7b_27b0_4fcf_ba46_8f300cf55bee"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_aee0a7ba_9067_4123_8fd2_ca1698542605"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">ATM Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Sales Agreement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> dated October 1, 2020 between the Company and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">BofA Securities, Inc.</span></a></p></td><td style="vertical-align:top;width:7.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:15.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;1, 2020</p></td><td style="vertical-align:top;width:13.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of December&#160;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Supplemental Indenture, dated as of July</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;25, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Supplemental Indenture, dated as of November&#160;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;1, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20200930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20200930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20200930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20200930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:10pt;">XBRL Instance Document - </span><span style="background-color:#ffffff;color:#333333;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_287f7ed5_356c_472c_a7fb_ae937e0f9244"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20200930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/29/2020 11:25:30 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20200930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/29/2020 11:25:33 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20200930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/29/2020 11:25:37 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20200930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/29/2020 11:25:40 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October&#160;29, 2020</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20200930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20200930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &7 Z$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$6M"QO$M\2C?N3=GTKLU544*JA5'0 8%(L:*S,J*&;J0.30][@MK'&:UI/\
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M^M244 1^1'_=_6CR(_[OZU)10!'Y$?\ =_6CR(_[OZU)10 A^Z?I6?\ #_\
MY!MY_P!?']!6C5O1-,MM,LBMLI E;>V3GFJYTJ<H][$<C=6,ETN:5%%%<YU!
M1110 4444 %%%% !1110 4444 %<$%63Q?=@R*K)R >IKO:\RAF\WXF7$.0
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M;#[1/93*R YB*_,WX5R^L06JS*+>*YMV3 D61,'GI^!JE%V)9J^'M-6XGY'
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M^SN<]9%'\Z]B^&1SIU_Z><O\JTP-+DJ*QCC'%P=CNJ***]D\H**** "BBB@
MHHHH *N:-J-MJ-GNMG+B,[&XQ@U3/W3]*SOA_P#\@V\_Z^/Z"JY$Z<I=K$>T
M:JQCWN==1117.=04444 %%%% !1110 4444 %%%% !7-O+J,^O8:$06,;%03
M]Z0XZCVKI*P[B]6;5$@C20[7*NY& IQTH BO);>**6>4HH((+8Y-<M8:0NK:
M=('MH1 92-SH"S?3TKJ!90[+B<J6D()&[D#Z"L_1;V&#255R6E9V C09)/\
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MZXW5M7T"%5T]TNA:7*@W+D;"TO\ >]JVM)\2V*V-GHJM';VT4F\7!E#D^Q%
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M=1_TUS_X[41_X]Q_O-_2L^A;T8^Z'[W'K/%3=>.[Q_IO^['_ #-.G/[]<_\
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MCK+6V-[X;CMKD$LK2F$#C# $USNEBUDDF2[5A%]BD#'/0=^*ZG0('ETVP)D
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M6SK\ TO[-:1RLJ*S$':#G)SS6M3X&]B8WYD<_&P-WNR.),\?1JQKK[D'U/\
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MEPTJW#7&U@7N8P%QT&0,4FKJPT[,]%O3C=D$XB!_6L36"!:G/3<M;EXWSO\
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MM%'!$F:[OPM(8DEF'#%<*U<:D"W.H%6D"$L<-Z5TGALS0W%Q:22^8L9^4@4
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M3EHRHTOG^.-'<C_7(DGTP2?Y9JWJ #0VAD;:[9.3TSNJ&VASXVT3'(2R+'\
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M(@99&7]Z2N<M_2NQ\/W<^?*E3S@PR<L<(?>J<&OSQZO>06UC#=@ODY0,%^E
M'#PZI>:VRVBVT6_.5PF"3Z5T^DQ:Q<PR?:K6PMY(OD&Z$?,*/$&MW5]IJ*^G
M0VKQSAEFBB"'CMFJ^H^)-4FCBWPA-R[<[* *>IW%QI-U)I6Z!Y)L7$BQH",_
MW1[>U5TTBWGU2"6YM%BG9U(=#L2/Z@5S^H0ZC<^(U\A)#>QQ9&T\X'4CVKJX
MK._@T:'708[^7G=9@\J/[Q'<T 3^*M'F#R6T2+<PLP82 YV^]9LFA#4]*B>^
MO5CEB8JC,""Z^GX5EV]W>2?;YYGN8&;F-&XVGZ5>TBUU+6KJ+3K_ %*$B9"5
MCDX./0>AH @M]-73E+QW7R6P8AA\Q /6LF71M.N[FWNI+N;==',8 ZG.*V+J
MV@L=9ALI9MT%O*%8H,EESSQWQ6=XV$'_  D5Q>:5N^Q$KY/&T\=P* %OK&ST
MD'R;VY7489 8U*X(;ZUU_P -'_XF^H^:7>[:(M+*Y^]D5YS=BYEMH99)7:9Y
M!\SGYB:[KX:PO%JVL(X=9EM^YSR1T% ',S7,HM+V#[*T:O*P\Q!\AYZYK:TI
M4'A="KJ22?F)KE+A[N&WN[2YN)%M?-9D3=GY\UOZ+''_ ,(H@R&RQYH TM,T
MN+6=1M+FX4K;VG[R2-3@R$=*UO"MY>"3Q1>+;P^7<RQ?NR>1\XZ5)X?LF2>T
MNK6SCF\V98I2S8(7':K5K EM<^)Q%%M,<T97;_!\XH ]_HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P?%VH7&FZ(9K9@KF15)*YX-;U8?BS3I]4T4P6
MY7>)%?YC@8%:T>7VBYMC*OS>RER[V(H&+P1NW5E!/Y5)3(4,<$:'JJ@'\J?5
M/<A;!1112&%%%% !1110 5YC\:9"FC:0  0UV^0?]P5Z=7F7QHC,FCZ.00 M
MV^2?]P5G5^!FE+XT>0PJC328R&,+C!Z=*KR*5EBSV85>$2"XQY@.8GR0#Z5%
M.L;6J[3EXG4[L8R":X.QVW.P\0\^'-./HR?RK/\ +9;N;/\ <<_H:TM9 ?PK
M8$D#&WD_2L[G[7*?6-_Y&EB/B_KL*E\)LZ'"E[/$&W$I)&&^@&17/>-(FGGM
M5._<]S,H"#KEL#]*ZKPM',MO=F$@221J$)[$K@&JMP5ECMM30,YM5=S JDNT
MO0#'U&:[::M!,Y9_$S'U/3KEM<@^R0&22*.-&P>  ,$GW[5V.AZ%9VT2S+:+
M#.P);G)!/7FJOAV&YNE+W5K+&^ 6=QC<:ZR* C':J$36L*K@  5K0KA:IPQX
MJ\N0.*8AD@ZXJ#;S4[9S3-O- $#K3#'5DIFCR_:D,J%*B9*OF+VJ(Q>U%A&?
M*IVD8!K!UVQN+JS\JUCCWL<$MQ@5U+Q54DBP,XI6&>?ZW$^DP:;#&2C/-''*
M4.-V2<USBZS)#K5[%(5:W\\HROS@DXXSV/I77^*;:\N[VT5+-WABF21G!&,#
M_"N(U.-8+Z=/++^;(TH= .1D\9]:.52T87L=?&437C=[/E@TEG7!QBI-;.]X
MF[,JD?B:;:(KWEZ\Z$H-&4.._)Y%7-1M&NIX(X5Y*+M&>@K&O'W+(VI/WM3.
MTG34O)I)+@[;2 ^9,WL.WXU0UB_?4]8AG9=J#"QH.BJ&X%;.I7$45DNFV9S&
MC9FD'_+1_P# 5@F/-Y;>F1_Z&:XOA]U'6M?>9>\9'=J5K[0G^=8%L.(VQG"L
M0/?<:Z#Q8N[58!D<0'K]:Q8H,6R$.F=A[_[1JJOQL5/X$):28:(R$D.75OQ-
M1 8$"GJ/_BC5NUMUE\@2.@Y);)ZC--DM_+FB4LI*D@@<]S2Z"N,T\XU>(X[N
M:CMTW^,M3;! "'^E3V:E=0C?>KL"P(]C4%DS?\)5KQSPBG ]*ZJ/PG/4?O%:
M?Y-*L(>F\&0^^6 J)>(Y,<_..<5-J%XZW=K ^PJELI.4!.<9HTV.7492(K<'
MN0JU-2#<M"H326I)E6BQR"8AUZ"O7?A2,:%=#_IJ/Y&O,9+4VZ!-N"P*YQC%
M>H?"W>-(O%<899%!_(UM1IN+NS&K.ZLCO****ZCG"BBB@ HHHH **** "KVD
M7]M?V>ZVD#B,[6QV-43]T_2L[X?_ /(-O/\ KX_H*IP3IN7:Q'M&JD8][G74
M445SG4%%%% !1110 4444 %%%% !1110 5YCX;E>7XM:^$4E8D 8GM7IU>>>
M'-%U#3OB'XEU6YB\JRN441.6^\10!\^>,KJ/_A*-7PPW?:7X';FO?_#(,7A;
M1"3U@!SZUX;KT$$FOZM+Y2/ON'.[UYKW/1-J^$]("C@0#% $&I6.+J0, 0TF
MX#K7F?C1[6*_>*5206RN/6O53<QF;$NYB < 5XQXWN$N-;%N4=MF22H_BH ?
M#=W:^%)X;1':[WAPP_AB[\U@MJU^+:)E+J ^ "?F/_UJE*WZV,9ABF4NI5CS
MT]ZKO:7TT6&BVE#UH 5[^>\0,]U;AXSQO/)/M741'?%&9 I8@9]*XM-"N)#Q
M%U.<FNFPT5K&&/*\?E0!K1W&FC3Y)7U0PWJ@QPJWRA,]15&/4D%LBPEY;>UP
MK+%)A\^JUEOHL=S(9)0SY&>:F&CE2LD>4P,8 ZT :=WJ,%WHL=S;VU[$T;X<
M/\S #H:QM#OK^>ZN9--M8IYE^<&0=:Z:UO;B"S:)8UVD8((J"TCCMV9HH=A/
M7;Q0!EZW?7%_H=OY]E&EP6(;8N G/45%IL=U#:;9+@QR#N%'S+Z5TMU'!=::
M;=HRH<8+#J*Y6ZOI8;Q8D (C&S##J/>@#<2#[;ILMW$CL]LQ 0'[@]:L>$M9
MMWU)'7?"ZM\S8R":@TZ>&\22W ^QF8?.6;Y6'L*32=*MEU80VESPK<D]Z .T
M\0>.I+>.6WM(UEGB4E6V[O-/IBN,L]7@N[Q-2NXVEU*[(C\K^&%<\\=C79W&
MC(;^TF@?;=*?E*I@&M33_AM86FH-J=_<LHE8LZ,,98^] '1V6B?V=II\DP31
M2 $9'3CUKA-0\/R6]Y.S20V]JX( @X:NXDTR1(A#9W3K$.F3D 5GS^&KJ<'-
MQ&1ZL: /-M7TR%-,0V]Y+,&F4%6/3GK7:6?ASPS8P1RZCJ"W+X!*@Y%5=;T,
M:;8_:99$DAB;,B0GDBJ]GX936M.%_!.L%NV0OFMR/K0!R7C6XTB^\<2"S 2V
M2R5 T1P0?K7,PNT-CY :?8A)$RMT/O76S> ;J;QK<V4-S$Y%JLN4;.035YO
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M-:%<QX\_Y%W_ +;+_6M*,5*HHLRKS<*<I+HBPC!T5UZ,,BG5%;?\>L/^XO\
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M$6T0(P0@R/PJ2@$$9!R#02!UK1F:T044 @]#FBD,**S?^$@TK)'VZ+@E2><
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M.MZLV9YFSM9><\]"#Q@4ZRL9H(M,F$<HG,K"8DG.TANOMTH Z&BBB@ HHHH
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MD66))$.5=0RGU!KAVT>_M?#D]S9V[_:94FBN+;&#*I9MI _O#/XBK$]G./M
MNK.[FD:VC6R:+.(V"8(X/RG=SDU-RK:G95&LRM,\0SN0 GCCGWK&U>VO)_#4
M%NP>2YW0"7RSR<,-QX_&J&I:;,EQ?Q6\-RMKL@">4,YP6W#&>1TR*;=A)7.F
MFNH;>6"*1\/.Q2,8ZD#/\A4U</\ V?JMQ;6D5O%):LEXYCF*GY5,9^;:3E1G
MBNBT])_^$=,4,#VMTL;H%D[28/.>X)YS1?<+&JQ"J68X &2?2J]C?PZC;"XM
M]YB)PK,I&[W'M7+V]A)(;6.*RNXG$$BWS39Q(=G3K\QW<Y%:VE:4/^$1@T]X
MV@9[<*XZ%6(Z_7-%]PL:\TRP1[WW8R!\HR>3BI*XYK;5;VPFNKF"9;E&@MTC
M'4JK@N_T)Y^@ITNGSQ:?>S?8YY)Y;]P>6SY6[(. <E?847"QU-Q=0VHC,S[1
M+((TXSECT%35Q%G97PD9/LTZP#4()8P4*@+M.X@$G S6]K\4LKV+&*6:S25C
M<119)88^7@=0#VHOI_7D%M39HKD?LI$\#7&GWS:8$<1P9+LK[N"1G(XZ>E%C
MI-U<W5FFI13-"MI(,.QX)D^0,1U8+1<+'4_:(OM7V;>/.V>9L[[<XS^=2UP]
MO97D#0W,EC<RW1TQHE;D,'#'@GL=M0K9Z@!>BWM;E(Y=.=<+&RYDR,=3DMC/
M-%_Z^\+'?4Q95:9XANW( 3D<<^]<K+H0^TW2K!/Y7]G!E&]L&?GGK][I4,UE
MJ-P")(KD[UL@Q&0>/O\ _P!>B^H6.SJ*:XBM_+\V0)YCB-,]V/05RUY9W-I_
M:-O;6D[VC7$)15+$!=OS$ ')&<9 JA'IURV3/8SO;Q:C%*B>61B,K\Q5<YQG
MM0G<+'<Q3+,I9-V Q4[ACD5)7'1VERLT;7UK=36(FN"T2 D[B^48@<D8Z4^Q
MTJYN;NP2_AG-JJ3D(['Y5+#8K'/7%"=P:.NHK,\/1SPZ)!'<B02(77$G4#<<
M?IBM.F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_>SC% &)+8W]U9-<2JRW#RH7C4C/EKQ@=N3DU?T>UDMS<,PE578%1)@=!U
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M# ))*]1CVJI)XDLA/+#$P?9;?: _1",^M"L@U8[4M.^VZ[I<LD EMX5EWYZ
MD#']:R+;3+JV>U>YLGN;6(SJ( 0=N7RK8/4;>/:M^36;"&412W*+)@9'9<],
MGM1)K6G17#0/=(LBN$8<_*3T!/;K18+Z&)I&BW":E;RWEO\ NDADV*QW"+,F
M57Z@53_L^Z>PL=/N=,E,2J3<2HH9R-Q(0'/'N:ZZ[OK:P1&N91&';:N>YZXJ
M$:Q8&U%R+E?*+[ ><[O3'7-%D%V<]<:;.R:B@TR222Y ^R29 \D;0 #S\NTC
M/%.N-$N9+76G:#S+MWC-O)W)"KDCTY!KH#J]@+5;C[2OELVP$=2WICKFD;6-
M/6".8W2;)&*KC))(Z\=>*+!<YV?3KR)M02+3]WG7JS>9M!!3:.0,C)!'0TVR
MTK4$G!>"01C4HYUW!5PFP@G X'/:MNU\164]C'=2R"(2.ZHOWB0K8)X[5J12
MI-$DL;!D<95AT(H2_K^O0'V,;Q%9278M6CCF8QLQS&%;&1W4\$?RK-@L+R/[
M++?Z;]HB6V:(01X^1MQ.<$]QCZ5UU%%@N<1J6F:E<1W$::?Y9-LJ1","3G'0
MLQ^7!]!4MWI&I3"=U20*TEL[J,;I%6/# 9X.#V/I79446"YB^';*6S^U/(LZ
M))("JR[1T')"KTK.6TU!8[>R^QRGR]3\]I<C;Y>\G(_.NKHHL*YQ.B6LMS::
M<UO9/%)'=-))=$C#(&;(]3G@8K5\36%W>O&;:-G MKA#@_Q,HVUOQQI$@2-%
M11T"C IU%M+#YM;F'9:8UGK-K+#!Y</V+9*1T+Y&,^_6L_Q#87]Y>W8BM-R-
M;A8I%0,6;!X))^7!]!7644-7!.QR2V%RC2->::]ZTMM$L7S#]V0N&4G/'/.1
M4L5A/%<SK/IAN)Y+D21W&_Y47C'/48].]=113MK<5]+'(VNF7:K8P_8G2\AN
M?,FO"PPZY.>>IR".*(-%FM].TUY+(RF.9WNH1C<^<[3[XSTKKJ*5AW.+73KY
M+8K'IICB>_DEV%0[(I P0N<'//7I3]-T:[,EDEW;,88KV>0J^,!"OR\#C&>U
M=C10E8&SD8M+N;:XC>:R>XLXYK@+;J0=H9@58 ]1C(J"YTB]>=96M)DMS;;(
MX(=LGEG)R#NZ9R.17:T4<NE@YC'DTV67PNMBS/\ :$A!4NV6#KR,GZBL2UTG
M59;Z&2YB98KYQ<7@+?ZMD)*K^(Q^5=G13:UN*^ECBH]'O(XK<O9,TAL)X"1@
ME'+$KG\*U-.TE[*^TIXK?RT2S:.<C^]\N,^O>NAHI)6_KU_S&W<Y_4[.0ZO-
M/-8-?026XCB12/D89SG/3.1S5&70YI+;6I#9 7,JQ_9\-D@A!T/L177446"Y
MQ.KZ;J=U)>[+1@Y9#$R("6 QR6)R#UX%6[G1IY;?5YOLQ:ZDN4>!L_-@;>GI
MT-=7118+G!W@1$DBD@\Z[.IJ1<JX/'F X]>!QBM.WT>>35H&NK8M;K=74C;N
M1AB-IKHOL5K]H^T?9HO.Z[]HS^=3T)6!NYQ4-JUA<P+?V_G0A)Q';EAE/WA(
M;!/3&![5M^$\_P#",665*Y#$ G.!N.*U+BTMKH*+B".7;TWKG%2JJHH55"J!
M@ # %"5@;N+1113$%%%%  >013?"FDS:383+,Z,99-XV]AC%.Z<U8T'58-5L
MF:!6 B;8VX=^M-N7(TMNHDH>T3>^MC5HHHK Z HHJ%OM&X[1'M[9S0!-5*_M
M)+A[:6$KYD$F\*W1N"/ZU-FY](OS-&;GTB_,T 9TUCJ$LD<ADC498LD9*=<8
M^8<FJEO8WEA=V$2+'(\<4V6.=O+ CGUK<S<^D7YFC_2?2+\S0!E#2+R)8528
M%0'+JK%/F9L]1SCVI++2;RP2,QF&23R/)8/G PQ((_.M;-SZ1?F:,W/I%^9H
M RY-)N29'#Q%S+#(O& =@P?I26]L9M>E="?LT3>:1C \XC:<?AS^-:N;GTB_
M,T?Z3Z1?F: *>IZ:]W=6]Q&03$&4H7*Y!QW'TJG)H,DUK%;EHXT1FERN2=Y/
M Y[>OK6QFY](OS-&;GTB_,T 9 AOGU&\58X0TEO&CLP. <'./7Z4EQHMV\,E
MNDX,1@6),L5Q@8Y ZUL?Z3Z1?F:,W/I%^9H SAI,WV>_0LFZX@2-3Z$)CG\:
M8VDW0NA)$Z1DLC,ZL>0,9RO0GCK6IFY](OS-&;GTB_,T=;AY&;#I=S:SI<1&
M-W#2@JQ.-K-N&/>G66DR6UW#,[HVU9=P Z,[ \>U:&;GTB_,T9N?2+\S0!'I
MEJ]E8) Y!92QR.G))_K5NH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">BH,W/I%^9HS<^D7YF@">
MBH,W/I%^9HS<^D7YF@">BFINVC?C=WQ3J "BBB@ HHHH *R/$FEG5M):W$HC
MPP?)&>E:]97B'4UTG2FN'C,@+!, XZU=+FYUR[F=;EY'S[%2)/+B1,YVJ!FG
MTV-_,B1P,;E!Q0V['RX_&M&9K;0=14?[WT3]:/WOHGZTAG+:-IM]=:9IR3+%
M#!;W#3@X(<D,V 1VZ]:N0:'=6MEI7E-"UQ8E\JV=KANOT-;O[WT2C][Z)^M*
MP[G/QZ'>PWBZBCP-=>?)*T1R$PZ@8!]>!S26VB:A;/;W*FW-Q%=33%!D*5D[
M#Z5T/[WT3]:/WOHGZT6"YSUGHFH6,T5VK6\EP&F#(Q(7#ONR#ZBBZT*_G$_[
MRW+7%B;9R!M"MN)! ';FNA_>^B?K1^]]$_6BRM8+N]SGY=#O?L^H6<3P&"^.
MYY'SN3( ./7IQ4DN@3-I^JVZNFZ[F1XV/8*%Z_\ ?)K<_>^B?K1^]]$_6@"I
MJ-B]Y<Z=(I4+;7'FL&[C:1Q^=8]WX:GGG>=9$+"]>X1-Q4%64+@D<@\5T?[W
MT3]:/WOHGZT6"YS#>%I?+@E7RQ-'.\K1B5P&W #[V<YXZU-::!=6%Q!>6X@\
M]3)OB9F*D.0<Y/.>*Z'][Z)^M'[WT3]:+!<YD>'+Q;*V0^09XVE8O&[1E=[9
M^4CM[&N@TZ":UTZ""XE$LR( S@8R:F_>^B?K1^]]$_6A: ]22BH_WOHGZT?O
M?1/UIB)**C_>^B?K1^]]$_6@"2BH_P![Z)^M'[WT3]: )**C_>^B?K1^]]$_
M6@"2BH_WOHGZT?O?1/UH DHJ/][Z)^M'[WT3]: )**C_ 'OHGZT?O?1/UH D
MHJ/][Z)^M'[WT3]: )**C_>^B?K1^]]$_6@"2BH_WOHGZT?O?1/UH DHJ/\
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M .?B3]*/(?\ Y^)/TK(NM5F^V,!'/#&MI+(5< $D$8(J636)DMYYH;<21VR
MR%GP2=H/'YT :7D/_P _$GZ4>0__ #\2?I62=4NH9M0E,8DMX&0G+8*@J"0/
MSJ[K%Q)!I;S0L5?<F#]6 H L^0__ #\2?I1Y#_\ /Q)^E9[:O*K3/]F'D17'
MD,V_D\@9 _&H1J-RU_!%'@QM=31ON/.%':@#6\A_^?B3]*/(?_GXD_2LE=:>
M.QADVH28RY,DF">3P /I5FQOGN]0<@D0M;12JA[%LT 7?(?_ )^)/TH\A_\
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M*GHH @\A_P#GXD_2CR'_ .?B3]*GHH @\A_^?B3]*/(?_GXD_2IZ* (/(?\
MY^)/TH\A_P#GXD_2IZ* (/(?_GXD_2CR'_Y^)/TJ>B@"#R'_ .?B3]*/(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4M5O;>QL'EN91&A^4$CO5VN=\:VLUUX?98(V=ED5R!Z#K6E*
M*E-)F=:3C3<H[DBL'4,IR",@TV2*.9-DJ*ZG^%AD5AP^(X8X(T-E=Y50#\GM
M6OI=T=5BD>&WE0(<'S!BMITI15VM#GA6A-V3U)(H(H%*PQI&I.2%7%25!J=P
MVEVZS2P2NK-MQ&,FLK_A)H/^?*[_ ._=*-.4E>*'.K"#M)D]KH5O9E1#/<K&
M'+>7YGR\G)&/3FG0:#96\T+KYA6%BT43.2B$^@_&M.S$E[:17"1.JR#(#<$5
M0U/5%TNY6"6VG=F7=F-<C_/%3&#;Y5N5*:4>9[%8>&=,$:Q^4VU;G[2/F_C_
M ,/:M"^LH=0M&MIP3&Q!.#CH01^HK-3Q'"\BH+.[RQ Y3UKH/LD_]PTY0</B
M5@A4536+N94FD6DL-Y$RMMNY!++\W5ACI^0IAT.SWHX\Q72X:X#*^#N;K^!]
M*BN/$$5O<20M9W19&*DA.#BI=/UA-1NUMHK6X1B"<NN!Q5.C-*]B%7@WRWU(
ME\-V">7Y?FH4C\K*OC*Y)P?S-6-/TBTTU@UN&!$*PC<V?E7./YUI3Q2P023-
M$Q5%+$#J<5@?\)-!_P ^5W_W[J84Y2^%%3JQA\3+KZ/:279N65O,,R3GYN-R
MKM'Z43:/:3PWT4BL5O6#2_-W  !'IT%3:7>'54D:&WF01D ^8N,T_4IFTNV$
M\L$KJ6"XC&32Y'S<O4:FN7GOH5)-$M'2W">9"UO'Y<;Q-M(7TILFA6DD4<8>
M=%1#'\LA^8'DY]:K?\)-#_SY7?\ W[K;LO,OK..YCA=5D&0&&"*J=.45>2%"
MK&;M%F5)X=T]U*!9$0P+;E5? **<C\JLS:7;3O=.ZMFYA$$F#_",_P"-)J>I
M#2ITBFMIW9EW QKD=:I+XDA9@HL[OD@?<IJC.2ND)UX1=F]2>30+.1V93-'O
M14D$<A4.%&!G\*E?2+1XKV,JVV\ $OS>@ &/3@5J_9)S_P LS6'<Z]%:W,D#
MVET6C8J2J9!J8P<](ZE3FH*\G8MP:=!;7LUU&7#S*JN-WRG:, X]<5!%I@2\
MO@Z)):73"4HW.'Z'CT. :+#64U"[2VCM;E68$@NF!Q6K+!-#"\K1L0BEB!UX
MI2@XNS"$U)7CL5+FR@NK-K5TQ$V.$^7&#D8QTK)3PI9_9)8)IKB5I>&D+X.W
M<6"_3)_&G?\ "30_\^5W_P!^ZTM+O?[6$IAMYD\O&?,7&<U4J4HJ\D3"O"3Y
M8LK#0[<VCVSRSR1G:5W2?<*]"OI0FA6@4^8TLLC3),TCMEF9?N_@/2KVI2MI
MEK]HE@D==P7"#)YK(_X2:#_GRN_^_=$:<I*\4$ZL(.TF79=(M)DNT=6Q=2++
M)\W5EQC^0HM[)UU:ZOYB-SJL40'\*#G\R2:NV)>_LX[F.%U1\X#C!X.*J:IJ
M(TJ5(YK:=RZ[@8UR*E0;ERK<IS2CS/8NT5B#Q+"2!]BN^3C_ %=="+68@'RS
MS3G"4/B%"I&?PNY#165=Z['9W4EN]I=,T;;253(-.L=:2_NTMH[2Y5GS@NF!
M5>RG:]M"?;4[\M]33HJ22WFCC9S&2%!) KG_ /A)H/\ GRN_^_=*$)3^$J=2
M,/B=C<HJII=]_:QE$-O,GEXSYBXSFI]1D;3;0W$L,CJ"!A!D\TG%J7+U&IQ<
M>=;$E%8?_"30?\^5W_W[K9L&?4+-+F.&15;. XP>#BG*G*"O)$PJPF[18^BJ
M>J:@-*DC2:VG<N,CRUSBJ \2PDX^Q7?_ '[IQI3DKI"E6A%V;-NBI5MIF4,(
MS@C-8MYKD=E=R6[VERS(<$JF0:F,7-VB7.<8*\C5HK+LM;COKN.VCM+E6<X!
M9, 5LM;3(C,8S@#-$HN+M((3C-7B145A_P#"30_\^5W_ -^ZT-+O_P"U7D6&
MWG0Q@$^8N,YJI4IQ5VB(UH2=D]2Y13-0=].M&N989&52!A!D\UC?\)-!_P ^
M5W_W[I1IRFKQ0YU80=I,W**CT^1]1M%N8H9$5B1AQ@\5!JE__931B:WF?S 2
M/+7.*2BW+E6Y3FE'F>Q;HK#_ .$FA_Y\KO\ []UT*6\TD:N(R P!YISA*'Q"
MA4C/X7<BJ[I&GVVGV>VVC""0[FYZFN>OM;2QNY+9[2Y9TZE4R*O^#[Z\OM/G
M:\W;DEVIN7'&!1*G-4^;H*%6#J*/77Y'14445S'6%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %'6BB@!NQ?[H_*E  Z "BB@ (!ZC-)L7^Z/RHHH
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7ZBB@!"JDY*C\J  .@ HHH 6BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20200930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20200930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )V Z@# 2(  A$! Q$!_\0
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M\7:5X(<92_U=W_=,AR$0@8/('2N:^+J""?0"<A$R"3[%:TO'WBAQX*M9=$O
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MJ-[!M<T;C5O%W@+5K)M9U#^T;&Y.'RQ;'K@GD$9K;^(GC.\TN.RT_1FVW5Z
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M?]!2U_[^"FU)N]B5**5KA>^&](U#4H]0NK&.6[CQLE.<C'2M6LK_ (271/\
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M!&/X47%4]8\.:3KR*NHV:3%?NL>&'XT?\)+HG_04M?\ OX*/^$ET3_H*6O\
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MD_[Y%2447"Q']GA_YY)_WR*/L\/_ #R3_OD5)11<+$?V>'_GDG_?(H^SP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM/\ [MU_X#/_ (4^678.>/<V**Q_^$FT_P#NW7_@,_\ A1_PDVG_ -VZ_P#
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M .[=?^ S_P"%'_"3:?\ W;K_ ,!G_P *.678.>/<V**Q_P#A)M/_ +MU_P"
MS_X4?\)-I_\ =NO_  &?_"CEEV#GCW-BBL?_ (2;3_[MU_X#/_A1_P )-I_]
MVZ_\!G_PHY9=@YX]S8HK'_X2;3_[MU_X#/\ X4?\)-I_]VZ_\!G_ ,*.678.
M>/<V**Q_^$FT_P#NW7_@,_\ A1_PDVG_ -VZ_P# 9_\ "CEEV#GCW-BBL?\
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M_P#A1_PDVG_W;K_P&?\ PHY9=@YX]S8HK'_X2;3_ .[=?^ S_P"%'_"3:?\
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M1-LD /W6ZX-2T &!Z48'I110 8'I1@>E%% !@>E&!Z5%#=03R2QQ2J[PMLD
M/W3UP:/M,/VK[+YJ^?L\SR\\[<XS0!+@>E&!Z44Q)8Y"P1U;:=K8.<'TH ?@
M>E&!Z444 &!Z48'I110 8'I1@>E1074%T',$JR!&*-M.<,.HJ6@ P/2C ]**
M* # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@
MP/2C ]*** # ]*,#THHH ,#TK-C_ .1I;_KT_P#9JTJS8_\ D:6_Z]/_ &:F
MB9=!NM?\A+1_^OAO_0#6I@>E9>M?\A+1_P#KX;_T UJ4WL@CNPP/2C ]***D
MH,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#
MTHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** #
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MG1ZQK>JS:';K*VGR744QN,Q#.4( (!Z9_K6W>>&Q-?S7EG?W%E).H6;R<8?
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M "BBB@ HHHH **** "BBB@ HIDTT5O&9)Y4B0=6=@!7/WOC?1[0E8W>Y<?\
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M;Z3_ ,EK=K"O_P#D9=&^D_\ ):W:I[(F.[_KH%%%%24%%%% !1110 5D7/\
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M'^R8\#'UI<BL/G=_Z\CH;+5DOIK;R7@:&:$R</\ -D$#@>E68M3L9KDVT5Y
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M1;=/7JU<CUHK54TCDGB)RVT+%U?75[)ON9Y)6_VFS5>BBK,+W"BBB@04444
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M?U_6@N>._P#7]:G0"*,=(T'.>%%'E1YSY:YZYQ6-%KT\U@TB6!-RLQA>/?\
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M4M-ZB6AS">%;EH[>SN]6DGTZW<.D'E ,<?=#-W ITWA(3MJ4;WC?9;QQ,J!
M&BD&,,&_#I72T4 85EHE_'>)<7^KO<B-"D<:1B->>[ =34>F^%QI\NF/]JW_
M &*-TQLQOW'.>O%=#10!S\WAN5KB_N(-1E@FN9EF5D7[I48P1_$*ETG09++4
MI]1N[L7-U+&(\I$(U"CGH._O6W10M ,C5M&EU#4+"]M[O[/-:,V,H&#*P (_
M2JZ^&MOAN[TC[3G[0SMYFS[NYL],UOT4>0'-OX8N8]1DN[+41 9HU20- KGY
M1C*D]*AA\'RVMC8PV^I,LUG<-,DK1ALANH(_'K74LZHI9V"J.I)P!2]1D4 9
MVM:2NLZ6UF\IC)*L' S@@Y''<>U9(\+7<NH6UY=ZH)'@1XU1( B888Z#O73T
M4 87_",POX9BT:6=CY8!291@JP.013M/T:_AOTN[_5GNO*0I'&D8C7GNP'4U
MM$@=2!WH5E=0RL&4]"#D4>8%'5--&HQQ%96AGA??%*HSM/T[BLU_#=Q.UY)=
M:B99;F'R2?+ "C/89KH:*I2:V)<$W=F4=&S=//YWWK3[-C;^M,CT%4_LX--N
M6SB:,C;]\,,?A6Q11S,.2/\ 7]>1@Q>'YT6*V.HR&PB<.L(0!N#D MZ4R?PW
M.\=W;PZBT5I<DLT?E@D$^_I70T4<[%[.)B_\(\K+<JTY*SVJVYPO3 QFM#3K
M::SL8[>><3-&-H<)MR.W%6J*')O<:@EL%%%%249%_P#\C+HWTG_DM;M85_\
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M>5;&"5-6[/07M=5M;PW1E$-MY!W#YF.<YI+I<'Y&VN=HW8W8YQ2T44 %%%%
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MHF70T:***11GWFH&UU*T@:6%(I4D9U?.\[0#\O;CO5=/%.B2.%74(<LI8$G
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M:* ,6_T.XN;U[FUU2>U,JA70 ,..XST-7M,TV#2M-BL8 3'&.K<DGJ2:N44
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MC'NY)_E5I?ACJ0(/]HP@CT!J?K#Z1-%+$/54F<[XS_Y&R_\ ]\?R%8-=[/\
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MH 6BBB@ HHHH **** "BF1317$8DAD22,]&1@0?Q%/H **** "BBB@ HHHH
MX'XL:[_9OAM-.B;$]\V#CM&.OYG _.O"ZZKXA:W_ &WXLN71LP0?N8OH.OZY
MKE: "BBB@ HHHH OZ7K.H:+<B>PN7A<=0#P?J.]=S8^*-$\1XAU9%TV_/ NH
MQ^Z<_P"T.U>;T4TVMB914E9GIFHZ+=Z;AW59;=N4GB.Y&'UK.K#T'Q?J>@GR
MXY!/:-]^VF^9"/Z5V5G/H7B@#^SY5T_4#UM9F^1S_LM_2M8U.YQ5,*UK R:*
ML7MA=:?.8;J%XG'9AU^GK5>M#E:MN%%%%,04444 %%%% !1137<(N6-)M)78
MFU%78ZHGG .U1N;VJ[I.BZCXAN/*M(B(@?FE;[J_C7I^A>"M-T95D=!<7(ZR
M..A]A7-*M*6D/O,:?ML4[45:/\S_ $//])\&:UK(61D^S6Y_CEXR/8=:[C3/
MAYI%DJM<AKJ4=2YX_*NNQ@8%%9J"W>IZ%'+*$'S3]Y]V06]E:VB!+>".-?15
M J>BBK/0225D%%%% PHHHH 0@$8(!^M9=_X<TG4@?M-E$6/\0&#6K12:3W(G
M3A-6DKGG.K_#$'=)I5S@_P#/*7^AK@]2T>_TF8Q7ML\3=B1D'Z&OH*H+NRMK
MZ PW4*2QGJ&&:45*#O!V/-JY7#XJ#Y7^'W'SK17HWB/X=,@:YT<E@.3 QY_
MUY[+#)!(T<B,CJ<,K#!%=E+%IOEJ:/\  X74G2E[.NK/OT9'11178;A1110
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MF>0/7%24 %%%1K<0M</ LJF5 &9 >5!Z9H DHHJ*YN(;2VDN)W"11J6=CV%
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MH]U))604444#"BBB@ HHHH **** "BBB@ HHHH *YOQ-X1M-?A,B@0WBCY9
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M .OI/ZUJU3V1*^)A1114E!1110 4444 %<]=_P#(\V7_ %XR?^A"NAKGKO\
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MSK1I0CRHG!8?V%%1>[U?JPHHHJSK"BBB@ HHHH **** "BBB@ HHHH ****
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MBI+7P[=P001O)"3'?&Y)48&T]@*NT#.]3^O0EEU^[M%OH[NVC6>W@$R[&RK
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MMQI<VM:G<)]DC60K$B\D*3R3^%3V<6OZO:)J!U!;,2C?% L88!3TW$]Z .J
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MV.@U*^9=%TZ."?'RDNJ-[]ZT+^ZB70VU)#BXO(UB/X=:Y!3M8-@'!S@U<O\
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M:J1^';M=&T*S+Q[["5'E.>" "./SH7^7_!!_YE&7QZ,3W4,=L;*&0H0TV)7
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M4 >"?%>/9X[N&_YZ11M_XZ!_2N(KT;XQV^SQ/:7&.);4#\03_B*\YH ****
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M_P#>VC/YT-!$SAVB0N/XBHS4E% #&BC9MS1J6QC)'-*(T4@JB@@8&!T%.HH
M888F4J8T(8Y(*CDT@@A P(D QC[HZ>E244    P.!4?D1;BWE)DG.=HZ^M24
M4 ,>&*0@O&C$="R@XH\J/:5\M=K<D8X-/HH 8(8EC,8C0(>JA1C\J<JJBA5
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M \9Z[_9@MF!2$,)R1@[>",?RJY8^&)K";1"LJ.MF9FG8\%F?DD#ZDTD-C_\
MA(-3N9[F.QTV.469V7#-)@%\9*KZXH_X2I[T6,.EV@FNKJ-I2LC;1&JG!S^/
M%(VE:SIU]J#:4;62WOG\TB<D&)R,$C'4<5##X8OM).GW6F2PRW5O$T,RS9"R
MACN)XZ'-"\P90T[7+NRN-3FN+<B674X;<Q%\A-P R*Z2]UU;'6#:2H!"MJUR
MTF>0%[5AGPQJ]Q:7\EQ-;"]EO([N+;G8"F,*?RJS_86J:EJTMUJAMTBELWMC
M'"2=N>^3UHUM_7;_ ##K_7?_ ")K37=8NH[>Y&D@6MT,QL),LH(RI8>E8^D^
M)=1L/#2W-ZD<KS7CQ1R/(< [VSN/8#&!6M8:=XAACLK&:YMX[2UP#-$3OE51
M@ CH/>JUMH.M6NER6*?8I(H[EI$60$B9&8DAO0\]J'Y!Z_UN;FBZE<:C%*;F
M!(VC; >*3>CC'4&M2N=\-:%<:5<7UQ,L,"W)7;;6Y)2/ .2,]SFNBIL2"BBB
MD,*\.^+NF?9/%4=ZJX2\A#$_[2_*?T _.O<:X7XK:1_:'A/[4BYELI-^?]D\
M'^A_"@#P>BBB@ HHHH **** "BBB@ HHHH ** "3@#)KJ]#\"7^HQ"[OG&GV
M'4RR\,P_V1WH YB""6YF6&"-I)&.%51DFNXTOP#%:1K=^([CR$ZK:QG,C?7T
MK=M[G3/#\!M] M0LA&'O)1F1OIZ5F2S23R&25V=SR2QR: -.;6!!:?8=)MTL
M+,<;8_O/_O'J:R>O6BB@ J"X@\P!UX=>A%3T4I)-69E7HPK0=.:T9WO@CQ<M
M]"FF7\FV[08C9OXQZ?6NXKP*:%@XFA)613D$<5Z)X2\<1WJQV&IN([H?*LC<
M!_K[UG&3B^61P4,1/#S6'Q#])=_^"=S11UHK4]0**** "BBB@ HHHH ****
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MO^VG_P"@==_]\C_&C^VG_P"@==_]\C_&@#4P/048'H*R_P"VG_Z!UW_WR/\
M&C^VG_Z!UW_WR/\ &@#4P/048'H*R_[:?_H'7?\ WR/\:/[:?_H'7?\ WR/\
M: -3 ]!1@>@K+_MI_P#H'7?_ 'R/\:/[:?\ Z!UW_P!\C_&@#4P/048'H*R_
M[:?_ *!UW_WR/\:/[:?_ *!UW_WR/\: -3 ]!1@>@K+_ +:?_H'7?_?(_P :
M/[:?_H'7?_?(_P : -3 ]!7,^//#8\2>&IH(U'VJ'][ ?<=1^(_I6E_;3_\
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M=P/2C ]*I?V@?^?2?\A1_:!_Y])_R% %W ]*,#TJE_:!_P"?2?\ (4?V@?\
MGTG_ "% %W ]*,#TJE_:!_Y])_R%']H'_GTG_(4 7<#THP/2J7]H'_GTG_(4
M?V@?^?2?\A0!=P/2C ]*I?V@?^?2?\A1_:!_Y])_R% %W ]*,#TJE_:!_P"?
M2?\ (4?V@?\ GTG_ "% %W ]*,#TJE_:!_Y])_R%']H'_GTG_(4 7<451&I
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MM_.>),#&Y0X++GU':@#*R<8R<>E*TCL &=B!T!-=+)X7^RZC8PR9F2="6",
M=V">*S+;0;V^:5K>-5B1RH:1PHSZ9[F@#-\Q\ ;VP.@S3:THM"U&6YGMU@/F
MPC+J3C J/4-(N],\LW"KMD&59&W _C0!1HHHH **** "I['_ (_[;_KJO\Q4
M%3V/_'_;?]=5_F* .TUC_D*S_4?RJC5[6/\ D*S_ %'\JHT %%%% !1110!I
MII"&UBGEO(XA*,@,IJ%M/Q;7$Z3JZ0L%R!][-:4]V+72+#]S')E3]\9Q45FZ
MOI%VS *IF4D#TR* ,@PR*@<QL%/?'%'DR;@OEMDC(&*ZBZ.([D[&:W,7RDL
MOMCWIEL)/[+6,L@O3&?+SUVT 84-B9DB(E :1]FT@\4RYM);:6164E48KOQP
M:UK08L;+=]X7)SFK4WGB34&N2#;%3LR1C/;%#!&#<V+VWD?-O,J!P .E5WC>
M,X=&4^A&*Z>(Q_:[3=C=]D^3ZU0U@D6<"RHPEW'!=@6Q^%#!&+1110 4444
M%%%% !1110 4444 .C1I9%1!EF. *[73K);"T6(??/+GU-9GA_3=B_;)5Y/$
M8/\ .MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** *M]_R[?\ 7=?ZUH5GWW_+M_UW7^M:% !1110
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M;BM?4;Y-.LI+EXY) N,)&,LQ/0"AZ M2U17/P^)9'O&L9]/FM[IX&FA5R"'
MZCV-+X0U.]U711<7T963>P#$CYAF@#?HK!/B4?VM=62V<K):$>?/D!47&<U#
M#XNC?R)Y+"XBL;APD5RV,'/0D=@:%J!TE%<_<^*!'=745K83W<=H=L\D>,*>
MI ]2*;-XLA^U6MO96LMV]U;?:(]F!QG'/I0!T5%<LGC6*2U6[&GW(M5D$4TI
MQB-LXQ[\UU ((!'0T +1110 4444 %%%% !1110!Y]XQ\/"TE.HVJ?N)#^\4
M?P-Z_2N1KVR:*.XA>&50T;C# ]Q7EWB/0)=&N\J"UK(<QOZ>QH Q**** "BB
MB@!T9 D4GH"*ZO7/%,Z7@33KB,P^4HWJHR#CGFN2HH WSJ2?\(@UO]H_TI[K
M>RYY*X/-:*7%E?G2[LZ@EO\ 8U421-G/![?6N/HH Z^74;/6+*^MQ<I:,UQY
MJE^ RU9.K:>->LF%VKQ"S\EI?1L8YKAZ*/Z_0#K1<V.F:.MN+R*XE6\$K*GI
M46K+92S7NH)JH*SC,<*$[B?0^U<O10!VWV^R_MC2;XWL7EI#Y;J2<J=IZU3\
MZTU324M!?1VLD,[.2^0'!/6N5HH [2?6K*6?4RDX -H(8W/!D(]*QM0O()O#
M.F6ZRAIHF?>O=>>*Q** "BBB@ HHHH *GL?^/^V_ZZK_ #%05/8_\?\ ;?\
M75?YB@#M-8_Y"L_U'\JHU>UC_D*S_4?RJC0 4444 %%%6M.@CN;Z.*5L(>OO
M0!6+$@ DD#I1D@$9.#VK9OK2VCMY,VLEO(I^0YR&JJND3M$'+QJS+N"$\D4
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M!S^O?#K2O$&K2:C=37"RR  A",<#%=18VB6&GV]G$28X(UC4GJ0!BK%%"TT
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MT:*'-M6"--1=T<M=:1>2?VAMBSYM]'*G/51C)_2K]Y87$NNK<HF8A9/%G/\
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M3"UQ:@RVO7CJGUH YJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6#>R7<?AI+&-K:6V\U$257RSC>,#;ZUTEIIUQ%/JKL%Q<X\OG_9QS3:BE?\
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MI+>6&.5"\4C]& Y_#BCD=KASQO8V**PT\2QL(YVM)ULY&VI<$<'/0_2K*:U
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M[:,B)CV-7J*;U5@6CN>?6V@WYU?1[H:;<1_9YMUQ)/<;V.5(R!Z9J]_8=_\
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M>T=@]DKW,318;W^TM0N[NV\@3E2B[L\ 5MT45+=RHQL%%%%(H**** "BBB@
MHHHH " RE6 (/4&N8UGP9:7VZ:S(MYSSM_A;_"NGHH \?U'1K[2W*W,#*.SC
MD'\:H5[;)&DR%)45T/4,,BN8U7P19W9,ED_V>0_PGE3_ (4 ><T5JZCX=U+3
M23-;ED'\:<BLKIUH **** "BBB@ HHHH **** "I['_C_MO^NJ_S%05/8_\
M'_;?]=5_F* .TUC_ )"L_P!1_*J-7M8_Y"L_U'\JHT %%%% !1110 4444 %
M%%% !115FVT^ZNSB*)B/4\"@"M4UO:3W3[88V8^PXKH+/PY&A#W3[S_<7I6U
M'%'"@2)%11V H Q;#P]''B2[.]O[@Z?C6VJJBA44*HZ "EHH **** "BBB@
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M&\3)\X8]!BHF\1(T5RBVMQ'=10F58I$P6'J*SKRSU..74I+:!\2W4;97&YD
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MO[0L?[LMG& :T[;6;>ZN[VW17#VBJSY'4,NX8KB;[^T='\'SZ--IDC+$^!=
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MK;/]ZWB/_ !4M% %-])TZ3[]C ?^ 52CTS3!K/V9=.MP%B$H8+SG-;-9\?\
MR,S?]>O_ +-0!+?VMJB><UM&[LZ@EAZG%2+8VB_=MHA_P&EU/_CU7_KHO\ZF
M[4 ,$,*_=BC'_ 13QA>@ ^@HHH ,GUHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY% $']IV/_/U%_WU1_:=C_S]1?\ ?53_ -GV?_/M%_WR*/[/L_\ GVB_[Y%
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M47_?53_V?9_\^T7_ 'R*/[/L_P#GVB_[Y% $']IV/_/U%_WU1_:=C_S]1?\
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MT-,^RP?\\4_[YH @^UV__/9/SH^UV_\ SV3\ZG^RP?\ /%/^^:/LL'_/%/\
MOF@"#[7;_P#/9/SH^UV__/9/SJ?[+!_SQ3_OFC[+!_SQ3_OF@"#[7;_\]D_.
MC[7;_P#/9/SJ?[+!_P \4_[YH^RP?\\4_P"^: (/M=O_ ,]D_.C[7;_\]D_.
MI_LL'_/%/^^:/LL'_/%/^^: (/M=O_SV3\Z/M=O_ ,]D_.I_LL'_ #Q3_OFC
M[+!_SQ3_ +YH @^UV_\ SV3\Z/M=O_SV3\ZG^RP?\\4_[YH^RP?\\4_[YH @
M^UV__/9/SH^UV_\ SV3\ZG^RP?\ /%/^^:/LL'_/%/\ OF@"#[7;_P#/9/SH
M^UV__/9/SJ?[+!_SQ3_OFC[+!_SQ3_OF@"#[7;_\]D_.C[7;_P#/9/SJ?[+!
M_P \4_[YH^RP?\\4_P"^: (/M=O_ ,]D_.C[7;_\]D_.I_LL'_/%/^^:/LL'
M_/%/^^: (/M=O_SV3\Z/M=O_ ,]D_.I_LL'_ #Q3_OFC[+!_SQ3_ +YH @^U
MV_\ SV3\Z/M=O_SV3\ZG^RP?\\4_[YH^RP?\\4_[YH @^UV__/9/SH^UV_\
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>plx-20200930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 11:26:00 AM-->
<!--Modified on: 10/29/2020 11:26:00 AM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20200930" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20200930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePromissoryNote" id="DisclosurePromissoryNote">
        <link:definition>10701 - Disclosure - PROMISSORY NOTE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails" id="DisclosurePromissoryNoteNarrativeDetails">
        <link:definition>40701 - Disclosure - PROMISSORY NOTE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" name="StockIssuedDuringPeriodIssuePricePerShareNewIssues" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" name="WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_NonRefundablePayment" name="NonRefundablePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" name="SeniorVicePresidentAndChiefDevelopmentOfficerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_PresidentAndChiefExecutiveOfficerMember" name="PresidentAndChiefExecutiveOfficerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" name="ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>plx-20200930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 11:26:00 AM-->
<!--Modified on: 10/29/2020 11:26:00 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637395675591938353" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637395675591938353" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675591938353" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637395675591938353" xlink:to="plx_ShortTermBankDeposits_637395675591938353" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637395675591938353" xlink:to="us-gaap_AccountsReceivableNetCurrent_637395675591938353" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637395675591938353" xlink:to="us-gaap_OtherAssetsCurrent_637395675591938353" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637395675591938353" xlink:to="us-gaap_InventoryNet_637395675591938353" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637395675591938353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637395675591938353" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637395675591938353" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637395675591948361" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637395675591938353" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637395675591948361" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637395675591938353" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637395675591948361" order="3" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637395675591948361" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637395675591948361" xlink:to="us-gaap_LiabilitiesNoncurrent_637395675591948361" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637395675591948361" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637395675591948361" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637395675591948361" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637395675591948361" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637395675591948361" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637395675591948361" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637395675591958349" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637395675591948361" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637395675591958349" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637395675591948361" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637395675591958349" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637395675591948361" xlink:to="us-gaap_LiabilitiesCurrent_637395675591958349" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637395675591958349" xlink:to="us-gaap_AccountsPayableTradeCurrent_637395675591958349" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637395675591958349" xlink:to="us-gaap_AccountsPayableOtherCurrent_637395675591958349" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637395675591958349" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637395675591958349" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637395675591958349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637395675591958349" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637395675591958349" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637395675591958349" xlink:to="us-gaap_NotesPayableCurrent_637395675591968345" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637395675591968345" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637395675591968345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637395675591968345" xlink:to="us-gaap_CostOfRevenue_637395675591968345" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637395675591968345" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637395675591968345" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637395675591968345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637395675591968345" xlink:to="us-gaap_Revenues_637395675591968345" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637395675591968345" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637395675591978353" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637395675591978353" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637395675591978353" xlink:to="us-gaap_OtherNonoperatingExpense_637395675591978353" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637395675591978353" xlink:to="us-gaap_OtherNonoperatingIncome_637395675591978353" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_NetIncomeLoss_637395675591978353" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_ShareBasedCompensation_637395675591978353" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637395675591978353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_Depreciation_637395675591978353" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637395675591988353" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637395675591988353" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637395675591988353" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_AmortizationOfFinancingCosts_637395675591988353" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637395675591988353" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637395675591988353" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637395675591988353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637395675591988353" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637395675592001241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_IncreaseDecreaseInInventories_637395675592001241" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637395675592001241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637395675592001241" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637395675592001241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675591978353" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637395675592001241" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" xlink:to="plx_IncreaseDecreaseInBankDeposits_637395675592008352" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637395675592008352" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637395675592008352" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592001241" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637395675592008352" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592008352" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592008352" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637395675592008352" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637395675592008352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592008352" xlink:to="us-gaap_ProceedsFromWarrantExercises_637395675592008352" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637395675592018349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637395675592018349" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637395675592018349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637395675592018349" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637395675592018349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637395675592018349" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637395675592018349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637395675592018349" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>plx-20200930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 11:26:00 AM-->
<!--Modified on: 10/29/2020 11:26:00 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637395675592018349" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637395675592018349" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637395675592048352" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637395675592048352" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637395675592058361" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637395675592058361" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637395675592188369" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637395675592188369" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592198380" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592198380" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637395675592198380" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637395675592198380" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637395675592208364" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637395675592208364" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637395675592208364" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637395675592208364" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592228354" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592228354" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637395675592238356" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637395675592238356" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592298361" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592298361" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637395675592308359" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637395675592308359" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherOperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NonRefundablePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592358386" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592358386" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_VicePresidentMember" xlink:label="srt_VicePresidentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_VicePresidentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637395675592358386" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_637395675592358386" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637395675592378362" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637395675592378362" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>plx-20200930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 11:26:00 AM-->
<!--Modified on: 10/29/2020 11:26:00 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Financial expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expenses, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss per share of common stock - Basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares of common stock used in computing loss per share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" xlink:to="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount from Receivables (Payments) from sale of common stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivables (Payments) From Sale Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable payment</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock award</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock award (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of share Warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (decrease) in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase in bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">PROMISSORY NOTE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Atm Equity Offering Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Per share price at which the new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Issue Price Per Share, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Warrants And Rights, Commencement Period For Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, commencement period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Proceeds from Sale and Collection of Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US">Other Operating Income</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NonRefundablePayment" xlink:to="plx_NonRefundablePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Amount of non refundable payment received, but not yet recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non Refundable Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non refundable payments not yet recognized to revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment on notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">This member stands for President and Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">President And Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">President and Chief Executive Officer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">This member stands for Senior Vice President and Chief Development Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">Senior Vice President And Chief Development Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Development Officer [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_VicePresidentMember" xlink:label="srt_VicePresidentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_VicePresidentMember" xlink:to="srt_VicePresidentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_VicePresidentMember_lbl" xml:lang="en-US">Vice President [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_VicePresidentMember_lbl" xml:lang="en-US">Vice President [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share Based Payment Arrangement Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Certain employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>plx-20200930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 11:26:00 AM-->
<!--Modified on: 10/29/2020 11:26:00 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosurePromissoryNote" roleURI="http://www.protalix.com/role/DisclosurePromissoryNote" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200930.xsd#DisclosurePromissoryNoteNarrativeDetails" roleURI="http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637395675592428370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637395675592428370" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637395675592428370" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637395675592428370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637395675592428370" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637395675592428370" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637395675592428370" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637395675592428370" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637395675592428370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637395675592428370" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637395675592438381" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3_637395675592438381" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637395675592438381" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637395675592438381" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637395675592438381" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637395675592438381" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637395675592438381" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637395675592438381" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637395675592438381" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637395675592438381" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637395675592438381" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637395675592438381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637395675592438381" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637395675592448363" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637395675592448363" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637395675592448363" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637395675592448363" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637395675592448363" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637395675592448363" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637395675592448363" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637395675592448363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637395675592448363" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637395675592458361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637395675592458361" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637395675592458361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637395675592458361" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637395675592458361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637395675592458361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637395675592458361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637395675592458361" xlink:to="us-gaap_AssetsCurrentAbstract_637395675592458361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675592469997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="plx_ShortTermBankDeposits_637395675592469997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="us-gaap_AccountsReceivableNetCurrent_637395675592469997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="us-gaap_OtherAssetsCurrent_637395675592469997" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="us-gaap_InventoryNet_637395675592469997" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637395675592458361" xlink:to="us-gaap_AssetsCurrent_637395675592469997" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637395675592458361" xlink:to="us-gaap_AssetsNoncurrentAbstract_637395675592469997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637395675592469997" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637395675592469997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637395675592469997" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637395675592469997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637395675592469997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637395675592469997" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637395675592469997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637395675592469997" xlink:to="us-gaap_AssetsNoncurrent_637395675592478377" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637395675592458361" xlink:to="us-gaap_Assets_637395675592478377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637395675592478377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_AccountsPayableTradeCurrent_637395675592478377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_AccountsPayableOtherCurrent_637395675592478377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637395675592478377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637395675592478377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_NotesPayableCurrent_637395675592478377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637395675592478377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637395675592478377" xlink:to="us-gaap_LiabilitiesCurrent_637395675592478377" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637395675592488370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637395675592488370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637395675592488370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637395675592488370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637395675592488370" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637395675592488370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_LiabilitiesNoncurrent_637395675592488370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_Liabilities_637395675592488370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637395675592488370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_CommitmentsAndContingencies_637395675592488370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_StockholdersEquity_637395675592498368" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637395675592478377" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637395675592498368" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637395675592498368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592498368" xlink:to="srt_ProductOrServiceAxis_637395675592498368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637395675592498368" xlink:to="srt_ProductsAndServicesDomain_637395675592498368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637395675592498368" xlink:to="us-gaap_ProductMember_637395675592498368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637395675592498368" xlink:to="us-gaap_LicenseAndServiceMember_637395675592498368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592498368" xlink:to="us-gaap_StatementLineItems_637395675592498368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637395675592498368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_Revenues_637395675592498368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_CostOfRevenue_637395675592508374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637395675592508374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637395675592508374" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_OperatingIncomeLoss_637395675592508374" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_OtherNonoperatingExpense_637395675592508374" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_OtherNonoperatingIncome_637395675592508374" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_NonoperatingIncomeExpense_637395675592508374" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_NetIncomeLoss_637395675592508374" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637395675592508374" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592498368" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637395675592508374" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592508374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637395675592508374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592508374" xlink:to="us-gaap_IncomeStatementLocationAxis_637395675592518375" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637395675592518375" xlink:to="us-gaap_IncomeStatementLocationDomain_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637395675592518375" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637395675592518375" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637395675592518375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592508374" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637395675592518375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637395675592518375" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592518375" xlink:to="us-gaap_StatementEquityComponentsAxis_637395675592518375" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637395675592518375" xlink:to="us-gaap_EquityComponentDomain_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637395675592518375" xlink:to="us-gaap_CommonStockMember_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637395675592518375" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637395675592518375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637395675592518375" xlink:to="us-gaap_RetainedEarningsMember_637395675592518375" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592518375" xlink:to="us-gaap_StatementLineItems_637395675592518375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637395675592518375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_StockholdersEquity_637395675592518375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_SharesOutstanding_637395675592528375" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637395675592528375" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637395675592528375" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637395675592528375" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants_637395675592528375" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637395675592528375" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637395675592528375" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercised_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercised_637395675592528375" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercised_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercised_637395675592528375" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_NetIncomeLoss_637395675592528375" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637395675592528375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_StockholdersEquity_637395675592528375" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592518375" xlink:to="us-gaap_SharesOutstanding_637395675592538374" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637395675592538374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637395675592538374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_NetIncomeLoss_637395675592538374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_ShareBasedCompensation_637395675592538374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_Depreciation_637395675592538374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637395675592538374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637395675592538374" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637395675592538374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637395675592538374" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_AmortizationOfFinancingCosts_637395675592548378" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637395675592548378" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637395675592548378" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637395675592548378" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="us-gaap_IncreaseDecreaseInInventories_637395675592548378" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637395675592548378" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637395675592548378" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637395675592548378" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637395675592538374" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637395675592548378" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637395675592548378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" xlink:to="plx_IncreaseDecreaseInBankDeposits_637395675592548378" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637395675592558372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637395675592558372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637395675592558372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637395675592548378" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637395675592558372" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637395675592558372" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637395675592558372" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637395675592558372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637395675592558372" xlink:to="us-gaap_ProceedsFromWarrantExercises_637395675592558372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637395675592558372" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637395675592558372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637395675592558372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637395675592558372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637395675592568371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637395675592568371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675592568371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637395675592568371" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6373956755925683711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6373956755925683711" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637395675592568371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637395675592568371" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637395675592568371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637395675592568371" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637395675592568371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637395675592568371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637395675592568371" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637395675592568371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637395675592578382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637395675592578382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePromissoryNote" xlink:type="extended" xlink:title="10701 - Disclosure - PROMISSORY NOTE">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637395675592588380" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637395675592588380" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592588380" xlink:to="us-gaap_DebtInstrumentAxis_637395675592588380" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637395675592588380" xlink:to="us-gaap_DebtInstrumentNameDomain_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637395675592588380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637395675592588380" xlink:to="plx_Notes2021Member_637395675592588380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592588380" xlink:to="us-gaap_StatementLineItems_637395675592598381" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592598381" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="us-gaap_TypeOfArrangementAxis_637395675592598381" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637395675592598381" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592598381" xlink:to="plx_AmendedPfizerAgreementMember_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592598381" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_637395675592598381" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592598381" xlink:to="plx_ChiesiAgreementsMember_637395675592598381" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637395675592598381" xlink:to="plx_ChiesiUSAgreementMember_637395675592598381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637395675592598381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637395675592598381" xlink:to="plx_ChiesiExUSAgreementMember_637395675592598381" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="dei_LegalEntityAxis_637395675592608382" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637395675592608382" xlink:to="dei_EntityDomain_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637395675592608382" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="srt_StatementGeographicalAxis_637395675592608382" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637395675592608382" xlink:to="srt_SegmentGeographicalDomain_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637395675592608382" xlink:to="country_BR_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="srt_RangeAxis_637395675592608382" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637395675592608382" xlink:to="srt_RangeMember_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637395675592608382" xlink:to="srt_MinimumMember_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637395675592608382" xlink:to="srt_MaximumMember_637395675592608382" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="us-gaap_DebtInstrumentAxis_637395675592608382" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637395675592608382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637395675592608382" xlink:to="us-gaap_DebtInstrumentNameDomain_637395675592608382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637395675592608382" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637395675592618373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637395675592608382" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637395675592618373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637395675592618373" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637395675592618373" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592618373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592618373" xlink:to="us-gaap_PrivatePlacementMember_637395675592618373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="us-gaap_SubsequentEventTypeAxis_637395675592618373" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637395675592618373" xlink:to="us-gaap_SubsequentEventTypeDomain_637395675592618373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637395675592618373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637395675592618373" xlink:to="us-gaap_SubsequentEventMember_637395675592618373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637395675592598381" xlink:to="plx_SignificantAccountingPoliciesLineItems_637395675592628386" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637395675592628386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637395675592628386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637395675592628386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_637395675592628386" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637395675592628386" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637395675592628386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637395675592628386" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637395675592638379" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637395675592638379" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_PaymentOnNetSalesPercentage_637395675592638379" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637395675592638379" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637395675592638379" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637395675592638379" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637395675592638379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637395675592638379" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637395675592648376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637395675592648376" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637395675592648376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637395675592648376" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637395675592648376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637395675592648376" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637395675592648376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637395675592648376" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592648376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592648376" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637395675592738389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637395675592738389" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_637395675592738389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_637395675592738389" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592738389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592738389" order="21" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637395675592738389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637395675592628386" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637395675592738389" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637395675592748382" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637395675592748382" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637395675592748382" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_StatementTable_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592748382" xlink:to="us-gaap_DebtInstrumentAxis_637395675592748382" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637395675592748382" xlink:to="us-gaap_DebtInstrumentNameDomain_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637395675592748382" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592748382" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592748382" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592748382" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592748382" xlink:to="us-gaap_FairValueInputsLevel3Member_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592748382" xlink:to="us-gaap_MeasurementInputTypeAxis_637395675592748382" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637395675592748382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637395675592748382" xlink:to="us-gaap_MeasurementInputTypeDomain_637395675592748382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637395675592748382" xlink:to="us-gaap_MeasurementInputSharePriceMember_637395675592758392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637395675592748382" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637395675592758392" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637395675592748382" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637395675592758392" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637395675592748382" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637395675592758392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637395675592748382" xlink:to="plx_MeasurementInputYieldMember_637395675592758392" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592748382" xlink:to="us-gaap_StatementLineItems_637395675592758392" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592758392" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637395675592758392" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_StatementTable_637395675592758392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592758392" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592758392" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637395675592758392" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592758392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637395675592758392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637395675592758392" xlink:to="us-gaap_FairValueInputsLevel3Member_637395675592758392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592758392" xlink:to="us-gaap_DebtInstrumentAxis_637395675592768379" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637395675592768379" xlink:to="us-gaap_DebtInstrumentNameDomain_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637395675592768379" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592758392" xlink:to="us-gaap_StatementLineItems_637395675592768379" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592768379" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592768379" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637395675592768379" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592768379" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637395675592768379" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592768379" xlink:to="srt_ProductOrServiceAxis_637395675592768379" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637395675592768379" xlink:to="srt_ProductsAndServicesDomain_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637395675592768379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637395675592768379" xlink:to="us-gaap_ProductMember_637395675592768379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637395675592768379" xlink:to="us-gaap_LicenseAndServiceMember_637395675592778395" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592768379" xlink:to="us-gaap_TypeOfArrangementAxis_637395675592778395" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637395675592778395" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592778395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592778395" xlink:to="plx_ChiesiAgreementsMember_637395675592778395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592768379" xlink:to="srt_StatementGeographicalAxis_637395675592778395" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637395675592778395" xlink:to="srt_SegmentGeographicalDomain_637395675592778395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637395675592778395" xlink:to="plx_PfizerMember_637395675592778395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637395675592778395" xlink:to="country_BR_637395675592778395" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637395675592778395" xlink:to="plx_ChiesiMember_637395675592778395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637395675592768379" xlink:to="us-gaap_StatementLineItems_637395675592778395" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592778395" xlink:to="us-gaap_Revenues_637395675592778395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592778395" xlink:to="us-gaap_OtherOperatingIncome_637395675592778395" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment_637395675592778395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637395675592778395" xlink:to="plx_NonRefundablePayment_637395675592778395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="srt_TitleOfIndividualAxis_637395675592788387" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637395675592788387" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592788387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592788387" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember_637395675592788387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592788387" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637395675592788387" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_VicePresidentMember" xlink:label="srt_VicePresidentMember_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637395675592788387" xlink:to="srt_VicePresidentMember_637395675592788387" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="us-gaap_GranteeStatusAxis_637395675592788387" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637395675592788387" xlink:to="us-gaap_GranteeStatusDomain_637395675592788387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637395675592788387" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637395675592788387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637395675592788387" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592788387" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637395675592788387" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592788387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637395675592788387" xlink:to="us-gaap_PrivatePlacementMember_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="us-gaap_TypeOfArrangementAxis_637395675592798392" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637395675592798392" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637395675592798392" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="us-gaap_AwardTypeAxis_637395675592798392" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637395675592798392" xlink:to="us-gaap_RestrictedStockMember_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637395675592788387" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637395675592798392" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637395675592798392" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637395675592798392" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637395675592798392" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637395675592808383" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637395675592808383" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637395675592808383" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637395675592808383" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637395675592808383" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637395675592808383" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637395675592808383" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637395675592808383" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637395675592808383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637395675592808383" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637395675592818384" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637395675592818384" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637395675592818384" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637395675592798392" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637395675592818384" order="16" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - PROMISSORY NOTE (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_NotesPayableCurrent_637395675592818384" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637395675592818384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637395675592818384" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>plx-20200930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20200930"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20200930.xsd" xlink:type="simple"/>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_1fRceHFMtEWWoTuOudr_4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E7ojsykV9EKg72W5j6pVFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-19</startDate>
            <endDate>2019-12-19</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IRzIhsYvXUKaSF2OewJ56A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O6L8OVTlsEu_2HaEKKHaow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8HscStIMCky71Xpz36-FCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rNDZG8xgrkK9Eqv3ngpLpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AHiYkPc4FUK56R6zTg4LjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cr_aPjmKT0mYjDg02J2Z7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_fef2AszHPU-bAj2nZEQDdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yB5LZFDEhEyvveEfDJ5-QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fK7QWqX6s0q9WkkFwHaS9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_awAX9aPeuk2iZshhHY-mww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-22</startDate>
            <endDate>2020-09-22</endDate>
        </period>
    </context>
    <context id="As_Of_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qrzLO1Itnk-vHNuLIHMrCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-22</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_okYXxp9UpUmRkgl9piR4yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z72QeSjod0mfL9i7a-nY-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_4CFqkzlEM0a0ykFUdbprNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JUeLT0AOY0GhjA3MadGoNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Mzmg7jvLfEe4iybt5-W0xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_V4-yU8AA-0avjmtvGhaOeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CsulLJ3GXEOV9Zoac507-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3utDIYnGnk23SwkpDHFalw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_c-o4-zlu6k-zZmFIhIvfgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ECNMuJ7DQkuqCfY-v0kl1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_m0iRbIUWmE-NwcxiFKbfxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uJj9XUZ3jEK_nwNQ1ytYrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_Gx20S_jXlEO4XT5ZwA9LaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-14</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_uMfCJEZpY02sFvVTznIY5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_7TPGAQhZOUmeeaZ_5HG55g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vbfxSpJnx0SCEmInPOXG3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VCj1F6qAZEeCpBg6hY-teg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sfvdWUnu6EO7cndkxiekuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZNbuEF-wWkuGqpCEaHk7nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bjCDIQN02Uam1toNzw9LSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2oLx1XpEpEeKkThOFBF0qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WZZ4r5XXfEOp6GCJNBLRVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_pJdr0YSp5USwhCNaVQZ9eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_Nrylmm7X3kaU8w3XPffnbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-18</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hXjv6Jrv6kedC9tuTT8GcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_pRcDTGYiEECDc0dojMQDWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZdfRPnCjeEyvM5HwjCNBXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4MopdnOnJEGxDhBhT6bjmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uoOZj9fvI0O5KtUKJ2QUVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e1_nZMaTIE-COHRAayOIMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oKcfDa3A0kGpkbFODB1jxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__Df5EeyoJU2aHMqKSUD2rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kM2vCYwSV0uRlWIJmg2-4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:VicePresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_KfZU-gIvU0mW3QuavJGUpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_edPTlz70sE-KPAY6iEzxFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:VicePresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_NLt0-efPfky_nzLBvyGDpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6ofRVpdY5EC3THAh6MbRNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Jv4KEHGwEEGDjCnT8dmZzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PdUn1DLSjky-oL6yd58gsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_2bYIXNG5N0WSrA0hwUb6RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_3_16_2020_To_3_16_2020_WyJvhboxckK2jqSgzcbqVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_qPVNjr3QxkiUTyW7b-790A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2020_ruhy-1MfX0uWd0p6iXkV2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      id="Hidden_xdFpZTDUUUmvlnSscrMvyQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      id="Hidden_nF2grAOuTEiTir1RtpXs8A"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_yaHo7uX_EEuZbcZG8U3Cww_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_H0OTMgO5_Ui1dv3MhmA_FQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_Iy_LBDBvvEqn2ojsncFkOQ_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_A-FYqUg1VEaO0Z64g0nUEA_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr__dHczwVpUk-w3sW-OBbolA">false</dei:AmendmentFlag>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ"
      decimals="-5"
      id="Hidden_2X7HaISLh0Kcb4gJc90IJw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_CyCKlZL-sEqnK8troakvYQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_e4QZBLRISE-05cnurUERUQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_E-G0GQshv0C4zX4MbDZNMQ">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_lh7O0SQ03UWUU3fTXeiecQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_vLJdIZGJo0C-hBSnSZqxxw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_C9ujogqWnUqjODkjW2o9Gw">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc__BpqH_3Rt0m-CoyQWx8NIw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_qSuGNJlz40eV4iD0tqMsBA">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_Z_5A5VVqWEemGLPToLkgBw">2 Snunit Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_5mL_DlE1q0GnPl8Hl_6Dqg">Science Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_Dy0X4urIVEmX5KvThGueKg">POB 455</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_ywLXmF0Ji0eFchac5kj0MA">Carmiel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_mgLAg9KKtkCP-hx6A9MxyA">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_SVq1qiKkmE2s_XIFIg82lQ_4_1">2161401</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_2Pt2HHYa20m25KOHrekSFw">972-4</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_NStUCrkwBEaAc5fP5EdcsA">988-9488</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_vXaDFNbXN0OBcVC8MNSxKA_2_0">Common stock, par value $0.001 par value, </dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_YoWXzpXhk0-KncP9ghZdog_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_7v5Ez7celkOJrpQ0UnGouw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_5qQ9gMDO3Eiv8KStcjonHA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_UCbrFH549E2OkJon3__81w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_84NN43IF1USN_gI6_GMSbw_1_2">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_ff_Py9lU7Uec8OtrcVZakg_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tc_BO4u_Dx8W0SLR4EiKIPI5g_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Narr_On8gfe3QK0ukBhk8DeI0ZA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_10_15_2020_ruhy-1MfX0uWd0p6iXkV2Q"
      decimals="INF"
      id="Narr_n6iUjCoSlEyAt6LdMmc1ag"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">33336709</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_LoqexGX04k-8dqS7UHEJwA_6_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">13533000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_L9vCM8v3rkmEGI3eeplQRQ_6_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_pKE0NzJlnk6xV030DwNvVw_7_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">27760000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_8Y0vRkpN1EixkwC8UtSO8g_8_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3146000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc__KgX0KrkZkW3bxhFhNrZyQ_8_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_ZMdGPKqyj0y13Eu4uALn8A_9_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2612000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_lEmTuJHUSkyCRGiHuEKh1g_9_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1832000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_0m9mNqnKYU269u3rCkJFbw_10_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">13281000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_RTlDA6mvk0WEkP5JR43OcQ_10_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">8155000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_DqBDn3kKZkqkV79f3uctoQ_11_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">60332000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_VLAz9hvETEOKgT4Ri_mFvg_11_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">32479000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_BkgbjyUdk0ycbXe7EvpFVQ_14_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1639000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_kIN4cRqPeUOYX53pVOIXbQ_14_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1963000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_GJZxr66KtEWjo7tPE58k4Q_15_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4639000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_FmvOIwiBgE6uSI6i1huyfQ_15_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5273000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_yWSY-Uf01EKGhvmQPMpJVQ_16_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_IBYsboH-F06rW-NwvPKVDg_16_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5677000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_9QCdlmk4RkWelM8K0qlLEQ_17_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">11978000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_Ac_e_wVHNEO9SBfiYPop4A_17_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">12913000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_iqtBukd_wUOlwl60ByDRYQ_18_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">72310000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_cymuoKOYzU6-kHM2cX4JvA_18_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">45392000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_ZqeNROjdpUa-bRQFnUoV0g_24_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">8351000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_C18akNK0fkWUsJjCcAyKmw_24_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">6495000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_d4kYEdG5l0WovMa-6LNOFg_25_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">13347000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_Rmf-XMRlJ0eE4muYQXFc9Q_25_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">11905000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_D8wb5mIaPECPa1BVAqwilg_26_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1176000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_HCnB2Jy07Uqanw8sKZsGow_26_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1139000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_xRYdYfsCg0-wbn-RuqjW5A_27_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">16720000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_G91iDCAza0ybUsNt8IxElA_27_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">16335000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_uov9kIss1kOtGxS8zfS6nw_28_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4301000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_ZGzw_D15mEiCj3on5Zkppg_28_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4301000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_l2fMhG2pSUyHdChq7yo0ug_29_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">43895000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_0aEGD7yu20-WWmf22Ppm2w_29_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">40175000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_aCj8F70rd0yLGDAR3gWKhA_32_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">53505000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_NO94G4pgH0iN-TyN3I4Elg_32_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">50957000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_rmexSZh4w02G1iUlFY-vUA_33_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1533000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_1ChgIa9QoEquLP5pN2z9vQ_33_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">16980000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_g0rOF2WkQE-8EqMcW2nJMA_34_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2088000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_YDL92BlNzkaxBvOgbRgEeA_34_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2565000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_HbHYlM9dRE28gApriGAZ9Q_35_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4558000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_esQjipZoYU2MhxtWL-VpYg_35_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4528000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_w9iQlHLoeEy7Q7ydA8126g_36_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">46000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_cXiL53R2QE-FuUhaJ8M48Q_36_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">509000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_E-RFqBngVU-5-8DTXZLPNw_37_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">61730000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_04YdR1VC1UuaKrY87AK8qw_37_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">75539000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc__svow_mJlU2QBrRx_BXSEQ_38_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">105625000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_xzazQEkPJE2e7dPqPjUiQA_38_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">115714000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_pctpvkvXY0quFzYhXcTk4w_42_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-33315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc__2hVDcVam0OU79NEvGVGpw_42_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-70322000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_cAW8KcrNxEuyghIten2okw_43_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">72310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_dt_F6MTKCUWr5ujueRwMsg_43_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">45392000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug"
      decimals="-3"
      id="Tc_foIAy4-Om0yEnXbQveIz_w_3_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">11975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ"
      decimals="-3"
      id="Tc_vUfcRHI4uUWoN_4F9Xe25Q_3_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">12086000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_okYXxp9UpUmRkgl9piR4yQ"
      decimals="-3"
      id="Tc_I0RyE2sbwkmhyWpNiOC2OA_3_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3296000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_V4-yU8AA-0avjmtvGhaOeA"
      decimals="-3"
      id="Tc_CPiSIbaOM02LB2PU-j5Ilw_3_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5126000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ"
      decimals="-3"
      id="Tc_oiPABCvOH02cnmvNrJfkQQ_4_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">31428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA"
      decimals="-3"
      id="Tc_I8cmOpKBV0C7KCil6K2QpQ_4_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">24848000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z72QeSjod0mfL9i7a-nY-A"
      decimals="-3"
      id="Tc_CpQB3f_h_kSq9wQXj1fNig_4_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7494000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_CsulLJ3GXEOV9Zoac507-Q"
      decimals="-3"
      id="Tc_gK6t3BKDP0GvqXyqRx11Uw_4_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">9122000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_4gIvhxfROk6iKHtyL4mNDA_5_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">43403000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_xdL7hLf0xUWuF6fI4wB5wA_5_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">36934000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_jcNYUgMwxEuVx8i09CZDGQ_5_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">10790000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_lokpR_DYzE6FDNQg5cxVAw_5_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">14248000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_zN9adkSrnUeKZolp586GHA_6_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">8121000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_5wgF2n7pMU2iT1MetBWggg_6_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7945000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_WWkAMpOKX0q4qZaZQQZH9A_6_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2868000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_KZ2Rl4I3bkW9_a327Hejiw_6_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3205000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">27214000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">35021000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7688000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">8197000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_iBvrbfXZck-rpBcJGOChjw_8_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">6885000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_EfV7eJncpE2tWe9AeHtcuA_8_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2816000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2587000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_GvkYeenIvEumaBuhujdlsg_9_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-129000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_E65KzrZz7Umy-vlku2jm8w_9_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-12917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_SKn1qe7CDUG37u794S_bNA_9_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-2582000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_b0HTvWBllEuL1uGqWZ7BEw_9_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-1544000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_L6d1cqtMIEeDygNXL4xBeQ_10_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7150000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_Tl4EyWQbzEOrM0iWzR6VaA_10_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5877000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_NyHELdJj90myT0-fqDPetg_10_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1973000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_LbNLgkWjIU-DT8SU796P0g_10_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2050000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_Ekvpvvia_kGR31_ThHsAyA_11_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">359000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_xctQp-4KTUKP3qLNaPrEew_11_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">227000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_euFCHphoUEaMNBIQqAedsg_11_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">118000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_fkkHD4O8JUyb4CNaA5vhUA_11_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">34000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_8YgF4ivIxkGTz6Vrqm9BUg_12_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-6791000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_g2JxUdYVeUeA__iwBhicTg_12_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-5650000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_oFjbOmx_Tkapay6FK7Zrgg_12_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-1855000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_0wqGKsCtF0i57zfGQKig1w_12_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-2016000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_-Tdy2p8VYUWSjJjMP2foTQ_13_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_S-HQkkkU4k-DvRFQ0WZu_A_13_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-18567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_W-9jny0JyEKqWtBN98uByw_13_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_ngmWNXoIpEWV9IFZJuOA4w_13_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-3560000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="2"
      id="Tc_AxcstOaPWUKuPZV9qgj27A_14_3"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="2"
      id="Tc_aHQuyy2UyE6jpBFfvoM2Pw_14_6"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">-1.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="2"
      id="Tc_dyly7YG_UU-xmkeUFSbM0Q_14_9"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="2"
      id="Tc__o9M78edu0Ci5uZOu1KUMw_14_12"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="0"
      id="Tc_66pRkI1G30qe_jiSJmT4Vw_16_3"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">27758104</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="0"
      id="Tc_tganHjo-fkyQY6Qru97S5A_16_6"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="0"
      id="Tc_fi7iNumVdE2ihL84ZZz6lw_16_9"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">32863788</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="0"
      id="Tc_6y5hMo-TdUyx1uWp4FQkyQ_16_12"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ZdfRPnCjeEyvM5HwjCNBXQ"
      decimals="-3"
      id="Tc_LF8Y-hPBFUex_AzWIJ1hrg_17_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oKcfDa3A0kGpkbFODB1jxQ"
      decimals="-3"
      id="Tc_vk_2031rKE-_-u1IPaHs9Q_17_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ"
      decimals="-3"
      id="Tc_ze7kHfT6mkKY6nmLl1bpUQ_17_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_uoOZj9fvI0O5KtUKJ2QUVQ"
      decimals="-3"
      id="Tc_gq6tGM-wT06tJAW5hYWOuw_17_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_pRcDTGYiEECDc0dojMQDWQ"
      decimals="-3"
      id="Tc_nNDmVVcbK0qi4Jutikp1BA_18_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e1_nZMaTIE-COHRAayOIMQ"
      decimals="-3"
      id="Tc_tWsCZ5M3x0SWoBpLSo-9dw_18_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hXjv6Jrv6kedC9tuTT8GcA"
      decimals="-3"
      id="Tc_2YMIJqqNrUSXu68t-bL3mQ_18_9"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">852000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4MopdnOnJEGxDhBhT6bjmg"
      decimals="-3"
      id="Tc_Re1b12ul5UOsTIYDrTO5zQ_18_12"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">86000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA"
      decimals="0"
      id="Tc_Z0C-RXLin0u-6-F5E72_fw_6_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRhST9wDNU2tW1LfEVFliA"
      decimals="-3"
      id="Tc_VanHg4cgLUCj7TMbwVJ81Q_6_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fK7QWqX6s0q9WkkFwHaS9Q"
      decimals="-3"
      id="Tc_CljsXcc4MEuFFt-iWbd_vw_6_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">269657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yB5LZFDEhEyvveEfDJ5-QQ"
      decimals="-3"
      id="Tc_BLksiTkHvUuQS3jyVOnPFA_6_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-322553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg"
      decimals="-3"
      id="Tc_gTH5W_4IvUChPRqx9UczOA_6_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-52881000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kM2vCYwSV0uRlWIJmg2-4Q"
      decimals="-3"
      id="Tc_OYkjckgCs0abp4DtakyrFQ_8_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_SmPUZf0K5UaHbyFp12jJVw_8_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZNbuEF-wWkuGqpCEaHk7nA"
      decimals="-3"
      id="Tc_-5EgfHdIyUKEpOFZDdaU1A_9_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-18567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_6aPKzBMsz0u1VllLhFQSVA_9_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-18567000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw"
      decimals="0"
      id="Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw"
      decimals="-3"
      id="Tc_cpbzx5G29EOxO_uDaWcaMg_10_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw"
      decimals="-3"
      id="Tc_TmvBahuVZ0-V-ulZGMBsXw_10_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">270256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg"
      decimals="-3"
      id="Tc_ik2gFmrr0kWpWKTAC6G9_Q_10_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-341120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"
      decimals="-3"
      id="Tc_iWjLXcVBNk-ZtLCcnzL4JQ_10_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-70849000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw"
      decimals="0"
      id="Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8Qqd96EZWUunNJIiGYP7sw"
      decimals="-3"
      id="Tc_tfspJqT66EKnDINCQoQffw_11_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rNDZG8xgrkK9Eqv3ngpLpw"
      decimals="-3"
      id="Tc_yU2ZGj3RG0anG2tYMhq9zQ_11_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8HscStIMCky71Xpz36-FCg"
      decimals="-3"
      id="Tc__MfxwZz2nUaeomGlVlckSQ_11_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_FGKu7XnBJUybUWoGfuKVCQ_11_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q"
      decimals="0"
      id="Tc_xRzNdpnGEk-71eO8pSDPbw_13_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q"
      decimals="-3"
      id="Tc_Yz_Sy5LAkUW4T--LMyBJCQ_13_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw"
      decimals="-3"
      id="Tc_YR2WzZ17vUKarr9Yylg1Ig_13_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_NJRMGAs-pkGFi9UGtqaFyQ_13_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw"
      decimals="-3"
      id="Tc_Jun5lBXS4EGh5jaxTY7qDA_14_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1607000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_QnpZyYOE6ky40Hb4zInUqw_14_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1607000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q"
      decimals="0"
      id="Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">694073</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw"
      decimals="-3"
      id="Tc_x_claHpmdkCTnJvo-D4ogQ_15_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_8lIVt50MukqMWtsq7YIlFw_15_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qSdOQbCt4UusKGmvv5oh0Q"
      decimals="0"
      id="Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">200000</plx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wUS6suwCQ0mAS_l_lNpWMw"
      decimals="-3"
      id="Tc_fdqN9TISAUiRcT_TuCG2kA_16_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</plx:StockIssuedDuringPeriodValueWarrantsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_Ub1Bw4_a6UarBS8OdnPI9g_16_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</plx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VCj1F6qAZEeCpBg6hY-teg"
      decimals="-3"
      id="Tc_l9IjhXAAhkaVKv1PhOlUwQ_17_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_s6DMSFeetkmXfGaPmn09Bw_17_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ"
      decimals="0"
      id="Tc_B85fPue9QEOekGI75LcOcw_18_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">33336709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ"
      decimals="-3"
      id="Tc_ecK5SVmXt0W0MNJ7_OydIw_18_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ"
      decimals="-3"
      id="Tc_LtmZTOVAPke1_QOvSIgR9g_18_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">314401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw"
      decimals="-3"
      id="Tc_wUdjZ3D2m0SOo7mo_n_Pcw_18_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-347749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_khQlbynj0kGZt-1AW-sxPg_18_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-33315000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ"
      decimals="0"
      id="Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ovnoRzg2E0-V9qRW2MyfyQ"
      decimals="-3"
      id="Tc_MHyXaM8T3keaaLV7CeaaUw_19_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cr_aPjmKT0mYjDg02J2Z7Q"
      decimals="-3"
      id="Tc_Z9s73ZwURkKlS1F9oVPuCw_19_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">270060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AHiYkPc4FUK56R6zTg4LjQ"
      decimals="-3"
      id="Tc_eQQSKmKflkWfoWAueSx3bQ_19_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-337560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_fef2AszHPU-bAj2nZEQDdQ"
      decimals="-3"
      id="Tc_tTsPeLcPZUynuXGFyLT71w_19_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-67485000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__Df5EeyoJU2aHMqKSUD2rw"
      decimals="-3"
      id="Tc_KSTzrJMPm0egfMd7MObdBg_21_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_uPgYQfHCF0O9gGHNlfIgPQ_21_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sfvdWUnu6EO7cndkxiekuw"
      decimals="-3"
      id="Tc_wIgPu60xyEu4VuI-LlvMTw_22_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-3560000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="-3"
      id="Tc_1R44scdbcEC7Pp34wbzFsA_22_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-3560000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw"
      decimals="0"
      id="Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_o_dd7UASTkKbDo60o4fAMw"
      decimals="-3"
      id="Tc_fG1tiMvqrECpXEN-jM4bqw_23_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d0d5AVfdJUirLT1EgDMVOw"
      decimals="-3"
      id="Tc_LK01RUXc2ECb97tuBwx34A_23_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">270256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_00WvTOh3eUabyIlslXy2dg"
      decimals="-3"
      id="Tc_kpmNXgqKcUC0xJT7IctToQ_23_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-341120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"
      decimals="-3"
      id="Tc_HWobNa4P0UmgZWq7a8VF4A_23_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-70849000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ"
      decimals="0"
      id="Tc_JkhJ73vHckieh1cGPG-l9g_24_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ajUJnCJI0OUsXTbC5G_cQ"
      decimals="-3"
      id="Tc_Yc87nQKkTkeC_Y4n72BNJA_24_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O6L8OVTlsEu_2HaEKKHaow"
      decimals="-3"
      id="Tc_qJlvL3spA0SN4n1CAMfDfg_24_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IRzIhsYvXUKaSF2OewJ56A"
      decimals="-3"
      id="Tc_YFPyg6m80Uau30g3EK1x_Q_24_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A"
      decimals="-3"
      id="Tc_UHg5AhBO8kuPyoS3mXK0kw_24_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-34764000</us-gaap:StockholdersEquity>
    <plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg"
      decimals="-3"
      id="Tc_COBB3OZxdkK7p_IboKFQ1A_26_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4000000</plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants>
    <plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_xii5ZmbQOEy5Pgx9Yl1Uew_26_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4000000</plx:ReceivablesPaymentsFromSaleOfCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg"
      decimals="-3"
      id="Tc_GUAzeJKrn0GFbfBaqwgM1Q_27_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_wVWzgX_YkEycxvNrHIOQbw_27_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ"
      decimals="0"
      id="Tc_qRD60oHS9UGoDx0QmtTcbA_28_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">694073</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg"
      decimals="-3"
      id="Tc_LsqT8XcLHE-_GUMIsa5cTA_28_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_TWIy7vb1ckCo9JvgY6ezlw_28_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DHNp4givQ0uEDBc3XwThMQ"
      decimals="0"
      id="Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">200000</plx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPnbvWyts0GFJaKx9cpmCg"
      decimals="-3"
      id="Tc_uCF6OpzVOESfzoWciB-tWw_29_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</plx:StockIssuedDuringPeriodValueWarrantsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_cGcMr92IokKadz2O9dP4iw_29_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</plx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vbfxSpJnx0SCEmInPOXG3A"
      decimals="-3"
      id="Tc_ykyMRT9naEmcDEaneaMbxQ_30_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="-3"
      id="Tc_LZe2ipUW7UidTv66v35_Gw_30_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ"
      decimals="0"
      id="Tc_zELekXqrakWfZkOwtmNM4Q_31_2"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">33336709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xQrpyrLW8E6N4pgqE8OxkQ"
      decimals="-3"
      id="Tc_GPUyJ_0VE06wpayrv6c2eQ_31_5"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gMPoLQ_ASU68JEKXc4WGDQ"
      decimals="-3"
      id="Tc_07h0EtapsUm0xFDL4FpqaA_31_8"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">314401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogbZtupvTke6blBImt17Pw"
      decimals="-3"
      id="Tc_Gnd1Rl95vE64ClQKNvUMzw_31_11"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-347749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_1cnDOKq6VU-tyXDPUviUJQ_31_14"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-33315000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"
      decimals="3"
      id="Narr_svRVGqUFx0GqtCx3CCW_Nw"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="3"
      id="Narr_vXSG5WYpUkaVtKuyw89i9w"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="0"
      id="Narr_5c_5IplAKEOrBMfFEWopkg"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"
      decimals="0"
      id="Narr_B8IPN6b6T0SHfRaCNRWQ-g"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_41zTmw1fskOzX3hkAE0U5g_4_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_djED8GJyw0SsJ1u6ADcsFg_4_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-18567000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_4OzFf5kMZkqd_Opjw7BXtw_6_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2112000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_u2-vS8Pu2kC0sJxUbq9NnA_6_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">599000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc__Uw3e_uxI0S-jmhCgxjCyQ_7_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1011000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_IASUgUTf9EaAaJ_gKKW1ig_7_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1205000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_4oBFMafwwESZMDNMda__9A_8_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">284000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_1z7yk2KmHUKdJA7BMjKmHQ_8_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-371000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_Iu5npIead0K2QxIHUwqPWg_9_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-488000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_YSAE1CrB50eVy0FtE1xRuw_9_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">51000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_8QsFsZAo90-0wzM8Gs2AGg_10_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">11000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_1mLdQzQuKUy9fMwhYxuJdg_11_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2548000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_QCwBW7B0Q0CN45voGOVTeQ_11_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2197000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_7wik-QUxBECIlTxYt9fQDg_13_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-15062000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_iSOrLTwrdE2y0NFlkyNSZw_13_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-2697000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_ytIKi6VjQUqncyiaK1iJ6g_14_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-783000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_D-Z7jzpNakeHxYQYp7pysQ_14_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4767000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_SLIOGO3FKUCTRqkoQIaH8A_15_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-53000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_eUiUPxXFuUqJxge0DQv55Q_15_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">92000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_L2HA8x0wc0-MclSzE8mWUQ_16_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5126000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_o_M2_o13FUmruNQLJNLu5w_16_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-1044000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_Udfz0uXozkevz3sooIJrZQ_17_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3291000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_XnN1s6fNt0uTT_55WDA9-A_17_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4905000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_p_hIku6gnE25L4dwgxCs4w_18_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-463000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_KhOGwwVQNEq9ToLDTXM4wg_18_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">80000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_6bFk8MoNzU6_USWFLTLWjA_19_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-18556000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_Gmc7hQ6qr06RbQFeRlUpNg_19_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-15671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_a8RNvTm8Kk24qCrINj2jbw_22_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">27500000</plx:IncreaseDecreaseInBankDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_FW-_8ITToUiDY4IBDbSTYg_23_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">380000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc__GGwgxmZ5ke8Wdl2-03Y7Q_23_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">599000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_H2Y-Xp7toEu4zcOyM9CBMw_24_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4000</plx:IncreaseDecreaseInRestrictedDeposit>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_i-DwASesbUyN6fb2uFBTlA_24_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">254000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_lalD5ehRwE2dhmZsu___Xg_25_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-340000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_OYypA_lQoEeHFD8wYCGkRg_25_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">59000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_e_iw5IwQFk6KO9-TJtK8NA_26_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-27544000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_gtWTPdRi8UaHNKO7W2Vy-g_26_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-912000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_XiIQRNJjPkiHMzsafiITGQ_29_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">41343000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_M9_lYTPCgUmfrEX4luFLkw_30_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_gJ1Jlq8JNEqKCf9BG7bnUg_31_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">41815000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_fpyJd6_rqk2LmDfutbVw_w_32_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">26000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_b0ceMmiKpUChMoIQjWzUGg_32_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">217000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_NprPkzrkCE6o6SAPfYEi9Q_33_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-4259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_FkbAqqgQ-0iBEwoMwy0VTQ_33_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-16366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_LDIXTvdPZUuXeShp5Bon3Q_34_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_Gqm3Ka6my0mijWTTtA8-kg"
      decimals="-3"
      id="Tc_0YusTHrbMEuTFWfHfTUY-w_34_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_-T7L7-soYkaH8ioW0mN3BQ_35_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">13533000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2019_TnJ0AY9ZrEWr4vY_aZeZnQ"
      decimals="-3"
      id="Tc_EbFSw2Zgi0iu_NsiOH9b1w_35_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">21442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_m5ZNew9e1kWabTN2Kt_Osw_4_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">95000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="-3"
      id="Tc_bFYP-_FcL0S8LK5MbwvtwA_4_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">14000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="-3"
      id="Tc_XyeeNZtwpUWUIGvwI9aFNQ_5_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">564000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_FhGK74rtfU-b5wVE3sRfGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 36pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A biologics license application (BLA) PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway. On August&#160;11, 2020, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that the FDA had accepted the BLA and granted Priority Review designation for PRX-102 for the proposed treatment of adult patients with Fabry disease. The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application. The FDA set an action date of January&#160;27, 2021, under the Prescription Drug User Fee Act (PDUFA). The FDA advised that it will have to inspect the Company&#x2019;s manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#x2019;s review of the BLA application. Due to COVID-19 related FDA travel restrictions, the FDA has advised that it may be unable to conduct the inspections prior to the PDUFA date. The Company, together with Chiesi, is in active dialogue with the FDA and have submitted a request to the FDA for a Type A meeting to seek resolution on the issue of the pre-license inspections of the two manufacturing facilities. The Company anticipates an FDA response to this request in the first week of November 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;(1)&lt;/span&gt;&lt;/span&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;(2)&lt;/span&gt;&lt;/span&gt;OPRX-106, the Company&#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;(3)&lt;/span&gt;&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#x2013; a chemically modified enzyme to treat Gout.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On October&#160;1, 2020, the Company entered into an ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with BofA Securities, Inc., as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of the Company&#x2019;s common stock having an aggregate offering price of up to $30&#160;million (the &#x201c;ATM Shares&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On March&#160;18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing &lt;span style="white-space:pre-wrap;"&gt;six months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; following their issuance for a period of &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;In October 2020, the Company collected total proceeds of approximately $2.7&#160;million from accounts receivable outstanding at September&#160;30, 2020; approximately $0.9&#160;million in connection with its collaboration with Chiesi and approximately $1.8&#160;million from sales to Pfizer Inc. (&#x201c;Pfizer&#x201d;) under the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#x201c;Pfizer Agreement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;&lt;span style="-sec-ix-hidden:Hidden_2X7HaISLh0Kcb4gJc90IJw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;million&lt;/span&gt;&lt;/span&gt; in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of September&#160;30, 2020 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, as of September&#160;30, 2020, there was outstanding an aggregate principal amount of the Company&#x2019;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million (the &#x201c;2021 Notes&#x201d;), unless the notes are refinanced, restructured or converted before that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"&gt;The Company expects that by the maturity date of the 2021 Notes its cash and cash equivalents and short term deposits, combined with the cash the Company anticipates generating from the satisfaction of milestones under the Chiesi US Agreement and from its revenues, will be sufficient to satisfy the 2021 Notes payment. If, prior to the maturity date of the 2021 Notes, the Company will not have sufficient cash available to satisfy the full principal amount of the outstanding 2021 Notes, and to otherwise finance its future cash needs&lt;span style="font-family:'Georgia';"&gt;,&lt;/span&gt; management may pursue corporate collaborations, licensing or similar arrangements, public or private equity offerings, and/or debt financings or restructuring, sell shares under the Company's ATM Sales Agreement, and if necessary, may need to scale back operations, curtail or cease operations. Other than the ATM Sales Agreement, the Company does not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. There is no assurance that the Company will be successful in obtaining the level of financing needed for its operations.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The calculation of diluted LPS does not include 7,826,946 and 21,405,733 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the nine months ended September&#160;30, 2019 and 2020, respectively, and 7,854,729 and 26,905,842 shares of Common Stock for the three months ended September&#160;30, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December&#160;19, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Effective January&#160;1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;e.&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January&#160;1, 2020, with no material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_NLt0-efPfky_nzLBvyGDpw"
      decimals="-6"
      id="Narr_MhskqdYfjkWDFBYrjkFRtw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">30000000</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ"
      decimals="INF"
      id="Narr_fCJA1rzLN02ibBWH5y4U_A"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">17604423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw"
      decimals="INF"
      id="Narr_x7j0FM0p8ke4V_F0plBPtw"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ"
      decimals="INF"
      id="Narr_W8HWmAJQ90WUBTmOBpNi7Q"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">2.485</plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw"
      decimals="INF"
      id="Narr_IXV5_C3Iuk2By9DEcV2NOg"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">17604423</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw"
      decimals="INF"
      id="Narr_L2gbHhXXg0eOnSnL1-vkpw"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">2.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HOMFXArpOUWuuJM44cvKZQ"
      id="Narr_KVxWDwqAbkaWdU_z4bKRjA">P6M</plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_QjIG63ePBkyt0QXMG-eLsw"
      id="Narr_ewRS_BEm9EaAEU9JHyxsZA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_18_2020_To_3_18_2020_uMfCJEZpY02sFvVTznIY5w"
      decimals="-5"
      id="Narr_PFchXNuH0kuyH0b1qQ1G-A"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">41300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromSaleAndCollectionOfReceivables
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uJj9XUZ3jEK_nwNQ1ytYrQ"
      decimals="-5"
      id="Narr_h7y62ru37kqrheWEbVT0VA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2700000</us-gaap:ProceedsFromSaleAndCollectionOfReceivables>
    <us-gaap:ProceedsFromSaleAndCollectionOfReceivables
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ECNMuJ7DQkuqCfY-v0kl1Q"
      decimals="-5"
      id="Narr_DP9DahaUs0WCGJQislmnGA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">900000</us-gaap:ProceedsFromSaleAndCollectionOfReceivables>
    <us-gaap:ProceedsFromSaleAndCollectionOfReceivables
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_m0iRbIUWmE-NwcxiFKbfxw"
      decimals="-5"
      id="Narr_pRBTNsFaq0ul_LBenubIpw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1800000</us-gaap:ProceedsFromSaleAndCollectionOfReceivables>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q"
      decimals="-5"
      id="Narr_9qmHWis0RU-ArXdLHl_-Qw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ"
      decimals="-5"
      id="Narr_4d9-GgfNFECbuO0ofwxfvA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ"
      decimals="-5"
      id="Narr_nHC2E3bAnkmK0s8uHT6zgg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_EWcrYEqUbE2wm1aEy0CuyQ"
      decimals="-5"
      id="Narr_MC4C5PiOdke0mn8hLcGIXQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q"
      decimals="-5"
      id="Narr_dypEXHW3CUmacHmTaqAgeg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q"
      decimals="-5"
      id="Narr_wuP_wsi0hkWGJcEjDVQNKg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_am1IP7Y84UK2WNjObRum3Q"
      decimals="-5"
      id="Narr_hi5mMgnGHkiQDWsPoq8jaw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PdUn1DLSjky-oL6yd58gsg"
      decimals="INF"
      id="Narr_M3CgzCb_E0GysNY1XeDJrw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_2bYIXNG5N0WSrA0hwUb6RQ"
      decimals="INF"
      id="Narr_PLCUtGkzIEeyExSaO4Uihg"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_6ofRVpdY5EC3THAh6MbRNQ"
      decimals="INF"
      id="Narr_UWEIN-_j7Eezk1qlHfIlnw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Jv4KEHGwEEGDjCnT8dmZzw"
      decimals="INF"
      id="Narr_9tQIt6vdJkyOItUyxKoBiw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_qPVNjr3QxkiUTyW7b-790A"
      decimals="2"
      id="Narr_oGxMvZnmP0eLxOqz8bRjPQ"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg"
      decimals="INF"
      id="Narr_J5OPXd3thE6NmJrMyIdlvQ"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_7_Cod923rEuC4pMZ7mmwDg"
      decimals="-5"
      id="Narr_nb8yxJTp9E-tkGeYicVlgQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">57900000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_a6hNdviYGECzHBbEEJWjKA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The calculation of diluted LPS does not include 7,826,946 and 21,405,733 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the nine months ended September&#160;30, 2019 and 2020, respectively, and 7,854,729 and 26,905,842 shares of Common Stock for the three months ended September&#160;30, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December&#160;19, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_RbQ_vSgGfUmRosqhIyJcyA"
      decimals="INF"
      id="Narr_oxYPhuyre0-bUjmPihpk1w"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">7826946</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      decimals="INF"
      id="Narr_EDuw9HEbN064XasrKX00oA"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">21405733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2019_To_9_30_2019_dy5UwcXXmEKuQh4eGLadxA"
      decimals="INF"
      id="Narr_WMceEtAICESmHKEH62vPiA"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">7854729</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ"
      decimals="INF"
      id="Narr_n0uoSvH1dUm6m5iWSH1DAQ"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">26905842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E7ojsykV9EKg72W5j6pVFQ"
      id="Narr_0mkHvalS_EWuXARHeYYjxQ">one-for-ten</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_7nLGZB21O06GEg47q6tpUg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Effective January&#160;1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_KsafjKpmM061wt1A59LueA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;e.&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January&#160;1, 2020, with no material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_4K4Ajx3TAU-8oD6zDkcoZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Inventories at September&#160;30, 2020 and December&#160;31, 2019 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,941&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,558&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,996&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_FbMsIfX1F0mNFwFXS68SgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Inventories at September&#160;30, 2020 and December&#160;31, 2019 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,941&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,558&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,996&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_W6gjZTdBNUSnWvnQpqdlOg_3_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3941000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_eC4bFmdYdEi9li1EEPAnFQ_3_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3607000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_N4Dw0xep10Gbwija3y1y3w_4_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">2782000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_cBIgL2Af50iu3v5uszVn4A_4_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">552000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_LgRVdE3db0etGei_avzwow_5_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">6558000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_otKkn4rkRUK0VHYIIvdvMA_5_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">3996000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-3"
      id="Tc_o1Rm7DN9rE6Uu6YOFs8jVw_6_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">13281000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_OzMtOalvCkSxpb1NqUCKgg"
      decimals="-3"
      id="Tc_apGU3NVW702bqY7X5EIHdw_6_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">8155000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_L_NVcHcca0aC2M8oUhh6yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes (including the conversion option) is based on Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT (Continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;As of September&#160;30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the $59.7&#160;million aggregate principal amount of the Company&#x2019;s outstanding 7.50% 2021 Notes as of September&#160;30, 2020 is approximately $62.4&#160;million based on a Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA"
      decimals="-5"
      id="Narr_rfsNO0eQEE2IQLan1Bs1MQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">59700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_Nrylmm7X3kaU8w3XPffnbA"
      decimals="INF"
      id="Narr_fanee0kgj0GS3I8msBi9xQ"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA"
      decimals="-5"
      id="Narr_SFW38Sqg5k2Qgi6Qnw_cOg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">62400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ"
      id="Tb_IEcmbdIKtUef_TAk83amaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 100.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug"
      decimals="2"
      id="Tc_xGzzpIjH90SroDkV-_cT3g_2_2"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.87</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WZZ4r5XXfEOp6GCJNBLRVw"
      decimals="2"
      id="Tc_lHg5UVfWQUisvwzvTiAP4A_3_2"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">1.13</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bjCDIQN02Uam1toNzw9LSw"
      decimals="2"
      id="Tc_AoRF_95GmkW0IVxbUyv2LQ_4_2"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.12</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_2oLx1XpEpEeKkThOFBF0qA"
      decimals="2"
      id="Tc_syAhdsc9vkeBKRnLDq7Xuw_5_2"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">100.20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_pJdr0YSp5USwhCNaVQZ9eA"
      decimals="2"
      id="Tc_esMGQ2TFwUK9Nz3Nvtf6JA_6_2"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">12.34</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_SDdO_pnRDUmqOIWPTfV8oQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,844&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,701&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 31,428&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;During the nine months ended September&#160;30, 2020, the Company recorded revenue in the amount of $6.7&#160;million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#x201c;Kirin&#x201d;) to evaluate the production of a novel complex protein utilizing ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, the Company&#x2019;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0&#160;million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_RSiy-sP3W0WvUNSLx30ZsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,844&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,701&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 12,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 31,428&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_4CFqkzlEM0a0ykFUdbprNA"
      decimals="-3"
      id="Tc_JEZWYC7NJ0yVZNWgYBJraw_3_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">5844000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3utDIYnGnk23SwkpDHFalw"
      decimals="-3"
      id="Tc_gFK5ueVbzkiPfh1fchAOkg_3_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4701000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Mzmg7jvLfEe4iybt5-W0xw"
      decimals="-3"
      id="Tc_dVu5WoKpVEOsLFWqArCO1g_4_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_c-o4-zlu6k-zZmFIhIvfgA"
      decimals="-3"
      id="Tc_IENN086tT0S2I0bmpQSdkg_4_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">7385000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_JUeLT0AOY0GhjA3MadGoNQ"
      decimals="-3"
      id="Tc_K6QZzr2yrESI6rmu9oHCrA_5_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">131000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_ca1KyzaPlEuonlMa0wlEug"
      decimals="-3"
      id="Tc_UzPdB9YSuUaO76y09JEgLg_6_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">11975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_56aO-unLlEK78KOYFc8sMQ"
      decimals="-3"
      id="Tc_sKrjuauUjEuorloeVLVg1w_6_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">12086000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_4a4DeM6WJEKlckK5Dm4hKQ"
      decimals="-3"
      id="Tc_rUvP4GgQU0ipAN9satYylw_7_3"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">31428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_AjgT1U1Z_0-fpVEr-VMZyA"
      decimals="-3"
      id="Tc_iqYyjbtpSkmZWSOYZt6siw_7_6"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">24848000</us-gaap:Revenues>
    <us-gaap:OtherOperatingIncome
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_7TPGAQhZOUmeeaZ_5HG55g"
      decimals="-5"
      id="Narr_dgh49FUg60CGRLRtl-Ib2g"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">6700000</us-gaap:OtherOperatingIncome>
    <plx:NonRefundablePayment
      contextRef="Duration_3_16_2020_To_3_16_2020_WyJvhboxckK2jqSgzcbqVQ"
      decimals="-5"
      id="Narr_E-P3o-6m40aTz80kpyPayg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1000000.0</plx:NonRefundablePayment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_8AhXMkrUyUa-fgkRfc_WMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On June 17, 2020, the Company granted, with the approval of the Company&#x2019;s compensation committee, the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;options to purchase&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;196,995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;shares of Common Stock to the Company&#x2019;s Sr. Vice President &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;and Chief Development Officer under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;. The options have an exercise price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; per share and vest over a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;and Chief Development Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;as those terms are defined in the Plan,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; and are subject to certain other terms and conditions. The Company&#x2019;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#x2019;s Sr. Vice President&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; and Chief Development Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million based on the following weighted average assumptions: share price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; dividend yield of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; for all years; expected volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;80.43%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; risk-free interest rate of&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0.59%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; and expected life of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;six years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;options to purchase&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;760,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;shares of Common&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;, in the aggregate, to certain of the Company&#x2019;s employees under the Plan. The options granted have an exercise price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; per share and vest over a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; period in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$1.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million based on the following weighted average assumptions: share price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; dividend yield of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; for all years; expected volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;80.49%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; risk-free interest rate of&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0.45%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; and expected life of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;six years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On August&#160;11, 2020, the Company granted, with the approval of the Company&#x2019;s compensation committee, the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;447,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares of restricted Common Stock to its President, Chief Executive Officer under the Plan. The restricted shares vest &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;over a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; period in 16 equal quarterly increments and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;246,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;27,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares vested on September&#160;22, 2020. The remaining &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;218,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; of the shares vest in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;equal, quarterly increments over a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;10-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;options to purchase&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;122,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;shares of Common Stock to the Company&#x2019;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; per share and vest over a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;four-year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; period in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#x2019;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#x2019;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million based on the following weighted average assumptions: share price equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$3.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; dividend yield of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; for all years; expected volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;80.51%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; risk-free interest rate of&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;0.365%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;; and expected life of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;six years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On September&#160;14, 2020, the Company issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company generated net proceeds equal to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$472,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; from the exercise of the warrant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;5&#160;- STOCK TRANSACTIONS (Continued)&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On October&#160;1, 2020, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million. The ATM Shares will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (Registration No. 333-230604). The Company intends to use the net proceeds from the offering, after deducting the Agent&#x2019;s commissions and the Company&#x2019;s offering expenses, for general corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; purposes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      id="Narr_Zidzb2p4IE2Iph6eA5ilKw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      decimals="INF"
      id="Narr_x2jyJDgtXEGgJ_ga7svZVw"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">196995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ"
      decimals="2"
      id="Narr__e1yRpmgTUGjAYiW0j4wQQ"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      id="Narr_rVrjTd9ALE2KH3nQHPDuyw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_UO_BxFDy0UmQVBKhnJ0dPQ"
      decimals="-5"
      id="Narr_s0csoNiTFUeAkC8oH9KyiA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      decimals="2"
      id="Narr_DLCdO_qxq0aDVd5UJNaM3Q"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      decimals="2"
      id="Narr_wSQBuQBj30GizjlCDgYLkg"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      decimals="4"
      id="Narr_emb2C_6Yeku0ypU7CGVU6w"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.8043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      decimals="4"
      id="Narr_gVkoEfIoR0SuqmS9kWatuw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_17_2020_To_6_17_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_bzXg4StCb0KRMKziIVOHcw"
      id="Narr_hk2thWiS8UqalZ3MIjRNIA">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      id="Narr_LgPz8XVMiky9z9LRxu5hkQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="INF"
      id="Narr_GWGYOa0y2U2t04DnyBwUsw"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">760311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA"
      decimals="2"
      id="Narr_CaabV06t0E6c7qK_ZU4fEA"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      id="Narr_c3VWQtC_4EqVQn3-k4tDXw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="0"
      id="Narr_dQhDgwRR70KYsy72ZqIrtA"
      unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ORs8wvKwh0-02nK1-SVvdA"
      decimals="-5"
      id="Narr_bwvfY2lhgE6A6TQlAfMCVQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="2"
      id="Narr_yOdbg6QgK0uwatW_eksaNg"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="2"
      id="Narr_sOBrbTQuvU69NJ4eDeIYuw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="4"
      id="Narr_bYSfNt1ukUedqwxkUrerrw"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.8049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      decimals="4"
      id="Narr_DXlRsPDGnkyF7vq8phQosA"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_17_2020_To_6_17_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_tfoBUl6vvEiUW8s6xroc8Q"
      id="Narr_76Oo3lU6NkOzkIQQ6TWaxg">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q"
      decimals="INF"
      id="Narr_GN89fNYluUi0_RGxGUezoQ"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">447927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q"
      id="Narr_G609BbsjQ0q_OKFM6urVlw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qu8swhMFUUSBsMSV78BG6Q"
      decimals="INF"
      id="Narr_VXfGcU-JW0iquJkHJT3myQ"
      unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_edPTlz70sE-KPAY6iEzxFw"
      decimals="-5"
      id="Narr_0W7L7bJ250KtPlR3XLuOHg"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">1600000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw"
      decimals="INF"
      id="Narr_-BY7rTi5ZUu_hIKtNvetFg"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">246146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_awAX9aPeuk2iZshhHY-mww"
      decimals="INF"
      id="Narr_ay91YIKw9kSYaawnwxbY7Q"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">27855</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qrzLO1Itnk-vHNuLIHMrCw"
      decimals="INF"
      id="Narr_rx1DICzZbE6BPJOEXK34Fw"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">218291</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw"
      decimals="INF"
      id="Narr_-sTJ7isaLk-nesKoVh4ENg"
      unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_kKb8u6j4Y0quknM4XTJEsw"
      id="Narr_HE5KORFonEqVPuHV_rhOPw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_KfZU-gIvU0mW3QuavJGUpg"
      decimals="-5"
      id="Narr_G8jnR4sgHU2s3TiY07DKzQ"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg"
      id="Narr_FbeVskc_AEiMgu3c6LaYlQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg"
      decimals="INF"
      id="Narr_XchGQRgTx0e8PQXOISBXTA"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">122656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g"
      decimals="2"
      id="Narr_CZgJZQPYaEK5gs76LxEwvQ"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg"
      id="Narr_Gs34OfzVo0WO0mV0tXDcVA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_Y_9rYOblO0ivxh0LioLcsg"
      decimals="INF"
      id="Narr_WwiB0HnRh0mpLmQJyEDHjA"
      unitRef="Unit_Standard_item_pNiiuaZ4KE620UBGwvXPyw">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_srt_VicePresidentMember_9UPVIRTvLkafYxAuGZi88g"
      decimals="-5"
      id="Narr_A6JynF759kmFEBXxh5PpGw"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">300000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ"
      decimals="2"
      id="Narr_lXtstp2RbkGsjSaAkvAatw"
      unitRef="Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q"
      decimals="2"
      id="Narr_2e2l6Bot_k2kRCIvuiJ-TA"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q"
      decimals="4"
      id="Narr_zlvxpKv8uE2cduZcbXKPfg"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.8051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q"
      decimals="5"
      id="Narr_8ZrgJpRiH0-3YK3sqraDAg"
      unitRef="Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg">0.00365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_8_11_2020_To_8_11_2020_gR_4igXg70e6-abWt2TI5Q"
      id="Narr_9zFBrAqOiE2GGqfdIIawsg">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ"
      decimals="INF"
      id="Narr_kb_bM17UOUKc7v8Igr21jA"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_9_14_2020_To_9_14_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lRWlTpC1cUWaYPFaHjQSdQ"
      decimals="0"
      id="Narr_0wESBgyjWk6t775My90DLA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">472000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_TypeOfArrangementAxis_plx_AtmEquityOfferingSalesAgreementMember_1fRceHFMtEWWoTuOudr_4w"
      decimals="-6"
      id="Narr_VQ0P6OARRk-k1sC9nvhkRQ"
      unitRef="Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA">30000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_JVoRg4PaZker-ipWQBoO6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; PROMISSORY NOTE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January 31, 2022 and (b) the date that the Company receive any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $430,000 to Pfizer. The payment is creditable against the principal amount of the note, in whole or in part, if the Company satisfies the note in full on or prior to September 30, 2021, depending on the date the note is satisfied. The promissory note is presented under the short-term liabilities.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA"
      decimals="-5"
      id="Narr_DJ4QAmBzLEWf8j4x-XHNuA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">4300000</us-gaap:NotesPayableCurrent>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="Duration_9_1_2020_To_9_30_2020_Gx20S_jXlEO4XT5ZwA9LaQ"
      decimals="0"
      id="Narr_oajqZgT170qK1QySAkjUbA"
      unitRef="Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q">-430000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA"
      id="Tb_oNoKN3DsfEK38UeCjaWgvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;In accordance with ASC 855 &#x201c;Subsequent Events&#x201d; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_xRzNdpnGEk-71eO8pSDPbw_13_2"
          xlink:label="Tc_xRzNdpnGEk-71eO8pSDPbw_13_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common Stock, $0.001 par value; Authorized &#x2013; as of September 30, 2020 and 2019 - 120,000,000 and 350,000,000, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xRzNdpnGEk-71eO8pSDPbw_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2"
          xlink:label="Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9Vut-m0U0EKNSz2tSAb0pA_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qRD60oHS9UGoDx0QmtTcbA_28_2"
          xlink:label="Tc_qRD60oHS9UGoDx0QmtTcbA_28_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qRD60oHS9UGoDx0QmtTcbA_28_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2"
          xlink:label="Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AvjqHsjKIkS2fIXeb_zQ8g_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2"
          xlink:label="Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GXsrbrI9Z0KzfP5wsJg2_g_29_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Z0C-RXLin0u-6-F5E72_fw_6_2"
          xlink:label="Tc_Z0C-RXLin0u-6-F5E72_fw_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Z0C-RXLin0u-6-F5E72_fw_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2"
          xlink:label="Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_mggHnBWkMk6Tjk3nmiBkwA_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2"
          xlink:label="Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_f8qRo4sJnEyZ3sNv1BTHSg_23_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2"
          xlink:label="Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0FeQ83RVQ0atfxGUe5d6jw_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2"
          xlink:label="Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_jowFDUNQyEqlsGhnx6SF_Q_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_JkhJ73vHckieh1cGPG-l9g_24_2"
          xlink:label="Tc_JkhJ73vHckieh1cGPG-l9g_24_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_JkhJ73vHckieh1cGPG-l9g_24_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zELekXqrakWfZkOwtmNM4Q_31_2"
          xlink:label="Tc_zELekXqrakWfZkOwtmNM4Q_31_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zELekXqrakWfZkOwtmNM4Q_31_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_B85fPue9QEOekGI75LcOcw_18_2"
          xlink:label="Tc_B85fPue9QEOekGI75LcOcw_18_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_B85fPue9QEOekGI75LcOcw_18_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6"
          xlink:label="Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) </xhtml:b><xhtml:b style="font-size:8pt;font-weight:bold;">Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_mTlSBUZlC0Ob0Q8QS0UFLw_7_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12"
          xlink:label="Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_dOHHZ-TIL02yuo6T7ujZoA_7_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3"
          xlink:label="Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_WFsXh7nADkCzjSXJO3Zbyg_7_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9"
          xlink:label="Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zu7TOHyKvE-FYZGAGRb7mw_7_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_iBvrbfXZck-rpBcJGOChjw_8_6"
          xlink:label="Tc_iBvrbfXZck-rpBcJGOChjw_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_iBvrbfXZck-rpBcJGOChjw_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12"
          xlink:label="Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IrHqPJlLCE6EEWuTe-mPvw_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3"
          xlink:label="Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vvjBTZ2ksUeVRCQ76UE6XQ_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_EfV7eJncpE2tWe9AeHtcuA_8_9"
          xlink:label="Tc_EfV7eJncpE2tWe9AeHtcuA_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_EfV7eJncpE2tWe9AeHtcuA_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791568960728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Snunit Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">POB 455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmiel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2161401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972-4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">988-9488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 par value, <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,336,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791574017128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,533<span></span>
</td>
<td class="nump">$ 17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">27,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,612<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">13,281<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,332<span></span>
</td>
<td class="nump">32,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,639<span></span>
</td>
<td class="nump">5,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">11,978<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">72,310<span></span>
</td>
<td class="nump">45,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">8,351<span></span>
</td>
<td class="nump">6,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">13,347<span></span>
</td>
<td class="nump">11,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">16,720<span></span>
</td>
<td class="nump">16,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,895<span></span>
</td>
<td class="nump">40,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">53,505<span></span>
</td>
<td class="nump">50,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,558<span></span>
</td>
<td class="nump">4,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">61,730<span></span>
</td>
<td class="nump">75,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">105,625<span></span>
</td>
<td class="nump">115,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(33,315)<span></span>
</td>
<td class="num">(70,322)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 72,310<span></span>
</td>
<td class="nump">$ 45,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791570205192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,790<span></span>
</td>
<td class="nump">$ 14,248<span></span>
</td>
<td class="nump">$ 43,403<span></span>
</td>
<td class="nump">$ 36,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,868)<span></span>
</td>
<td class="num">(3,205)<span></span>
</td>
<td class="num">(8,121)<span></span>
</td>
<td class="num">(7,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,688)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(27,214)<span></span>
</td>
<td class="num">(35,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,816)<span></span>
</td>
<td class="num">(2,587)<span></span>
</td>
<td class="num">(8,197)<span></span>
</td>
<td class="num">(6,885)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,582)<span></span>
</td>
<td class="num">(1,544)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(12,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,973)<span></span>
</td>
<td class="num">(2,050)<span></span>
</td>
<td class="num">(7,150)<span></span>
</td>
<td class="num">(5,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,855)<span></span>
</td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(6,791)<span></span>
</td>
<td class="num">(5,650)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,437)<span></span>
</td>
<td class="num">$ (3,560)<span></span>
</td>
<td class="num">$ (6,920)<span></span>
</td>
<td class="num">$ (18,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share of common stock - Basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares of common stock used in computing loss per share - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,863,788<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">27,758,104<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,296<span></span>
</td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">$ 11,975<span></span>
</td>
<td class="nump">$ 12,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,494<span></span>
</td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 31,428<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) </b><b style="font-size:8pt;font-weight:bold;">Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791571488088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791569408520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (34,764)<span></span>
</td>
<td class="num">$ (67,485)<span></span>
</td>
<td class="num">$ (70,322)<span></span>
</td>
<td class="num">$ (52,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">909<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants', window );">Note receivable payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,437)<span></span>
</td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(6,920)<span></span>
</td>
<td class="num">(18,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33,315)<span></span>
</td>
<td class="num">(70,849)<span></span>
</td>
<td class="num">(33,315)<span></span>
</td>
<td class="num">(70,849)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,336,709<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">33,336,709<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 308,515<span></span>
</td>
<td class="nump">$ 270,060<span></span>
</td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="nump">$ 269,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">909<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants', window );">Note receivable payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">314,401<span></span>
</td>
<td class="nump">270,256<span></span>
</td>
<td class="nump">314,401<span></span>
</td>
<td class="nump">270,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(343,312)<span></span>
</td>
<td class="num">(337,560)<span></span>
</td>
<td class="num">(340,829)<span></span>
</td>
<td class="num">(322,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,437)<span></span>
</td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(6,920)<span></span>
</td>
<td class="num">(18,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (347,749)<span></span>
</td>
<td class="num">$ (341,120)<span></span>
</td>
<td class="num">$ (347,749)<span></span>
</td>
<td class="num">$ (341,120)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common Stock, $0.001 par value; Authorized &#8211; as of September 30, 2020 and 2019 - 120,000,000 and 350,000,000, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount from Receivables (Payments) from sale of common stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share Warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791572909864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791573384168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,920)<span></span>
</td>
<td class="num">$ (18,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
<td class="num">(284)<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(488)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">2,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(15,062)<span></span>
</td>
<td class="num">(2,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
<td class="nump">783<span></span>
</td>
<td class="num">(4,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(5,126)<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">4,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase (decrease) in other long term liabilities</a></td>
<td class="num">(463)<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,556)<span></span>
</td>
<td class="num">(15,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Increase in bank deposits</a></td>
<td class="num">(27,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Increase in restricted deposit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="nump">340<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(27,544)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">41,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">41,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(4,259)<span></span>
</td>
<td class="num">(16,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,792<span></span>
</td>
<td class="nump">37,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">13,533<span></span>
</td>
<td class="nump">21,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791572963496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder. A biologics license application (BLA) PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway. On August&#160;11, 2020, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that the FDA had accepted the BLA and granted Priority Review designation for PRX-102 for the proposed treatment of adult patients with Fabry disease. The FDA also indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application. The FDA set an action date of January&#160;27, 2021, under the Prescription Drug User Fee Act (PDUFA). The FDA advised that it will have to inspect the Company&#8217;s manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#8217;s review of the BLA application. Due to COVID-19 related FDA travel restrictions, the FDA has advised that it may be unable to conduct the inspections prior to the PDUFA date. The Company, together with Chiesi, is in active dialogue with the FDA and have submitted a request to the FDA for a Type A meeting to seek resolution on the issue of the pre-license inspections of the two manufacturing facilities. The Company anticipates an FDA response to this request in the first week of November 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(1)</span></span>alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(2)</span></span>OPRX-106, the Company&#8217;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(3)</span></span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated Uricase (Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;1, 2020, the Company entered into an ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc., as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of the Company&#8217;s common stock having an aggregate offering price of up to $30&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On March&#160;18, 2020, the Company completed a private placement of its common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing <span style="white-space:pre-wrap;">six months</span><span style="white-space:pre-wrap;"> following their issuance for a period of </span><span style="white-space:pre-wrap;">five years</span><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">In October 2020, the Company collected total proceeds of approximately $2.7&#160;million from accounts receivable outstanding at September&#160;30, 2020; approximately $0.9&#160;million in connection with its collaboration with Chiesi and approximately $1.8&#160;million from sales to Pfizer Inc. (&#8220;Pfizer&#8221;) under the exclusive license and supply agreement entered into&#160;between Protalix&#160;Ltd. and Pfizer (the &#8220;Pfizer Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;<span style="-sec-ix-hidden:Hidden_2X7HaISLh0Kcb4gJc90IJw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">million</span></span> in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">The Company believes that its cash and cash equivalents and bank deposits as of September&#160;30, 2020 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, as of September&#160;30, 2020, there was outstanding an aggregate principal amount of the Company&#8217;s 7.50% convertible secured promissory notes due November&#160;15, 2021 equal to $57.9&#160;million (the &#8220;2021 Notes&#8221;), unless the notes are refinanced, restructured or converted before that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;">The Company expects that by the maturity date of the 2021 Notes its cash and cash equivalents and short term deposits, combined with the cash the Company anticipates generating from the satisfaction of milestones under the Chiesi US Agreement and from its revenues, will be sufficient to satisfy the 2021 Notes payment. If, prior to the maturity date of the 2021 Notes, the Company will not have sufficient cash available to satisfy the full principal amount of the outstanding 2021 Notes, and to otherwise finance its future cash needs<span style="font-family:'Georgia';">,</span> management may pursue corporate collaborations, licensing or similar arrangements, public or private equity offerings, and/or debt financings or restructuring, sell shares under the Company's ATM Sales Agreement, and if necessary, may need to scale back operations, curtail or cease operations. Other than the ATM Sales Agreement, the Company does not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. There is no assurance that the Company will be successful in obtaining the level of financing needed for its operations.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2019 has been derived from the audited financial statements at that date.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include 7,826,946 and 21,405,733 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the nine months ended September&#160;30, 2019 and 2020, respectively, and 7,854,729 and 26,905,842 shares of Common Stock for the three months ended September&#160;30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of one-for-ten, effective as of December&#160;19, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January&#160;1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January&#160;1, 2020, with no material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791577120456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at September&#160;30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,941</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,607</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,558</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791577022008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes (including the conversion option) is based on Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT (Continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">As of September&#160;30, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $59.7&#160;million aggregate principal amount of the Company&#8217;s outstanding 7.50% 2021 Notes as of September&#160;30, 2020 is approximately $62.4&#160;million based on a Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791573578824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,844</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,701</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 31,428</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the nine months ended September&#160;30, 2020, the Company recorded revenue in the amount of $6.7&#160;million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the Company&#8217;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0&#160;million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791571718232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June 17, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">196,995</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">and Chief Development Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;)</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">. The options have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.59</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">and Chief Development Officer</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">as those terms are defined in the Plan,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and Chief Development Officer</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$0.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.59</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">80.43%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0.59%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">760,311</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.66</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">16</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$1.9</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.66</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">80.49%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0.45%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On August&#160;11, 2020, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">447,927</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of restricted Common Stock to its President, Chief Executive Officer under the Plan. The restricted shares vest </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">over a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in 16 equal quarterly increments and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$1.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">246,146</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">27,855</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares vested on September&#160;22, 2020. The remaining </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">218,291</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> of the shares vest in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">16</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal, quarterly increments over a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">,</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$0.9</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;options to purchase&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">122,656</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.59</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> per share and vest over a </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">four-year</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> period in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">16</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$0.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million based on the following weighted average assumptions: share price equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$3.59</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; dividend yield of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> for all years; expected volatility of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">80.51%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; risk-free interest rate of&#160;</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">0.365%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">; and expected life of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">six years</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On September&#160;14, 2020, the Company issued </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">200,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$472,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> from the exercise of the warrant.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;5&#160;- STOCK TRANSACTIONS (Continued)</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On October&#160;1, 2020, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$30</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million. The ATM Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-230604). The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the Company&#8217;s offering expenses, for general corporate</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> purposes.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791587561992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791573572424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>PROMISSORY NOTE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; PROMISSORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a) January 31, 2022 and (b) the date that the Company receive any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $430,000 to Pfizer. The payment is creditable against the principal amount of the note, in whole or in part, if the Company satisfies the note in full on or prior to September 30, 2021, depending on the date the note is satisfied. The promissory note is presented under the short-term liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791577120456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The calculation of diluted LPS does not include 7,826,946 and 21,405,733 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the nine months ended September&#160;30, 2019 and 2020, respectively, and 7,854,729 and 26,905,842 shares of Common Stock for the three months ended September&#160;30, 2019 and 2020, respectively, because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The computation of basic and diluted net loss per common stock was adjusted retrospectively for all periods presented to reflect the Company&#8217;s reverse stock split at a ratio of one-for-ten, effective as of December&#160;19, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Effective January&#160;1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">e.</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Recently issued accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January&#160;1, 2020, with no material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791571634216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Inventories at September&#160;30, 2020 and December&#160;31, 2019 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,941</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,607</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,558</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791573062392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 35.3pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791571668056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,844</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,701</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 31,428</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791496626968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Sep. 14, 2020</div></th>
<th class="th"><div>Mar. 18, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,905,842<span></span>
</td>
<td class="nump">7,854,729<span></span>
</td>
<td class="nump">21,405,733<span></span>
</td>
<td class="nump">7,826,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables', window );">Total proceeds from accounts receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants', window );">Exercise of warrants, commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-ten<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember', window );">Seven Point Five Percentage Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables', window );">Total proceeds from accounts receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables', window );">Total proceeds from accounts receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price at which the new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the proceeds from sale and collection of receivables during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791577005944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,941<span></span>
</td>
<td class="nump">$ 3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,558<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 13,281<span></span>
</td>
<td class="nump">$ 8,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791588546568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">3.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">100.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">12.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791572940792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Seven Point Five Percentage Convertible Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 62.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 59.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791577395240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,790<span></span>
</td>
<td class="nump">$ 14,248<span></span>
</td>
<td class="nump">$ 43,403<span></span>
</td>
<td class="nump">$ 36,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NonRefundablePayment', window );">Non refundable payments not yet recognized to revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other Operating Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296<span></span>
</td>
<td class="nump">5,126<span></span>
</td>
<td class="nump">11,975<span></span>
</td>
<td class="nump">12,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,844<span></span>
</td>
<td class="nump">4,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,494<span></span>
</td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 31,428<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable payment received, but not yet recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791499135000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 22, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.365%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Certain employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember', window );">President and Chief Executive Officer [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember', window );">Sr. Vice President And Chief Development Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember', window );">Sr. Vice President And Chief Development Officer [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_VicePresidentMember', window );">Vice President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_VicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_VicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139791572902408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>PROMISSORY NOTE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="nump">$ 4,301,000<span></span>
</td>
<td class="nump">$ 4,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payment on notes payable</a></td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ME4GUL1MT:1E@,'+Z>+7"#^W*WYV.:4*>DS01/18%=6V',.B:NA&%>PP M@X
M(_M"C>6"RUU$V;!\-W*,#%(<(&V(FV 8]W04M8:"[(8BQ3A+RI+Q=ZD8PC@2
MD6X#+G:Z(_$2ZIQ?:Q;(;A;G7G_A>R.#5>#P9#K45 TP!P9]O3Q9Z]L7^\N'
MU1]@,W^Z!\O%Y&ZQ7&P6<ZOOHU;3T855/Y.+,2X2)4+J.YG+UU7:PYZCE6^
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M=C^$"1<X&/4L87'K2=B^@=&&B]IFJ0U,3(I$/=K271(G-(^-8EUG/ST;,BW
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M02 T -_/.%>;C18H+E:MGU!+ P04    " !/.UU1XGJ87'4&  !P'@  &
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M_P;'X,MR =Z^>0?>@# !MYMTE_O)*I^.&3=0=#,.2F/F>V-PAS$$7*4)V^3
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MQSP+B/6$">T*%#T'>4\5T(_7%X.Q,LYCTRX:*3QR!\-*[!4NM\+E&O7WHK_
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M J=*EY8C/I),E# ]?F7IK0H\-D SDHVPY?0&0DR/CUZ%?Z![L3$6/.37LLQ
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ML758CP]\PYTN[MSX9JV#1")ZC9;37PQ*OWJ2@7_U  .UTIM%BZJ)P_=N"?!
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MVT@0_BNC7'L"B7,2!PI- 2G05(=46@Y*3_=Q;4_B/=:[9G=-R/WZFUF_Q-"
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M0LL&]'YAB*?FAA-TWW&G_P-02P,$%     @ 3SM=44Z/MWZ9 P  $0@  !D
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MZ"0DQS"T,6PU::+=NO=ONY.T,_7-'U@3B0>KL;X@$!*LC@E62NU!@>IE=5%
M75'=1,_K2N$6AVL4;YBOIXHL.\N97'$B.,,2H%7AW&MSA4Y"HTKC)&*51. [
MLTGK)@RHZ)8ZJ*'%/@(*3^F6'H\E2J;".<#'91L*NZP_O^=)[:+>VEZRAX!4
MR(6!5!CT-;$,O$_[&/\LP.WG"DN]^ACM)EW$1FH"SS)T@>D<8!_];$CE=2Z2
M'(0%84R-Y$\9;N7?AI^ L%2Z_' YSH0&K \UWT:7\O%)*=2XY1U3&\(AK9\6
M++G=6R:Y*DBB(]JC5* #I4JY2X:;I@+=.Y$(ZV_#X11;5U$0:JB#IJV@KMK
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M%@Y96"5A;VIZ+=[0KT+WZ&2:3>-KY00E]+IX$VT'7"/\,_&62T8;4EA#*Z/
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M)NB+%4\UQ@HRQQ%2Y$7"\QU;C(9B<YWR!+2&$^?2$..^,87'G6_QJ)XE_^)
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M:7RY&V&J_FVS[?2[J)I^5UZ-SENJ,B8TX9 B-.B>11Y1U3BJ B-+-P+6TN!
M<=L<)S@H6X#GJ92F">P%[7_"["]02P,$%     @ 3SM=4:DQDFK\ @  8 8
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M-+B>W+' _P$HZX#V3$IS$&R"]@\S^PM02P,$%     @ 3SM=48<0I]^3"
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M^G%-\()P^0#\?\F8V%[(5R%W+SM?_@]02P,$%     @ 3SM=4;J0Z&); @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3SM=4>GE6*OD @  3Q$
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MGV1]=V[YUY_,[5H8J>S!GW7_)6:?4$L! A0#%     @ 3SM=40=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !/.UU1N<\H<NX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !/.UU1F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $\[
M75%\ZC(C?@4  .(6   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !/.UU1)WS)89X%  "I%@  &
M        @('!#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ 3SM=4=[5P2-V!0  $14  !@              ("!E1,  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $\[75%AN/:"$P,  &0)   8
M              " @4$9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " !/.UU1XGJ87'4&  !P'@  &               @(&*'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 3SM=42AT'Z=- @
M@04  !@              ("!-2,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( $\[75$0G/DI+ <  ,8:   8              " @;@E
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !/.UU1%Y*+
M@Y84  #G/   &               @($:+0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ 3SM=438Q/>*1 @  *08  !@
M ("!YD$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $\[
M75$V:J5YM04  -,-   9              " @:U$  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ 3SM=44Z/MWZ9 P  $0@  !D
M         ("!F4H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " !/.UU1G2^9BP0'   >&0  &0              @(%I3@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $\[75%VG0I@? (  *0%
M   9              " @:15  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ 3SM=4998S\8\ P  ^P8  !D              ("!5U@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !/.UU19%.G
MSB@)  #V&0  &0              @('*6P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( $\[75$V85L.EP(  !\&   9
M  " @2EE  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M3SM=4:DQDFK\ @  8 8  !D              ("!]V<  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " !/.UU1@P9A<< "  !M!@  &0
M            @($J:P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( $\[75&'$*??DP@  /@L   9              " @2%N  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 3SM=4;J0Z&); @
M%P8  !D              ("!ZW8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " !/.UU1'3=E:<<"  !$"   &0              @(%]
M>0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $\[75&#
MJ4?/;@(  $X%   9              " @7M\  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ 3SM=40Q@3OF& P  ? P  !D
M     ("!('\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M" !/.UU12C)35",'  #V,@  &0              @('=@@  >&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $\[75$*]NNM.@(  %X%   9
M              " @3>*  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!
M A0#%     @ 3SM=4>D6?YQ/ @  7 P   T              ( !J(P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !/.UU1EXJ[',     3 @  "P
M        @ $BCP  7W)E;',O+G)E;'-02P$"% ,4    " !/.UU1Z>58J^0"
M  !/$0  #P              @ $+D   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 3SM=47[94"(\ 0  L@\  !H              ( !'),  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3SM=42O0<HYR 0
MGQ   !,              ( !D)0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "$ (0#>"   ,Y8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>225</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40701 - Disclosure - PROMISSORY NOTE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails</Role>
      <ShortName>PROMISSORY NOTE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePromissoryNote</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20200930x10q.htm">plx-20200930x10q.htm</File>
    <File>plx-20200930.xsd</File>
    <File>plx-20200930_cal.xml</File>
    <File>plx-20200930_def.xml</File>
    <File>plx-20200930_lab.xml</File>
    <File>plx-20200930_pre.xml</File>
    <File>plx-20200930xex31d1.htm</File>
    <File>plx-20200930xex31d2.htm</File>
    <File>plx-20200930xex32d1.htm</File>
    <File>plx-20200930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20200930x10q005.jpg</File>
    <File>plx-20200930x10q006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20200930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 103,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20200930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 257,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 2,
    "http://www.protalix.com/20200930": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 8
   },
   "keyCustom": 27,
   "keyStandard": 198,
   "memberCustom": 14,
   "memberStandard": 20,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - PROMISSORY NOTE",
     "role": "http://www.protalix.com/role/DisclosurePromissoryNote",
     "shortName": "PROMISSORY NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_MzER1Phhr0SrtQovRmiRDQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "-3",
      "lang": null,
      "name": "plx:ShortTermBankDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
     "shortName": "FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_UU_RC9Ef40SNeYYPgQtfug",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_Nrylmm7X3kaU8w3XPffnbA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_aT3k5NSVGUaj0chAW44LDg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_FcQomBH04EywHtTWFP8VpA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
     "shortName": "REVENUES - Company's disaggregation of revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_3_16_2020_To_3_16_2020_WyJvhboxckK2jqSgzcbqVQ",
      "decimals": "-5",
      "lang": null,
      "name": "plx:NonRefundablePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_8_11_2020_i2rNAvxU8U-U3qVQwrkzXQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - PROMISSORY NOTE (Narrative) (Details)",
     "role": "http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails",
     "shortName": "PROMISSORY NOTE (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_9_1_2020_To_9_30_2020_Gx20S_jXlEO4XT5ZwA9LaQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromRepaymentsOfNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_oN6zVxxEZUCI28Wiu-XbqQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-nt3AdJs3kKqJ1tJyamePQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_6_30_2020_DYy0hSRX7Uad1qw_FiBw0A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_GJufDbtOn02AMn9xs5c8pw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_ELzlUb2BzU2Y9GgGThOonA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_T-PT4pJClEqOBYVnYXU2mA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_gwVgdZlwfUaq3UjjCp9Y1Q",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_E3tMeQxln06Ke1EmmdFqoA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "B [R]",
        "terseLabel": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement [Member]",
        "terseLabel": "Amended Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "Atm Equity Offering Sales Agreement [Member]",
        "terseLabel": "ATM Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements [Member]",
        "terseLabel": "Chiesi Agreements [Member]"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chiesi Ex U S Agreement [Member]",
        "terseLabel": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi [Member]",
        "terseLabel": "Chiesi [Member]"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chiesi U S Agreement [Member]",
        "terseLabel": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Increase in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Increase in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Yield [Member]",
        "label": "Measurement Input Yield [Member]",
        "terseLabel": "Measurement Input, Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NonRefundablePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of non refundable payment received, but not yet recognized as revenue.",
        "label": "Non Refundable Payment",
        "terseLabel": "Non refundable payments not yet recognized to revenues"
       }
      }
     },
     "localname": "NonRefundablePayment",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_Notes2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes2021 [Member]",
        "terseLabel": "Notes 2021 [Member]"
       }
      }
     },
     "localname": "Notes2021Member",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for President and Chief Executive Officer.",
        "label": "President And Chief Executive Officer [Member]",
        "terseLabel": "President and Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "PresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Cost",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]",
        "terseLabel": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReceivablesPaymentsFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount from Receivables (Payments) from sale of common stock and warrants",
        "label": "Receivables (Payments) From Sale Of Common Stock And Warrants",
        "terseLabel": "Note receivable payment"
       }
      }
     },
     "localname": "ReceivablesPaymentsFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for Senior Vice President and Chief Development Officer.",
        "label": "Senior Vice President And Chief Development Officer [Member]",
        "terseLabel": "Sr. Vice President And Chief Development Officer [Member]"
       }
      }
     },
     "localname": "SeniorVicePresidentAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Note [Member]",
        "terseLabel": "Seven Point Five Percentage Convertible Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNoteMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Notes [Member]",
        "terseLabel": "2021 Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock award"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share price at which the new stock issued during the period.",
        "label": "Stock Issued During Period, Issue Price Per Share, New Issues",
        "verboseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodIssuePricePerShareNewIssues",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share Warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of Warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_UpfrontNonrefundableNonCreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non-Creditable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNonCreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights, Commencement Period For Exercise Of Warrants",
        "verboseLabel": "Exercise of warrants, commencement period"
       }
      }
     },
     "localname": "WarrantsAndRightsCommencementPeriodForExerciseOfWarrants",
     "nsuri": "http://www.protalix.com/20200930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r84",
      "r106",
      "r108",
      "r173",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r85",
      "r106",
      "r109",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r86",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_VicePresidentMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Vice President [Member]",
        "terseLabel": "Vice President [Member]"
       }
      }
     },
     "localname": "VicePresidentMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r5",
      "r36"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r5",
      "r36"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r25",
      "r87",
      "r88",
      "r107"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r118",
      "r121",
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r121",
      "r133",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r52",
      "r66",
      "r149"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r160",
      "r168"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r47"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r122",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r35",
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r148"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r97",
      "r164",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r104",
      "r105",
      "r107"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r104",
      "r105",
      "r107"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r161",
      "r162",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r98",
      "r162",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r17",
      "r111",
      "r112",
      "r113",
      "r159",
      "r167"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r94"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Supplementary Income Statement Information [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Loss per share of common stock - Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of liability component based on income approach"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r141",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r141",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r67",
      "r145",
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial expenses (income), net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r117",
      "r119",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Increase (decrease) in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r92"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r45",
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r92"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r30",
      "r92"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r163",
      "r169"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES NET OF CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License And Service [Member]",
        "terseLabel": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r48",
      "r49",
      "r51",
      "r67",
      "r78",
      "r165",
      "r172"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Financial expenses"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Financial income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r74"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Net proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "negatedLabel": "Payment on notes payable"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePromissoryNoteNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndCollectionOfReceivables": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the proceeds from sale and collection of receivables during the period.",
        "label": "Proceeds from Sale and Collection of Receivables",
        "verboseLabel": "Total proceeds from accounts receivable outstanding"
       }
      }
     },
     "localname": "ProceedsFromSaleAndCollectionOfReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r95",
      "r170"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r139",
      "r178"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r80",
      "r81",
      "r83"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "Total Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r122",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55",
      "r90"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r120",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r119",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Employee [Member]",
        "terseLabel": "Certain employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r128",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r26",
      "r27",
      "r89"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average number of shares of common stock used in computing loss per share - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=SL116886442-113899"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4549-113899"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r179": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r181": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r182": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r183": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r184": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001558370-20-011974-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-011974-xbrl.zip
M4$L#!!0    ( $\[75'W&?NG PP  "MC   0    <&QX+3(P,C P.3,P+GAS
M9.U;6W/B.A)^WZK]#UI>=LX# 9+)S$DJF5,.@1EJ"7" S.7IE+ %J,9('DE.
M8'_]MF2;JVULD\RPN[PDV.IN=>MKM5IMZ>:/^<Q%3T1(RMEMJ796+2'";.Y0
M-KDM^;*,I4UIZ8\/?__;S3_*Y:]W_39RN.W/"%/(%@0KXJ!GJJ9HR#T/,_1
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M_%J/[Q!$(/WCL=]*5ML@,0"91N<Z9PYA$'CAA^0N=324=]C5\V P)43)$J*
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MV?P2V[UD1V#>324X>OCA/U!+ P04    " !/.UU1H\[JWOX)  #Y?@  %
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M9+7\IW9".&2ET2JW&N5RJ]FLM=H9[<X69TL!RP,E+Q@<ZG;S"-XXL';I4<>
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M@Z-#$]H;1T&*1,H[6GB'JJBD\*(!0B-Z=M0%=I1"2PG;\!OKL#]2&1,1$QJ
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M"H.ED/;#6PT;]5S&Q?S3]/Y^OO@5,J8G0]&0)K>HA!Z"CFA=H@(464N:7 E
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ML_H#/)&JNSRH1QG"D_1R,=3/TI?AD9^FES%3+ZL;!H\7"?AJ0!Z1CU$8GR>
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M2Y=[&GAA](41K[%_39^H'^Y <9O<12<J"/4HNPN;UYUL3P*GOF17/DW=BVB
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M<BF@=3/5<"$YBLQ@LS(TJ(%8[ZRG?]^RMMB_V;_8'U"[\M_^'U!+ P04
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M=VUH86W=&S:F:[H$(/!Y*RY49+7UWW_KC^:C-?!"HTD"0BM;!:*QX:&/EB"
MIF%7">_HATZ'M;<TG 7P!T[/6$,$Y ',H0E1#[R5#Y?U6SH@KIAM[A\^H2T,
M?_EHNS\J:+J)HLOB>8"^:;O^Q@-3N'#0@&L:J-LV37>#^FUG,48_C^S(C8&[
M.'GU'C@OR"JN5ZB6J<SRZO1H0.^+86_ )V#@?V/>Q"M'+D5>+2< @=\4,=LA
MIT3]!:[Y?>89CF^80D,>LPB)]=L\^^#/#>*@CS53I'J9$N35;NRY*^C[KK<=
MN@$0K]MQ_A/U*Q7U+Q7W,S/CV2[9V\1%5-OG%*THJRSY_4_16A[G/Y%F'T!@
M0%NV9/>E5J+8PG4FE5&M9I^@\0QMM&;LN:NUZZ!/OAI^F,@*_0HC9^"@BH+N
M&M7;,)>%H4G]\6IMTK4LB <TPTXLI*4"9_^"_#:/[6LXVRGZQE@L/+ (?W T
MC[\O#$[X!RJ<P13O*:@E535C&!H>7BZ_@,)USBLOJOG: S[26\C&$ZIH5%U<
MF!3G4M(BX#4 :"EE[3^% ?Z5<V2.\];[5EQ0\D_#L5J[4EO)8L.ZH]K;KIGZ
M!1M[]UPO;72,PD<P0A^>#\P/"_?ES +P[.*\?8?_>(__>'_>CCQX_XD^^M9S
M7X#7??8##U$>EV<;S\#^_1WA^[/J:Q3;9(;*)50H^?6WZ\Y-Y^[J^N;JZN[B
M\N*V<W.>J&*2\JZ7KJ[AF7'9Z,^,"M)NT"C%V3I<T[\WE]#><SM'\B-:*OHU
ME[/6KF<![_=W[7>MC8_JXJYWO>*[%D(Q!YX'K*>=#:BU#*L8&NJD-/UK8W@!
M\.SM!*Q=CR0A2LKZD<<#(.+Q@L C1-.98!M^=\IFA+OS<(S-)>@X:?T8XD(0
M4=31AJ(Q0#^,!A7KP0A875XJ7?W(R:]^Q,QE;3K!W9#]"&TPW*R>@4<@[SA)
M?7CCJGE$V97RQK2K[00L($;C!$-C16I+I&1UHX2C]A$MUS5K27B5ZZ&..S1V
MN/70P_X*#ZV++3J;S%QU(U<<3,3UC29-<&:\#BQD@]#EA*N2TS52TM>--Q$8
M$6.WFC#6M2QD3C_Z#UH=@S:5+4+:NC'%"R%BZ4Y;EBX$6+I(0^S<=F[;-6.)
M#"%>.)]K2U-'@*9._6DB0XAI(CDX%-+40W^.O)G[P\DCZ9"RIA3E (@)4N^Y
M2-=Z-_G)96>7K*[4,&H?\Z+>79&J\MCU \/^7[AFSLQ)B6O*43Z&F"F2^^*T
M3.&FWO6 0>$F^75]V,BM=6Q_];X(''QMCY>N0W<+'2>I#P]<-8^Y(#D@3LO%
M%)@;_'OMB^<9WH<C<'&<I#Y<<-4\YD*]@V#F&?@0R'2[>G9M A&I[^O#0GZU
M8PI(*WX]_7&QLOJO9ACC3'&GDI+5ASCNVL?\Z>(+Z&T\#'JWR86EA^RY\:G3
M,'+R^O DC"+>A=7%*3!P H"!X< 4(S B) R'-BEYW?@20!'SI8MW &]Z>3TC
M  N7L?9,I4KCNKSM7'>T9B>_\C$I)(^ GH/6#MET9=CV_<:'#EJV4<E+I:H;
M>?F5C\DCN0UT)J^_ MX"=>X?/?='L(RB*:DD$E/7C4Q^$#&I=0N0F"Z!;>=Q
MF4Q4-PISZQXSI]XW$<VEW-4*;R^[YO?I$J'W1YL GS?'ZQCZ-)*1J6Z,"6.)
M&:Q;2$4/V<G#X?46>/TGH#>_HW2UXY.C^C&%)$>(GA1&<^9'Z)N&_0<P/'J0
M("UI?8@40A!S61^/2AP&><#WB#XA35 I*>O#I B F$B2:Z4.1.ZB6OFH3*1-
MV^(*V4+7Q;P8A#BXFN1YT9/.+@)GA0!M@S3W27U?']KRJQU3)?7,R6]GQR>M
MRIZ_$KHC)VEQZC&L]CD^AK4O%_W=&PT?^L-I_P'_-1T]#1ZZ,_2/^^Y3=]CK
MMZ;_Z/=G4_'36+$4YX;_'!IMX[]?&,9ZIT=@!W[\R;$PHX^_[2LYFC]"!R&%
MJ FZNR,.E%-;(EFQ+LXOVY<7%W?7-YV+\YN[\R)MKCS.KN\C_G(0I1-ITQ1+
M&_S0< 602CHP%@#/!T]%.UM9Q$=3/R[^C])J)P,.[FB$\T!K"._X+J&N8^'_
M]/_<P!?#1L#];M S/&^+UN#A07&*#KCRIHUW?7=W=Z.#+G@HSLJC.&+E<LD<
M!4<??)LN72^8 6]U;SC?'\ :]Y+'TV=JND8P*X:.<:JT*(L'OV-'4<^_NXO$
MGP 3($4_VV ( O+.*$^61JBB,%#&F=8ZC0JC8(E6-$G#49203=@H_CGA23HO
MJYKU^+*?+1(YA>]DDD8QG0N,<<"V3ASS-.KFMF?NIEQV=RG WA/E- ]=QQ18
MT663:TI^(=8YT54PQ5,A 'P#K@.L>^"@/X*Q;3@[*SRZ'OY']'G"*!1E")>C
MJ60XV<^*1XX!E"__Y*AJ[+EKX 5;C#R\@ LM@M?8U4:?,;"R-$TKPE@;TME$
MEZT[BR=@^& "%\M@-/_L@]"<M)4#*T_3A"$.5M)"\@5XSR[!U]#68UK".1U)
M6^CFMG-3;SEPX9.UJ$S,1 _\7ZKDG\FZIEP7FG*R>"WM(E*\PHBORH7 1R-=
M&,"W=&T$S<>C7K#-67'P9M=.#A)W%TO90-+4(3U *!82W_8C/8-V8BG%,%,P
M/,@E+3IH<XA"<=+R]BO&QA8[Y)%=T2?>!H$1%5*!DG16&$]5Z5L<98W0D!7N
MD3GPD6+ MQE&R*&=6F21G2NC7"LT4R[A?I&07)(YWJY<<JW02$?)X;4)]AXK
M,],;$DT!0U3L1E$4LM%SG=!N7V&P[&W\P%T!CU-,/%FUDU1IY11&W9!^!S_)
M$3=(MCX(*9LG!UZ0%43S*'?!98W'O<QNGA X,5;@BE5,/7=D #-/VEBWZFX<
MKM[?P@F^(>,%&B_1E"> J']\ ,]![H8--;W."N&DE#B;$$#;D)4N<PK%(Q">
MW$V52V'L#>E/QL#Q,6F.%:[T\1VN'@A@]/:@8^$/P&IMNUO\02+6QB<20 LU
MD?LKC13C*6S4E"!XLKLA5X:Y^1HIK&*H*XB</ZRPKA0>GA#IM^@9FJD4,;@-
M";P7$43MM%#98JO2\46?Y7B^#MX0^Y4.%(HYQ]>=P0!/K;#5\,H C9C ,>D:
M8.1HNB9$H3=DI,C:C2*-;,*T6>YN.]>WC5($)V)9A[B(L\IKY:,%T9(%XRR;
MKIA"^!DO.98/O=[O&9_ZBJ;]M_YH'JW6T+?O4J12[VJZX+VK:3I#__G4'\ZF
MK=%C:S3N3[JS 4J@XM8F_(;G"NPK3=GJ0!7XEI/CV\6-HA,3^ZK,\&8E=2!(
M)M*F27,;EM31YR*2Y%<O?,%=AEO?"Q*\HG\=<XH^PD?$K(T9C+PI\%Z@";JO
M\'CF1TNF#:\")!V8%4)%Y?;$-(5CQJZN_H.[,N#Q\X3,M-H0)F1[(F6<X!JR
MUQ6!_@0(CX81T^C(-"=EA"V"7&0-H?D)F09-D@YV8A).2=THZD4P-F1K<C^(
MH:DV&* _:8Z8;$)MJ"\T( OBDD2WO.F6,-,3\ *<#=71%G^M+ZML@K+,,A$U
MI _ON7XPFD=(J2[41)J4,:[.;SLWES6E-Q]6V39[M^/8 0OL/U#(\@2Q@BR*
M[]Y\0'AM-[Q5H_^ZQJ,5M3TS\C1'!>(PRVZ?::.**;!M_%X3<(!GV/B@B;6"
M#L2>!?S8'5L>?)F;HY,2>,ONO6DCF'V,RLX;]>1FWJ5CI&R.%'C!R=I/([K!
M%9T>#X-/AJ[CQC9@]Q*TY T2@PC"LAMK^O0$QZAW38%7!;O4#18! Z"LS3'E
M1^*.T;)[ FKZYJA #&*D@[(/?ZF.R!F"('<VD$K3(+YS844<EWT33#7'?<-S
MD*;],?#"1R;O#1^:>,$$[4UPV.P^8CTG5W-T4 1H[#XJ^[Z89I<+?07X;D9@
M=5&]C 48;K#[>S0/S9)XF91/0,4*:XZN).*/Y5;Y759Z!.6,0U*6(( FQL@9
MH7-5+D*G]4OJ9_^[WA$[E^WVS;6B7J1LT([*5B]B6Z&XG>.F7-^-I".S/.%?
MPL1D0WDX<J1MU$8VNM*DNZ=3F.5=%&"5 3ZR^"0&_'#ET8Y347JX"6;@;<@&
M(W-_A1DPPI&S+D)AT"RX(\7 W1#!\&VT^$SI")712!&5MT!#XI/ZX6%\ **
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M'C;8^;H;2W98AN!'^!7]6#9/YC<LL>+VD?0"+.V(\%4]YZG]5^"9T,?KVZ\
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MVY],C>5#\\5B<3=U;$\VM.6=8IOAP#&6Q':-#<W2G[1>#APC? !L1_X(OAY
M!N^:*[9O><[JX1=A:Q<H=R-[_F/[94!2XBE)2U=[\I %N7L$_J-;*3>5,3!E
M5+-<3[:4AX<%G:O>TV=M?T;_V'RY:ZHM/122\>0A.[(T"XX"!'/SPW-DRQW:
MCBE[<#X#0FD42^X1ZCK>(:OAAT?8K"U?XAM.[CUSU]P!PQ?YS/R W^Z/6GME
M2IYS207:\>F 7QPCV[4I D^\]H!-B^T/CLT;SK+LCV4@I0]$'\C1DZ;!MX^R
M\ NB .?W.,5O32Z!$LP3>=*.RA.SD2?MYN??8R"K/_\V@2<CBFUY$*K^N?'
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MLB=[W<'HZ5/N=1^UGWD23E=]:5@84P(X;YIJ=F9'#<\_S<ST+6W#-1&^" Q
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M=6KE>!U-X$!(3IN9VF AX=  ND$\>]-.8F!WC)I0I42"'D@423.23*I#:3@
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M@R+U[$YW/>V.=0PM64J-'8W[JCV"BD2\H4BU<O?3->3*3(I/4)%XM?K8&:?
M:#A+JMIN)>.W5LGCZ6JHA(DYS:\3"C!TH>A,ZYAHY6P_.%9)O:&$U5Z31[AP
M*++UICJ>(9,EV!G='>A]W""*6&;+^P\\%2PU.%0 D,$*4<9 T1$SJ+&X&(/P
M>$JP^[9W#/P/?+LQ-Y;=L."$BLB&L=TK#7;W9KX6[.UY-C( VP:PXZ?;>V1P
MFF2O*M%VDV]OEW G,L'&7V#=!E6)$!5^"WVYH.G4 0H(/3N<V/01UEYSD3]@
MSU# $=>'QJ\[MH/SZ;MZ/-Y8]IZ/9R$_)3JLH1'^>#ND/V_#O>,_B+UQ#Z"N
MP$:#"1Q5\*.P/?QE0,^VLZ# E!M2$I(;[">SV*8'55ZY=P^FUMGS#-.^XT!B
M-C6N@L70DSW?W4\OG]79424CD+PV3Y::GC*QK3SWAM3T@/N2[KU]NN[I&;MW
M5][_Z["W),NR+W?TPH.K]JG)8!/$5REQ% H G0ML EV#:F9JG@>U$QA0W1S;
M"E9]8X4 : &LD$*PW,E*F*69D3T9"6H!/8>AQS[V4PX:O@$V(D!A=  R#3#R
M-]=F($VTA?P1?)GX"R%(XF[;PAMK8=6+:5#UXE/P:$/Z \( ]\]/A(X]Y@:\
MW2+)'G2(Z8&3S=,4RQ."7K0M4I*2^.(\T(%\ 5X@,52<L=+SQ\  :IZ,&/#W
M )$5:#<&U]Y"'0F4P@G6Z*.?(E"ZT*-?N"9$$?@49[<N0@4RX6!7MX%Q KN#
M2WA ZP@9.?;"&^^^OH-F"@AI4\%0L\+]J#!O/& 9@?WU$H7AU_A?NV9O-GB9
MOEW#P"S9-GZ!UEU+S=H#.YP8H 2R-;GV[:S[BQ+'7>T7-D$/"8:1AHR2D"@L
MH4JRG,0DBE  DR H2@8'U5<,?,*.ZV9CI>>F%2.-MFHV,3Z:7-4=@ HI4G9=
M)U(FWTVBBT[#&AVK$N,OS 2V2',#/>?8O<4Z/\<[3)"&11X\70)U<ITJRKR0
M8SS12&:M1:)^K)Y,J]I,I,>#M(*E]2Z[6AN6T4(7Q^K)S!.<F6UZG(TU1_.I
M/UYA@U1UL8UH/&G9!"J1[A<G!=%/]1LS89);^MI"(A]:1C$)C,7N\-\M$T/0
M=RS[VF&,=\<7DG<8<8J."/H4O>#8'9MXLZ./A/O?Y-3I5X+R<=#\6-SGK7DY
MPU4%+QH"!Q6!]PH ?SRD];JDG .QWX@8A=9A.$7!^CVRG=69SCD&UKR3WC[C
M(7:4I*I5BBQD<;%9E48%1LI5FH-=SNMK5AUW*&&_'\Y]4P,_4_ .+- #J_>7
MM@"_ !.JQRRW&!$^!1$.QM5\R1J-F*9\&,K.66A^ V$AZU*^JUG =1\@;#B4
M:BO6$!,B4)*"YRCMOJP'>U#DAX3HF'\9WG[RGK#XJ70_8I;3Z:6?/^Y>Q;+_
MENSO&)<+^9;>L.U!!U("Y4N99;*#-<L-BM=*A5J!'D%?Y 0Z0+U3!Z[[D/-A
MR&7X2F@C.%]Y-"*C#8]%9L-X+%R8+3L,I_KN)BP"16AS8<Z1"Q%L)WR6L0H>
MOM#@H^%C$0L.Q0[6%LB6<*&W9$O19"-P"(("%T%CUY,M5794%PFJ,6KJJ\?'
MR#_DISM+^V&..^2#UM/WC=B=-;@?QO/<,3",G?PA?T"I"J-JFQ+3[XA9_7F'
M](![+$;[U=#7#$;V!/'"B+E@)4=#0-9+F*^GQGHR PI8_^AFVZGP[M68^LO;
M8F^'VS]LC'PGU3E 7L%"!,6S!\#9BC2]N6'K%I&G$-*6&I1/8*R0K>!FPWT7
M")U!%;10+D7X0FIN85!RQ[(#7*F%UEK4M)@V^)F0ZK6M7E<D3"B-^S>36;ZI
MVIX*%/@(XP8)#C_#@6%/I9YS)6$HX9@47#0?R+GCCU<H7AEV,;^C8E-&Z^IM
MHGZ#;/MQ_[DI5+-'=IO#7,-FD&K8#$D4?"_$;@CB>VI@,9HX2=M-@U]Q'E-6
M*Z:"RZ.;GR1Y2Y+,;0)C=W*\8\1/9#/D'0H<J1>@/,ES/,QN7  '(/8C/7??
M2R3?>UW[T\RI8[>O[Z<__<;E["?@A:JY4T->;6K:?XPQ^VD\[YU![+>HWFY9
M*'(2KF?X0&+P!) H(D%)2?@CB4XD5&6(RYB",=M@_.8HT]YA*,4 LA.DRX^?
MT4$D[DAZ>IXS<2^FEQ'4WEU91QCW\4-R__U?[[K\8(\-VQDD0D$> 71SLDP>
M0C+O96,AK]PM3Y+).X)ZN 3A04K)34)>,OEOY/'EXV&R/6J"W8T]]C[9O=C\
MZNG^Q?:S-XZW;:<QT"42.],$/HIV.%/DWG3)R-@)\/]?+2']D;CB6X_<O TZ
M@KH)UR+CR6&2[4=[@A5P,3BO$^X^08A/;[:1'C,%Y'U9>4DCGD[0,<Y_1=VH
MPSO'D<<KO!]P83,!P3B_GL86ERKSP6V ::':XJNMYA?4WOB];.%3;6.>OU#%
MDTK'B3LF&;E;'X(B=J$S'UB5]^$K^&OP!W:+PJ_^O*YSV$^F(\G<4?%T1&8Z
MZ+M7X] 7,!N_<$+]0_AP[MD^R5F-#ZG8Y8WH#2D]FQ]WN."_=0;F_09!#9K6
MOWZ ]#6I?? ?$G<X>[8I?_>] X]$?XY@OF:E;8SU([9ZC6NT"ME"E:NF"URY
M4 U,2BZX]5DB&9))4 >3>1XK_K%XX),!0&F!]"&%,#D1Q_]"'BA%]DC=2)/\
M'NW:*Z?[LFJ=38X^<M;M(V!R*@4Z%T@^2%O! R:>W6W*A+?7A*=;))9A<?KH
M<:U/]AH#"K=1U;L#A_']A0>^8BFZ("X_$(<\4O=KW!YK'D#A#Y6 @, ,B]7[
M\JVZZ*A26JAF^&J3S\ 73:%<R' M/I/BRG 1XIMYGF\U)8JE6#H".I6V+<CN
M8-<;O@J-LS#7+24;<E"'MCD&P'.1/T1+]E6H-.J?NT65"S="FF *%?%A3XG$
M-GM*X=& #%#VO\*#KW#VZA66B%4PJBK8;,&_E2"<*&2%&M^ =F!T5?!QC0L4
M39B"35; 467,;H_Y5C4+A+K7@FP 2,4.CP#R83;,:ZKZ+123C!7S$A0SG>>J
M.;YY*8J9#E.!W"!=*"U/-0]:IQDPU,+KSE;'=!7Y!&4]W+<<AO_]=?E:3,5:
M?!%:S#7SV;)P,5HLNV,D:]B+MY?76$_?I:=TK*<1T-.JT.+Q9B%7+60+::[:
MXM)I0:RV"M5<#6IMNL WI01+4D<+^'VRGE9M#S[&LY$7%/9;1G\2EZ-%3P*)
M1$6VY-%FDC*:J_BN"WT7B(J<)1LK5W/M838",O<8MR4N.FY[(>Q^I/(A9?:1
MVG#-W-$;K,F/"A\@PN8<1]"F 5S?>.X57ST2X!>TH#Z13;(>G)&!CE&0T0#G
M#[XUMN^"R3=LUW<B()N/4$!>-!1<"+OWJ0RU>H].Y(%02 DWL'T/J<B.#CRD
MH;GZU6LZ<:F+/A7DS#JVX<+YK#FV M1@!J4D0Q,$$P&9>U1QZJ)5/.I\WI$7
MZO4C@;'BQME)GY>=5!!:>;ZQGYJ42&!4$HM&:M)C;E)(9IR7=$&)"T\S9LI@
M)!LAR(7E-UV)23 D>[0.4)R4=&TL#BE#]DB[_C6.O51%Y0+G(2LKGNVX$ILD
MR40B A*TIZ3<96MI-/D;$(5LJ8J5,ZK*28C6XSU13=D KCWD9WY0Q>*A)'\$
MA.EJPL67P>Y]*I&0S"#FNR%T_ZZ&P,T4W?#4[G8ICE4]LJI.9L!0#N+WXM2V
MFL#2;.=Q*B4:HPDR"KGF5Q,.O@QV[ZA$ C*1#9U[*AZK<U35F:IH%FC*0^"M
M'J/V$H%1B20> ;FZFI!OM-D<4(=LR-O?O(G5-JIJ2PM!1;R"M2G3%12;8Q(L
M@44A#^A19>F+5MD(LSBD#-DC+5;4J"HJPR_'VD#S7"E)L#0=A:#GHX(R%ZV@
M$63MCJ)OJX^*;00C_^>&N'E3-UGJ#ON$0A<O2%"05,NUQ ;?E.@$E<#8"(A/
M$[Z6O6]A>9'/CUE^?AWM#Y0;BDC6^N?63OM844I2E@&-#Y(2 88#B4HF6$DF
MDY@TQ'":I!EL*%.!BGVL*.79"AI^I"(E'M>8W,Y*7&/R<VI,;E3J'45Z3E?L
M\1VY+T]P(R!N8T06=D6_7ZW5\P 4;Y<I.>.@GLD8\R!B^[D6+YQ4.1G^?IC5
M#:$%Y[^+I#8Y45R-%UN%=/-VR_]J^FZ/OQ^H7?%UTO- )+)/);(E$]G0>4*6
MOT'.'^)=\PY1@Z*>3G@2V!O;?I"=Z?[YF40\G%O\O(>^L/PS#WC\&V6J"08,
M!HED4F('I"I1ZF @)>EA4I)5668).4'0Y& KA0^W2]98B5?J9;7.YSJ38J72
M7RR*M?KV8K8G+=>=*3<:]-B.**\+OJ WU+:7#JYPHY^W%/*3<<KD4J)>FJ?I
M94$NBVT[N+'RX+Y,E'=-%7?S&4PNSP'P2HOQB!Y)]&%+#A0%S['R0Y[I5@QB
M4!TO5[!/YK!E5:RTYW2/S>M";EIKU#(KJ>*-8,N#$2T]S9 )-9<7M4Z[G"IF
M!FRQ$?1Y,**YG:\,R\NJ)VHJ-JSD5TMVIG)2XLB(UNU)J8):#5[6VZ*+CI*"
MARU@2^9Y2XHP\2GAIE-\1YDDL]6V-.)3=2EYV"=.Z<G!;)(C],X0<WHKME(W
M,R.)/6R9K*90K$REY[R@JBM^VNTLV\U1<$G 05.E66V@N>R($(5UU<1SBW0M
M9\*F1^Y434JU7@O+Y7H\RN;K S7M)@TC;'K TKPVY+DEZ[6QW'S6JV)#RY_U
M%T'3 YX.QE)/6C+&A"=(EFJ0Z*(QS4').R(F=3F?7HQ2Y3(_ZW?'G=G4J,H4
M;$H=-LVT],3 <O05K\T*@S*VP/19<10T/2! TGC=,TIJ113:G88PS1O2,+,(
MKE,XG &[1AJ= B7I:51,%'@YURC:G(0?$;\I9SKK%%;H8G+)SG9KSGQ$=R"M
M1V2EC^7G;%DWQCPS3[A$1RUTB\0B:'K 5V*:&HT;HK,0@;Z>.S-9X);SL->#
M84U+E"%.:TY&E\V<4"^J<TH.KEH\(EALW7(,NZ@8F#9A>0L3F&2?&@5-#PB8
M"/V1@@]L5)2G:I5,-*%(#L->#P@06R6MJ'=7!B\TT#88"G5]7*E+Q!$A=!I)
M?T#R]08&TAVFEEL/V!'D ''D:EVZX^K] <F1&)&02\TR5Y[H<TXBCH@+-V+R
M Q+,3&SF8ZP*A*'-#6'3(^*BMC*]'!@2J#C3.8WL09NPPX1-#T4;-^:KMD:0
M_*S'*;Q8F!DMK!XT/>! ;5W+SXRL.M*)E<U-J0:O*^1((HY(UC)EULPV::=Y
MK2PP\VQ)4283V.L1R2*;:JGDD6,=*U4L<Y)3Z-((0%J/2%9C1G'FDNBC6$>6
MAER=D";5->SUB PHO(WY7-8KBF9S62O-,J1)EF#3(^A27\Z6D\8$FV$,VE#[
M9+8XT\51T/2 69JCN:8])TF=\-/+4MGT$[-5V.LA#@! I0J]&:G["IBG#6I>
M'K8XB3P"1&@YX:X=@YCH):;.D U=*RX*(XD\(BYZK;YNFBRHZ*9%.Y6^I74&
M8CUH>D!KN=3GY^L68^BS0BV5JE2$=F:\")H>T)HN$%U95IH,G_8G!9);-B8E
M#1)P1 AUC])-O8L5,;/%5]5,1F&K'=CTB!#Z691K"-W.A,_Q,\R<T!6AG(<<
M."(NDVJ+ICH)QQ$U=&2VA_F<U1O#ID?$Q<])\^6R6EGIN<RJ/ELXN;9=@L,Z
M)BX^EBD[8%$34:6)-9C"D*IF1T'3 V8))5&9>:F>JC?E:ANM=%V*T<->#YC%
MRPG3Y%-Y&3,'1M'NM 5^68:]'A'"?A=+,[4R7133BIL7R5I9+@9W7!\!(GXN
M=N9VME#$<EPK*V3]V;J<"YL> A'9$;J4-LWKI9*.Z:2=SU=SG$0= 2*Z1*9
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M8LW.ZX'.;DZOL<FSG#>]+EOI8@-?#S(2B!H"S*EAKP! 0A5Q$7\*)=\!GN8
M$TI/["A_%T<Y+O5R$99:#5@NI)*SU+!D7\UVO4=MA9\&'VQT.O@@!2PPU+R:
M(5ON7@+CJZO#"'.$+-'1ZSR:Y&<5I4-8Q0JTZ,+"Y\0MEDS&X;08)6*4B+1Q
M>'Z8Z&7*+)$RJFM=7J;FPFC0&/$@A DF@ F:B2NF7V\@[H,50;\AY%\1LL<
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M+P_"I@?CRIAN+E/3NFELQ:3H=F[86N5G(0&'XYH6%]R*E66?;];RS@J,>]-
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M7S(4O41G3&I<.HL]96LU+I6>"WF,4"QS7G6*0[U>EZBPWCA^2Q')<Q1UN\(
M3 P4,5"<+R;S$E!PDU$+%_&^A*'#:9MWT':EOSJ+555(*J8P+:7:6#I12FL&
M4R+JTP HF)N?!'6;I,X%%-<6A(F!(@:*\\5E7@**?H*H@^;$5C%S6&:UA(Q:
M/?0\[M>TGB*'TOC_L_>E38IJR]K?WXC['XR^YT;L?4/[  )B[W,[ A$5)QS
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MK>RBWI1;'JNO (Z \L'8,2<"0T,@CD <N3V.W(:>>1%']+#$5.835V3E1K/
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MQ\Z\GFSI\]8' L5_0+*55(GOI(0*FVJQ'8Y_L1@PC*JY ?V<C>!&<T/%UI,
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M"DTO<,U<9\M-_.%R(-;D;@GC]565(*]5Y'-8:FW&Y(Q"1#G,(N,L6T/74AN
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M"')\-PIB%,2H1,T,U/E0GAZL#.?-!>JSE:KX5>F[37+;6Z_9D<AP&-4WP\Q
M6;P_Y/Y\BGIMFL1HIK1Y=D.TQNO\T$9%?044-0@ ^9VFOK?0#UA^%$9PP",+
M>&X'S^V@$$ A>$ A2+X%F$#:YX:%S\HBO=6K-<^)1J 8!7FQ&C?0MH3E $^4
M1XZS84 <@CAT!SB4^!F 0O" 1 WD8V[$Q]Q0@ZYZ_>UX( TM=J.NETVOPO%M
M904T*"!P7E>A#Q-\]!9>Q]/]P#-5\->.XI%7T48ZR?#  *7[#U"Z(/:\(TW4
M69V!XPPNQ4ISCH_-91L)V6)!S0Y6PJ3Q[JQ1@$V.):APC$H'F=E1R;'$-/6
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M)F*&4M,W^4I>05< .>*#]C2.O\T+A>SDSE;]=R!'F_K\_?RU8\\:/K5[\O=
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M8@L3$#8J ,A39:K0.9N?Y<\\<<XN":@_70<QB71'V8UO#R2$@E$@;+-0Z)>
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MOU3D 3*0ESVP:.F+)1)NZ<,["B7B^V+$0"7$R[/I ,%"3'BU.$((G-:PM[.
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M@YMCN9[@#(@."&:*A#T#86<H9P(?_^I5G[H4O(L_UZ&@UI7BN\*A/I@4'+_
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M&U XRZ9/B#@*1*23)T0< R+$LUCBA(ECP,1)-AT+(E(G1!P#(G)GZ=P)$4>
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M)&U1F'96\V&L_M@K7(W'AV5I4D@.RS/E3BFI.4V-E4K-O%YN 4NGD:738N;
M+/VU1MG>??>#;JUOF%/TNN>F,3:)%6I?_2-D[O%;2VZ [-?7?K*,/LLR0O:I
MZDW3P$.D7I.C]61Q*:[(/"96ADOU04JL8^O$<I!$TR@>R61W1Z>?N/%H#9W#
M;_)D_7R:]?,NMI7/J^/K>'Z4$E4GL4@YUM.-GLP#VX+YDTKMB6F_M8WS72)+
M9557K0E1V&"[DQ^ZW]#2%\:4WV-,?7+\Z:MW_?7R?/]6F,O'%63CU\3Y];A]
MHY02RE D=H6H VGQM#26@Q1:8>E(*I4]!:@.'*#Z:A8Y5N@P@^^KH?/U N0
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MEF_!*OY#:/C8Y_#R .*)$DX6. COD8'6V 9C1!@Z-J@.TS3 ^*4CZX9K5P@
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MC3_AY<L$V0DOQXB7V%GBA)@C1(QX%D^=\+(WO+RS4.%5Q^7W[_O:^[D(V=<
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M&)3'#L'_^SCIB%;C2N"7883 ^ND7GB\,K'BAY=DG)OA")DA^-1/<>(3P/!O
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M18/9+.Q=QSH,<8\,F!O$XX%#:]P/Q\& TC)_FY.:Q)G&U7MK,KFXB\Z6O\J
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MXH;*7C=9W"LIG6*A"_I*V"#+S!6B660Y(:Z- <O&T" 8#MSQ?ADP,3':HF_
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M6'R%M%#Y?<N+BUPG\YCMF^\6^<$3>,-!C.'22@("(YYD>H[(N?T"6MZQ*7>
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MDQFB^I-/\K[D/MVQ+76Y6M-Y!EFTE8+QQWCOG[E+EZBI>)E<7<#M)!2*H6:
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ME\_$6F;"06RWY])O9^6H<CXO5)O3<,O#(+>$D;=W@CE.^.5C!9&%< CGS#>
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M1^TX Z^GV;!3=;4?*)C^(6"0AG-D5YI+D;>_8I7WDEIM&S!%VU^NJ*CG,R$
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M$FPDO!\\6:X>4DYN>0!F9:(@3Q1A<TU"<::6AG4P7"LVZ$3A,J\T<[TC9;1
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M-%12\ZJNEL,Z2C'JW,C[+X<%UT3/O4R:3! M6#AI%4)0F1EHW0CM!P%"P?&
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MB]-5#$D@;",$> CC1 7?=R[4E8!V81\;TT::%_("7KKA1!%HV^^G=C#IW,1
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M9^SZ0D&R."!<$GE\DY^X5R[QV>6I<&50\YOK(XJ[C?H-7_@."C*RP8IQ60A
M=A@L6*(SJ_<S)@(Q;-:2)C&S*C:%1LBDK@C)G##IK^!IP[I-\%!?AU-&&&4^
M )$=^!2VA1E>5HOZI;#Z,&/LVK4:V7#K:3?Y@\S(5R!$-J#V9;(:04W7$[E(
MX+#J4=6' <',.'C@DWRJY<;EYK4X5?0$6@;3,GD-JY24*4=DLM)+:8 Y<.=
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M6'W45M5:5T@FK-4ANWZ$G&&$)RC3#*]S'.UCI\_FNH=I)P'%^A6@6 4H]@P
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M=WL)'5/UL9H> ;$H^<M/..\P#HYD0)WA><%EJODK-4WR[*U=,2] &9FQ<GR
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MI::7<>@OJ30U]1C#V+^!_QEGT\D__C]02P,$%     @ 3SM=45ZIL)'TPP
M4-4  !<   !P;'@M,C R,# Y,S!X,3!Q,# U+FIP9\2[950=V](NW+B[NP<+
M! \."2PTN+N[NP>"NTN"NTMP#\$M."P([N[N7/9^SWG//GN<[QOWON..<><:
M]6.MGEW]/%4UJZMZ]GJ9>UD%T*7$),4 "$@ @'C] "\+@ @ #PL+!PL##P<'
MAX  CXB,C8*,A(1,@(F%ADU"2$9*0DA,3$[-3$M.^9:*F)CN/?U;%E8.#@XR
M6AX!;C9^9G8.MC^40" @(" C(>.CH."S41!3L/T?CY>?  8\1 I4#A0$)0")
M 0&% ?'2 Y"]XH2!^', _Q@0D%#0,+!P\ B(2*\3ZM$!2 @H*$AH*!@8:.C7
MHSZOQP%H#!A,"M8/L%@*!G"4#MAL7^)RX*D^5G?B*$Z<4K,;.OHC(.+BX1,0
MTKRAI:-GX.#D>L_-PRLB"A(3EY"44E)64553U] T,C8Q-3.WL'1R=G%U<_?P
M# @,"@X)#0N/3TA,2D[Y^BTU-R^_H+"HN*2TIK:NOJ&QJ;FEJ[NGMZ]_8'!H
M<FIZ!CP[]WM^;7UC<VM[9W=O_^S\XO+J^N;V[OX/7A  %,0_QW_DA?'*"Q(:
M&@H:[@]>$)!N?TS @(:A8(7%_*  9^" 1<GV!1[[8UQ.=2<"%;OB*8ZAXP0B
M+C7'&LW9']3^9/:_1\S_?\3LOXG]B]<\@ P%\>H\* Q "+BYI\OU0_Q_(L7,
M54R'.1>5QAC]Z;94[1QI$PAU2;\%<.)>  3!L!?@ [ZOWFE9@V=2<@Z10$&7
M5*F]U#6G;/IDJVAI;$*->3U(I6VZ_)!*@[D2D]K(3ZNY5.\TT3SK$B/DZ@5
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MQBIG25@2G!!MEA'4,,HD%^2B8BI*/^X'4XP#MY*<:BN]&E;]P$1,HT@O,.?
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M23G7SP3?W6%0HR5Q)\J'U+XD. .N&1PB\9.VXH<AI<OR&B/.FA_=M,F,(!=
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ML0$A=&;+$6B7!*XJX;],LF:*MP71Y&7T_;WO$T"S<"[ET?P%$",,>0$8*+T
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M6>I!7*KU;SHPTH6LFP&.Y']3_1#I2(1T]@+XF\$'_-)1LBO*"LY2*9@7P%G
M,QZVJU#6\ZW(ABA)7TEA:+,(8\D03X&34G[N$42/H=P=Y=<(P&$+VLZRR9D@
M/?\"N#E^ 00ZMR3&3PW$EG,04=GZUS1231>\3P]J1DOBSTO>H(' 8.31\1Z$
MY11HKQ84+51M?@I!?EM-=+3:(A IH)FX^QFA;3*G?\38]G7:^_*[IQ8P)^=*
MY=J?N+:A> K%'M ]N(X966*90P,(&*/]REQ- /.EJI X6!UO(.*E&V)VM\R[
M2'PW8J(AV\5_55UURRN9BQ.&%\ 2[6L27#VQQ7DB+5<B8W><:2K75.J Q(4K
MC($Q/?JN8(2'2+"&4+A-4\]Q@[>217BJ>A2OB]!".GI$Z+8LU2Z(LPG-H6 :
MULF=ZFNZ:O6I>O7T<Z\)0L?F*A!AD*_,7U ]#G[MHMO^X7)M0Y8BC?SPE=]/
MA6?<<@(J"3B\R5O?)_E7A6+N:'TB\MW[OG9S\K.[\1+!+,QGX.@"S4Y5P&M6
M/,76YG52,OWW91C,_M>$K'5<TVE[G@^ZRXZ0J.XZ1N!(@ T9LJ!;X9XE[PW-
MW^@3NMPP1KC\5V^N-L"_D[P"P(S[Q7E9 D04:X'<SFX)*\M0:LT=33Q IU<L
M:GL><3D*_/_VI9*-(Z-D/PAOIDL#XB;4C!-H0\TB ZC02DA[ 63R!A>C(@R"
MR<&//PR&LA2TL3,@6OBZ=G#U +H$\AN"/WE#T<^>53M*A7),#L56A/1,N#B'
MB@@ LB^^%Z.^#(+%+X"]U.<O$IS.'RSGV?V_0 YY.>\!D=FA0>^HJ58D.(XU
M\@KJ#&XZ2PYJ!F*S70R'P%B6L!]K@)D-Y[YKL-$UP!? ^-_?][-17@!&=?V/
M7I__NKQ%S<(:O-3[UUMF&*#JFO@UDV7BM0/#1E<#?<?+16XZRW"5$7RK%WW'
MZUX3!?C_XK.?C2S<:_,"$/X'_<57^FW_S%?(J#FR)WCZ_4&X'Q3AD\GDV\0
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M54'#)5;;MF.*94GE75A='IHRA4G 081QJ\A_\):%/K?"F4LV&)Q<"SNF6[T
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M-+\%^3MK+:@XU<RL&(C; #E>33(%<F[QF4ZHS_;H++Y!(7HURM_)A4P=B<L
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M(_O]_8EY+0E\U RR]=<R5/&8_-\.;"2&F@2]_+?F _H8%;](92GH(C8W,CM
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MSG]_I__'60X*7?%/P"_-*'Z9U!^4F_<7C/'A,=?M8;>3OST,^W\+G_C$ Z-
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M77U#1V=7=T]O7_^/<<C$Y-3TS"QT>65U;7UC<VM[Y^CXY/3L_.+RZOJ778\
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M0'B+D1E,#_B;U-G@>4@H/MMERDOA*]6.Y#6.(74WP@T7XI B9H,ZO F,3%6
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M(D*J1O#:E_P\I52#@0[DVZC%"H=:5KVDA8HA72\+TG_,42"Q7 9O>=CDS^Z
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MS_?USVCI[2']^L.-&.><SEQ%8Y*X3ZL#@3%^W71_MS_K'EOOQ;U/7.O%H?(
M:_L(V7H5Q'(5\C0YDK[R^94H*\S-,&/\5)!3HC8:G7^,(EBL?M+M1:B:P6]L
MD6)N1!)P_VIUB[Z\JZ?N2&^)RXI[48"XQ%/*X(B)X.*NVL(3K^/&U;4>2/-4
M:*7TH23[C3D_28[V.811MR)WL!8E\D3C7WVFCI)$_<RN[[KJ:;+?V]5!ZBSA
M?R$]_RW[N,6J;HMXFGMK\4\Z135)9/!V6FB$"C[SE?MC?4=()NA\>]QJXG,O
MG27=@4"G@<@FM*AH6XBW/LPY5\<"C]RHV9ON2_X3W8_JXD=/?;&ZW/P2(\ZU
M4)W_ 2P@) $;]X0I(<#A0II3K9)Y_P;#CP-:G[2,DH$[_A'5*A 0YK+IW9 5
M&OQ0;Z*P!L$!(G(&-Y?T_P =NX'O]KWUL3:'FQWG%X^-(<K?2#X/2I/[.3(6
M!C['8?3^#%A"'?@MV(QG^++F)BA>47P6V4&WYP%C-G&Z.UC30HPP%( ?&%&N
M4<=_]ZINQ*]YG7YT3,M7 T&\V 2:F11MA7'ZI.,.>Y*@&SGZE89OSVE"DFL4
MY'G^A(L_&\)P/.".Q.547Z3M%A# E:)QSC0 H]^H"R FK8QM[_N]ASPHO3HW
MN:VL"Q-SM:*M[D"AC))M2/VB ?Z74%19]WS8LO[3$G+%,9;$184:.9>$VEC]
MS:D8]3&'/8O%O@DKHQ0D^<ZH4V[,?SF JFW,%LF1GJR;@8^ <-9<2)*\(&+G
M?J-'MU="J>(J,X=<MOD*[WS?MS7&&&CCGP$L<O32WVW'*>_^*0.OS"E1LJ8J
M-J1M@7RBF)F-]72"\QLUJZ3D:I4C+J0FS0SJ^OT82^?KC"$"@DV.ZE]-3_DG
MTZU93FEEF0J$8K/,KVD;@=M3_38O7J\4S5U/\)"1CEM7FYW)_,QRG^EC8!^6
MY%?YK7\O=&Y$V.D!Q2". [9/LT D6_S6)!$9A412OERDV*M[>!K(E4Y.5X'7
M)B6_&0*50P\AE2W_SE0$XGAC[*M<HQVEH"F *]13!'-1E*@:6QO/JA SI;9V
M@26G&8SG_'L,20ZTI9)\UQ;GMY0:4@DUV%@Z(YMT$D8S&S/G,)<Q(BB/W#>S
M^Z1@+_=['[CZ Q'5>>8U;O*)4*VV[VW9D2&CFC&W(D>V1T\/,+2V(=5=SK0$
M4=&RR;;!IP=_VJ-W9!2C"/%$?JFKD[5HXY]BW#(*NBU[7*0D[ML.AU*\ ;(%
M#;K.]OTE#3]^9X253.-,+'T.R._ _S1,3"5"J:$\'%AW5*&:'.I0HO/;UQY0
M['&T;]!8Y7,]+@?\UA4IVZB'*<I8XN^7:QZ'K34[VXM;]24^%,TWM=F"[<^L
M^'>,YORX>2#(A/.%1X>3.1?0%0CU"6<DAC32C(9_VO(0M:Q[0'E%^(M/[*QS
MMYVWB7_>/_(_T5O:'S0;,5Z%SB9^ JZT'%\<HFB9NYT(6=ZCY?8M8OEJ>'N6
ME'S:_3LOIE^/_Q6QT$T[B%ZV?JK<P0/1%+(W8:.0Q1:9FC_Q2]:(ZZ/VH44.
M?O-(#?P;%<*UG3!<+F@FJU@X=<-YSYC$Z[3ZZ<D%B'Z08S8Q"F^@(^W><V?]
M?OOK#7XIX,DC":ER&73S3-;8F7=B,^BI/ ,_W=)9'ZUO*9=*:O3U\:HK$OZW
M8;,/R?<4<#[,U:>^5[Z.BXC;/B1?? F2GHX%5UFN)GS]8)"%V1/_[U>A-&JI
M&4F\[D8BUH>Y,SOLY/GID-E.P^NT$J!GFE)UN$LOQ:LU<B.EW[@5!L<?D3=1
MT\<!G6A+=W:&:E!HMWQ.<SMQ<L(!)J@S5F)3,NX"+*PK_%W\EV).>_N@1EB>
MMP"/*=J85*ZXQH> ^6CITR%+<ZA5:LS'.*=7S'A;,FKZOG0O"_]=R!S;-WM@
M"%<0;767H?1'O=*\#%Q-V0?"Q)Y?@I2H+-!9#1:E*I:(_:? 5*0=_Q 2;!RE
MJYE"Z->:0HAI^7ZLYOP'++& .A)Y DEI)BS'M7'>\RZM0KCQ;RF%2&ZX7F_*
M^@Y\V5? $#D;TOFM:_W"@ZTC&-,\<2_;">I7.$ "MA?4W+(@!J.:34&Y$F6U
M&2JB:@7>R:!9&/P[UXH[O>.'R%;*R='C$;S8SSS%C2ITH>Z\[NZO:X2L<I)I
M0];I=H/K_Q,O)?U:-CQ8'V3/R$?H1HINQX+F<#\ZL=-BP)B@U2B&AT_ ,.:W
MZQ%WCF&V9^>I*O5]JL2O)LLR'LM_#K?!="KV-(F0J^QG38V8<:5I#,PF1_/?
MDZQ06M:,N=/+'S]F*6OY!D&0U&JRV'1S-[JDNR23N'OS@;T1KI%_O11Y#ZG<
M$-E&B6OFK,RR8K"!F33L1E@#:4.YHWX'<_5VM^8?)B;'-@LHS7M D6<PSL>4
MGQBVU:7X]R3CW&\NR\J8LQ(W*!Y+S_:U]Y7HQ\;^)^AX[4\]VY6QLC;"%F/<
M<Q!$+KS6C_B0"2/VY)]E66:I*SP=$OE/0[ 699I#Y^L"E*O"'4AY,*1&I[QB
ME](PMZ:I5D8415YM[?UR4.#O5@[G8\,#"!+K^KH_Z+OP=$Y?/'5/89Q?HZ.M
M616.U?KM>I?]FMFN5Z$2\AY+&RB%:'2I;*MV%H%ASG_,N//:G-V@H=>?/(S\
MMU2DF&[?[4@UUD27N<7Z$?(SFD_QJ=B ETE>T^%^#+A (G]>6XIE3FN685B3
ME.'W/-"(Q.4>XKX\3Z<\0=7:6!$.S+>MD!S61***43^<BBB5(4F,#77&)-I3
MN5I2_@_4:O_F'O?"#[SU!P];8R*;O9Y2G>W,DXP[B31^JT!,RCDD_Q]]0'[,
M89YJ:(_9BMH'B::"?FESJFB[A6"L*J2FX7MY.$HRUN"7$X5_GZ9.%B]B68C)
MC-JP23./]3C1$])& +P<1OXQX0J4Q,BS "\9QGQ)K/;/P[G@&_%WPVDP": ]
M@^(VM("Y?3%$STM7*EK_8#NZ_RT2)85XHJA$V&L$_X>X;3&F_>_+EL0J#<V_
M^U#F7R(<MUEF<+0_%SO[@.27U#45SU3RJ[6TB[X"^G1FJ7,7\&8T>)$JHK(3
M#A"(N;_"I<71_6_S?YO_V_S?YO^!S<'1P:QX_WPD]S]#"C4;2DJ^%."L7]0Q
M%P9JK1ZFR^?4._T1DOQ[;VJ%+Y8?$O>(2VE+<*,]'.!%?LLP&Y(J.*3#Q'2/
M34R^/_<0A0+@@(>,GK+\?F_D[A)\F#GXZ\0D\R'L_:TIZQ_Z,G?^=X#_#O _
M=8""GV<@N6THP;M4P]*54C^76[/*)_0M.3N,J1D%,/,@8MU*3/::?#5FF6O4
MO(=,]W7:':SL]BGX,$/BNUWP?!*.AO M#11\8=UZ2/B'9\I4P0'[\^ E3CC
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M -;?OYN(K[B;=^5[WW*B\%!ZHH7  5>$#C;9<$ _R.E[V4/:9CS6$@,'T)9
M\RI>OFG=35>6P*7]VR<'_BEKGRX.2;LB+&G=G6T]I91_P>H?AJ,LG9G3/>MS
MOD UAABE6[/1^>D-QOUIU [4 U+\?*%M_/N/],B/][@Q#U/UV<C# :7XPM>
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M!OW?0;D%TS380+;P=*&5/B9NA<,FC8&K3C/!1H4@+1"&)JC^":)V_1504_!
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M;$;V^;Z"F>>R_B IGV+]I5:+Z 0R+,?<;<9\7(9S4V?(X-O?_.]7OWN,053
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M+;LJ%4V1>Q_UDP<>E.-:AG!YQ3]=8K/01""N^(&](#L4D&8:HP^9:C?"4<!
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M$2V"L>]+-#94?BLO:[ZA>I^TB6<0P/8W?XP96ED3;ME?JAYE(NC. #S7C!#
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M*V/GZ@^*-:?_\NI_IL]0W#,N@M1GB4$7,=7G*#>9C_:#P7A]5]C^+TUI.6"
M6S4LC_*%6XKGT'LTERZ<"QGEH_QHATI"]8%!YBHYM8B3\?4)/<O&)%-EB4$%
M*7R$%&U1& T^7D;]8^L:*O]R;YW<[]H:JS&Q"VJ^P2F+WVY<6 N_R&4E;H=/
MBPH:)!)'M/,BRD,8BU'&_SM;I_],_[9Y@2JP8FIYQD9]_CQ=K\?4.80IR:J/
MV/MC2O<7_6M0C3=]RQ$MX;,GL7'S''%S41\<?LD=')P5[Y^WC:OZ]39^H8\4
M1.KZ#+$L+ZT<3S^V_BUK,B0K$9:(BY(T5LG2,<FV3S_.RCKVU+I2QE'X9020
MJ>4P8ND!T(9>KT1SH_*=7\ ^DL?5*-OY5 45WWTY-,\9?),$$>T[XR =>.8R
M^\G:^$[*$G2--9D"RU'2>HG?E-3)$,<?OMMZ"!2:4I#"$/?XR?8 "*Q2*(0I
M#-;X[NQA=SU?_W&_+?O;YKS019>BT,0S8YY5I=9W8%:?*8;406(>Z*%M]+?S
M#$J"^!2!K'9L<,+&:G>_=\/']<(6)29CT1?M]<4Y\5/Q&,@&\[S,I87KFB\K
MINIV#&!X2*&>N?K]*T#1>\X4Q49NEO52!_O(=6W>T-XJ+'Z6A.47/>OE/FN?
M95&/NJS.  #.9T__Z3YTD\OB_AO)ML3D:F[=9Q_/R!X \E??P\BTX:P%B)YV
MYE9?H$3)#[Z;9V-G-S?TE AS,\KW1^+$E?\5N;'F'8OT!%]ANEWNG,B0Q^_/
M+>JS#0TXZ):+E!WUE:%Y1MA2C187EI!A#T#W84HZ)*O7)O^*^ZL)).6C&GZW
M?<K9P;FKO=&'3D>49Q%2F%G:$8CZY*["%X&*97.YU[4F1)JW+$:MAK1"SJ-C
M'$8O9)?J36[9MD_YXG]QT+LSW2F_M#A4/H0>*JMEA+"HP__7@[> I MFE[%=
M;JC/V189ZUFV^Q1K.F&(,_1[<K1@ZE?=B^G*Y9S6!\ VH9@;=CKT^FR@?;FP
M 8M;.!:#6RC0)3(Y=V12^+5H74%_H>'MC'4>$%BVRY)3W9 X>O%NS2.B*R<L
M,;Y2I C($)K4,2Q5"1&^';(-09A7CU?9ZF H9-XJ7!#=1$P&0;,-MH=OMNXE
M+TP-->[YMM\6691ERW,'KC,S9E1R_\N[/[5#_[5F^2*:T^S3YLGJ:8EP.&8T
M*_CBAP\+G"V= /ZMM8E&O"7;\1-%,+F.SLU@].C_#/;RWTMX?/\^^_Z57ET$
MEK*TS-<&N<]]68*D2FV.$6<17F9Y[#]G$\8F9F3$HM?D3EXUV(I?K]3PA7-[
MWDG*IU!_L6$ T<Z[4^63>3M_7R1I%'T1([]$F#(E:BFX2F$)77][WP* 3JW(
MWM,W57INE5BK":97@&M]FR49=R';-EX*D&11\!W0N*K93';!B$XG+"S2([3C
MVG3S1D&][XHE:Q")>--5-^C].%^X6K\4B=\<6VQ>A#/7II<_1W^J/.'91<L(
MY=GE*X90]L8FZ7T]6CU2IJR GV(#N[DH*$LA910M>;_L+1/C4KY)N;F\W:;?
M@X7Y3$S?\K F$A3F#C-G&BPHB-@V[O6;.<KRPL"J#>,/@"H2N+ GTY.66MH$
M'4S,S;1TIY9'"QGB#3U$C<3C&O&>.K<_;ZF\B^\9OJU<"//6GR2^M>V[X);
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M,5N(7<_(5ICV^Z'@#-IH.ZL8);/L0GM<%2'3]I>G]Q,&T[\(C/CS#1L,]AB
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M>(T.)QTEDSQ].5/#H9-LF#DX.%@@F,8U3'&0PF4,RUQ'.C'96UD5L:#O.+>
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MR_!NY\!D41H1.B<]C1)Z([F?$:Q2C^@8TFYF_1_G@OY/'817$_\"4$L#!!0
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MY^S1$-("!Y5K433GF;7QG6\VT;/ZU5=7JX?_4+7J#O#ITAD[M]%'9-!VB-M
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MTMTR4Y_0FFL7^FX]VH#J7.]D42Y3K(D)I')O'[4B3?37PG0Q[RZ=7^_05'J
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MUJU^6:8X(IQX']_CO$XP)R!JV:H#>"4=JPH6)N<@IT'47J/?&-[<6!H.EKB
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M%IMFS+<7Q<UMLKV>/OX+4$L! A0#%     @ 3SM=4?<9^Z<##   *V,  !
M             ( !     '!L>"TR,#(P,#DS,"YX<V102P$"% ,4    " !/
M.UU1H\[JWOX)  #Y?@  %               @ $Q#   <&QX+3(P,C P.3,P
M7V-A;"YX;6Q02P$"% ,4    " !/.UU17V0F+V@7   H7 $ %
M    @ %A%@  <&QX+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !/.UU1
MX4/98E$\   W,@, %               @ '[+0  <&QX+3(P,C P.3,P7VQA
M8BYX;6Q02P$"% ,4    " !/.UU1 "2L=?TI  #NL0( %
M@ %^:@  <&QX+3(P,C P.3,P7W!R92YX;6Q02P$"% ,4    " !/.UU1I0X)
M4]92 0#4, X %               @ &ME   <&QX+3(P,C P.3,P>#$P<2YH
M=&U02P$"% ,4    " !/.UU17JFPD?3#  !0U0  %P              @ &U
MYP$ <&QX+3(P,C P.3,P>#$P<3 P-2YJ<&=02P$"% ,4    " !/.UU16@RM
M[@KQ   Z(P$ %P              @ '>JP( <&QX+3(P,C P.3,P>#$P<3 P
M-BYJ<&=02P$"% ,4    " !/.UU1L]\C+F((  "W)@  %P
M@ $=G0, <&QX+3(P,C P.3,P>&5X,S%D,2YH=&U02P$"% ,4    " !/.UU1
MP,5(V'@(   ?*   %P              @ &TI0, <&QX+3(P,C P.3,P>&5X
M,S%D,BYH=&U02P$"% ,4    " !/.UU1K^>][X4%  !8%P  %P
M    @ %AK@, <&QX+3(P,C P.3,P>&5X,S)D,2YH=&U02P$"% ,4    " !/
M.UU1E-=*A8D%  !R%P  %P              @ $;M , <&QX+3(P,C P.3,P
A>&5X,S)D,BYH=&U02P4&      P #  F P  V;D#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
